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1 SUMMARY  
1.1 Scope of the manufacturer submission  
The manufacturer’s scope encompasses the clinical effectiveness and cost effectiveness of 
belimumab plus Standard of Care (SoC) relative to SoC alone, for the treatment of adults with 
active auto-antibody positive Systemic Lupus Erythematosus (SLE) and also for a subgroup 
of these patients who exhibit signs of high disease activity.  According to the manufacturer’s 
scope and submission the population of greatest interest is the sub-group with high disease 
activity called the Target population.  No subgroup is specified in the National Institute for 
Health and Clinical Excellence (NICE) scope.  The Target population is a subgroup of the 
proposed licensed population; a decision on the manufacturer’s license application is awaited.  
The manufacturer’s scope specifies that belimumab is delivered at 10mg/kg via a 1 hour 
intravenous (IV) infusion at 2 week intervals for the first 3 doses and every 4 weeks 
thereafter.  The NICE scope merely states that belimumab is used as an add-on to SoC.  The 
manufacturer’s scope specifies SoC as the sole comparator, and considers there is no credible 
evidence to enable a statistical comparison of belimumab with other drugs, either rituximab or 
cyclophosphamide.  These additional comparators are however specified in the NICE scope.  
Outcomes listed in the manufacturer’s scope include: disease activity, incidence and severity 
of flares, mortality, health-related quality of life (HRQoL), adverse effects of treatment, and 
fatigue; these coincide with those in the NICE scope. 
The manufacturer’s scope for economic analysis specifies a lifetime horizon, a National 
Health Service (NHS) and Personal Social Services (PSS) perspective, and a cost 
effectiveness analysis expressed in terms of incremental cost per quality adjusted life year; 
this corresponds to the NICE scope.  
Special considerations raised in the manufacturer’s scope include: 1) the innovative nature of 
belimumab for SLE; 2) the inability of the utility method to sensitively capture the quality of 
life (QoL) of SLE patients; and 3) the impact of SLE on particular ethnic groups and on 
women of childbearing age.  There were no equity issues identified in the NICE scope. 
The Food and Drug Administration (FDA) granted marketing authorisation in the United 
States of America (USA) in March 2011. Belimumab does not yet have marketing 
authorisation in Europe, the decision on an application is pending.  It is therefore not yet 
certain if the manufacturer’s scope will conform to directives from the European Licensing 
Authority. 
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Phase III trials have examined the effectiveness of belimumab at dosage regimens of 1mg/kg 
and 10mg/kg.  The evidence relating to the 1mg/kg dose regimen has not been presented in 
the submission.  
1.2 Summary of clinical effectiveness evidence submitted by the manufacturer  
A systematic literature search was undertaken by the manufacturer although the results of 
subsequent analysis of the retrieved studies were not clearly reported. 
The submitted clinical effectiveness evidence is mainly derived from two international 
multicentre phase III randomised placebo controlled trials (Belimumab International SLE 
Study (BLISS)-52 and BLISS-76 lasting 52 and 76 weeks, respectively), which compared 
SoC plus belimumab vs. SoC plus placebo.  In each trial patients were randomised 
(approximately 1:1:1) to one of three treatments: SoC + placebo, SoC + belimumab at 
1mg/kg, or SoC + belimumab at 10mg/kg.  BLISS-52 was undertaken mainly in Asia and 
South America while BLISS-76 patients mainly derived from North America and Europe. 
There were 288 and 271 patients in the 1mg/kg arms of BLISS-52and BLISS-76 respectively, 
but results for effectiveness in these groups were not submitted.  Of 865 patients in BLISS52 
and 819 in BLISS-76, 577 and 548 were distributed almost equally into placebo and 10mg/kg 
belimumab groups, respectively. 
Several sets of results were presented for placebo and 10mg/kg belimumab arms of the trials: 
[i] those for the whole population of trial patients, separately by trial and also after pooling 
patients from the two trials; [ii] those for the “Target population” after pooling data across the 
two trials; the Target population is a subgroup with high disease activity identified by post 
hoc analyses.  The submission of multiple sets of results complicates any summary of the 
clinical effectiveness data. 
For the Target population some outcome by-trial results became available during the 
clarification process, however the Evidence Review Group (ERG) was unable to comment on 
within trial comparison of belimumab vs. placebo for: the mean change in Short Form 36 Item 
Health Survey (SF-36) Physical Component Survey (PCS) score; time to first flare; 
SLICC/ACR (Systemic Lupus International Collaborating Clinics / American College of 
Rheumatology); and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue 
Score.  Box 1 provides a summary of the manufacturer’s response and reasons for focussing 
on the Target population. 
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Box 1: Interpretation of marketing authorisation population and the Target population 
 
Our submission is based on a high disease activity subgroup of the marketing authorisation 
population, defined as the Target population. We acknowledge that NICE will be unable to 
make a recommendation for the whole of the expected licensed population (marketing 
authorisation population), but are aware that our Target population falls within the expected 
licensed population.  Mindful of the need to make the most efficient use of NHS resources, 
this subgroup allows a Targeted approach to selecting the patients who are most likely to get 
the greatest benefit from treatment. 
 
1.2.1 Primary outcome  
The BLISS trials employed a novel composite outcome measure called the SLE Responder 
Index (SRI) which aimed to detect any improvement in SLE manifestation while guarding 
against the possibility that worsening involvement of other organ systems or a worsening in 
overall disease activity might be masked.  To be classified as a “responder” a patient was 
required to satisfy specified minimum criteria in three measures of change in disease activity 
relative to baseline.  The measures used were: [1] the Safety of Estrogen in Lupus 
Erythematosus National Assessment-SLE Disease Activity Index (SELENA SLEDAI) score, 
which detects an improvement in SLE manifestations, it scores disease activity over a range 
of 0 to 105 points and encompasses 24 weighted items scored as present or absent in the 
previous 10 days; clinically meaningful differences have been reported to be an improvement 
by a decrease of 6 points or a worsening by an increase of 8 points1; [2] the British Isles 
Lupus Activity Group (BILAG) index assesses organ system involvement over the preceding 
28 days and is capable of detecting worsening of organ system involvement; it includes 86 
items grouped into 8 organ systems, general (5 items), mucocutaneous (18 items), 
neurological (15 items), musculoskeletal (9 items), cardiorespiratory (12 items), vasculitis (8 
items), renal (11 items), and hematological (8 items), (Isenberg and Gordon, 2000).2 A score 
is calculated for each system depending on the SLE clinical manifestations (or signs and 
symptoms) present and whether they are new, worse, the same, improving, or not present in 
the last 4 weeks compared with the previous 4 weeks. BILAG uses classifications ranging 
from A to E as follows: A = worsening judged to require intensification of steroids or 
immunosuppressant treatments; B = worsening judged to require antimalarials, nonsteroidal 
anti-inflammatory drugs (NSAIDs), or low dose steroids; C = stable disease; D = 
improvement; E = system never involved; [3] a Physicians Global Assessment (PGA) score, 
employed to monitor for worsening in patient overall disease activity (scores can range 
between no disease = 0, and 3 = severe disease).  The SRI criteria used to define a responder 
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were: an improved SLEDAI score by ≥ 4 points; a BILAG index showing no new grade A 
organ involvement or no two grade B organ involvements; a PGA score that has not increased 
by more than 0.3 points.  The primary end point in both trials was the proportion of 
responders at week 52 relative to baseline according to the SRI. 
In summary, the primary efficacy endpoint was the response rate at week 52, assessed with 
SLE Responder Index (SRI).  A responder was defined as having a reduction of at least 4 
points in the SELENA-SLEDAI score, no new BILAG A organ domain score, no more than 1 
new BILAG B organ domain score, and no worsening in PGA score (increase < 0.3) at week 
52 compared with baseline. 
In both trials at 52 weeks SoC + 10mg/kg belimumab delivered a greater percentage of 
responders than did SoC + placebo.  The difference in percentage of responders in the 
belimumab group relative to placebo group was 14% in BLISS-52and 9.4% in BLISS-76 and 
11.8% for the whole population pooled across trials.  The corresponding adjusted odds ratios 
for a response in BLISS-52 and in BLISS-76 were respectively 1.83 (95% CI: 1.30, 2.59; P = 
0.0006) and 1.52 (95% CI: 1.07, 2.15; P = 0.027).   
For the high disease activity subgroup (Target population) pooled across trials the difference 
in percentage of responders between the belimumab group and placebo group was 24.8% and 
the adjusted odds ratio was 2.7 (95% CI: 1.8, 4.1; P < 0.0001).  For the Target population in 
BLISS-52 the difference in percentage of responders between the belimumab group and 
placebo group was 25.9% and the adjusted odds ratio was 3.0 (95% CI: 1.7, 5.2; P < 0.0001).  
For the Target population in BLISS-76 the difference in percentage of responders between the 
belimumab group and placebo group was 22.4% and the adjusted odds ratio was 2.5 (95% CI: 
1.3, 4.6; P < 0.0045).  
The percentage of responders was also reported at multiple follow up times. For the Target 
population pooled across trials and in BLISS-52, at many times, a significantly greater 
response was observed for the belimumab group relative to placebo group (significance tests 
uncorrected for multiple testing), however for BLISS-76 the only time a significantly (P < 
0.05) greater response was observed for the belimumab group was at week 52. 
1.2.2 Secondary Outcomes 
The pre-specified major secondary outcomes were: the SRI response at week 76; the 
percentage of patients with a ≥ 4 point SLEDAI improvement at week 52; mean change in 
PGA score at week 24, percentage of patients with prednisone reductions ≥  25% from 
baseline to ≤7.5 mg/day during weeks 40 to 52 (in subjects whose baseline dose was > 7.5 
mg/day); mean change in SF-36 PCS at week 24. 
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The major secondary outcome of percentage of SRI responders at week 76 failed to reach 
statistical significance (odds ratio and P value not submitted; odds ratio 1.31, 95% CI: 0.92 – 
1.87, P = 0.1323 by logistic regression, taken from the FDA briefing package).3
Mean change in PGA score at week 24 was defined as a major secondary outcome.  For the 
whole population in BLISS-52 the change in PGA score (week 24 relative to baseline) for 
both groups indicated disease improvement and was greater in the belimumab group (-0.54) 
than placebo group (-0.39; P = 0.0003 in support of belimumab). For BLISS-76 the difference 
between groups was very small and in favour of placebo (-0.49 placebo and -0.48 belimumab) 
and did not reach statistical significance (P = 0.7987).  For the Target population pooled 
across trials belimumab delivered a greater reduction in PGA score than placebo (P = 0.028 
with mean changes of -0.42 and -0.52 for placebo and belimumab, respectively).  Target 
population data was not been provided for the change in PGA score separately for the BLISS-
52 and BLISS-76. 
 
Components of the SRI at Week 52 
A further major secondary outcome was the percentage of patients at week 52 that achieved a 
SLEDAI score reduction of ≥ 4 points.  Both trials delivered a significantly greater percentage 
for belimumab than for placebo (P = 0.0024 and P = 0.0062 for BLISS-52 and BLISS-76, 
respectively).  Similarly, the Target population data delivered a significantly greater 
percentage for belimumab (P = 0.0004 and P = 0.0063 for BLISS-52 and BLISS-76, 
respectively).  
 
Results at week 52 for the other two SRI components (i.e. the BILAG index and PGA score) 
were submitted (non-major secondary outcomes).  The percentage of patients in the whole 
population that satisfied BILAG and PGA criteria in BLISS-52 was greater for belimumab 
than placebo (significant at P = 0.0181 and P = 0.0048 for BILAG and PGA, respectively); 
however, for BLISS-76 the differences between belimumab and placebo were smaller and 
neither component reached statistical significance in favour of belimumab (P = 0.319 and P = 
0.1258 for BILAG and PGA, respectively).  Similarly, the percentage of patients in the Target 
population which satisfied BILAG and PGA criteria in BLISS-52 was greater for belimumab 
than placebo (P = 0.0099 and P = 0.0063 for BILAG and PGA, respectively); however, for 
BLISS-76 the differences between belimumab and placebo were far more modest and did not 
reach conventional statistical significance (P = 0.1297 and P = 0.1312 for BILAG and PGA, 
respectively). 
In summary, in BLISS-52 for the total population and for the high disease activity subgroup, 
belimumab at 10mg/kg delivered significantly more responders at 52 weeks than placebo for 
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SLEDAI score reduction of ≥ 4 points, no worsening in PGA, and no worsening in BILAG.  
However, for BLISS-76 at 52 weeks total population and high disease activity subgroup, a 
significant response with belimumab 10mg/kg compared to placebo was only seen with the 4-
point reduction in SELENA-SLEDAI component (difference between belimumab and 
placebo = 22%, odds ratio = 2.4 [95% CI: 1.3, 4.4; P < 0.0063]). 
Reduction in steroid usage 
Reduction in steroid use was specified as a major secondary outcome.  In BLISS-52 at 
baseline 68.6% of patients were receiving ≥ 7.5 mg/day prednisone.  The corresponding 
percentage for BLISS-76 was 44.9%.  The percentage of these patients whose steroid use was 
reduced in weeks 40 to 52 by the pre-specified amount was greater in the belimumab arm than 
the placebo arm in both trials.  The difference (belimumab vs. placebo) failed to reach 
statistical significance in either trial: 18.6% vs. 12.0% in BLISS-52 (P = 0.0526 from logistic 
regression including baseline covariates) and 16.7% vs. 12.7% in BLISS-76 (P = 0.5323). For 
the Target population pooled across trials 15.9% and 7.1% reduced steroid use in belimumab 
and placebo groups, respectively (P = 0.0389 from logistic regression).  For the Target 
population in the BLISS-52 trial there was a large difference in reduced steroid use between 
belimumab and placebo groups (18.5% and 5.3% respectively; odds ratio = 4.11, 95% CI: 
1.29, 13.2; P = 0.0171).  For the Target population in the BLISS-76 trial there was no 
difference between groups (11.1% and 10% reduced steroid use in belimumab and placebo 
groups respectively; odds ratio = 0.88, 95% CI: 0.21, 3.60; P = 0.8586). 
 
Quality of life 
The mean change in SF 36 PCS scores was specified as, a major secondary outcome. At week 
24 relative to baseline it showed little difference between belimumab and placebo groups in 
BLISS-52 (P = 0.8870), or in BLISS-76 (P = 0.6601), or in the Target population pooled 
across trials (P = 0.4276).  
 
Change in SF 36 PCS scores at week 52 was also specified as a non-major secondary 
outcome.  No significant improvement was observed for BLISS-76 or Target populations (P = 
0.5134 and P = 0.1124, respectively) however in BLISS-52 there was a difference between 
belimumab and placebo arms (4.18 vs. 2.96) (P = 0.0247). 
 
In BLISS-52 over the course of the study there was a statistically non-significant difference (P 
value not submitted) in favour of belimumab relative to placebo in the absolute change of 
EuroQoL 5 Dimensions (EQ-5D) score from baseline, however the results for belimumab and 
placebo groups in BLISS-76 were indistinguishable.  For the pooled Target population the 
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difference between 10mg/kg and placebo groups reached statistical significance in favour of 
belimumab at week 24 (P ≤ 0.01), but the difference almost completely faded by week 52. 
SLEDAI flare index 
Other specified non-major secondary efficacy outcomes for which results were submitted 
included: time to first SLE flare (assessed using the SLEDAI Flare Index which categorizes 
flares as “mild or moderate” or “severe” based on 6 variables (see Appendix 1); disease 
progression at week 52 relative to baseline assessed using the SLICC/ACR index; fatigue 
over the course of the study estimated using the FACIT-Fatigue scale4 which ranges from 0 
to 52 (0 is the worst possible score and 52 is the best).  
 
In BLISS-52 the time to first flare and time to first severe flare were delayed by belimumab 
relative to placebo (HR 0.76, 95% CI: 0.63 – 0.91, P = 0.0036; HR 0.57, 95% CI: 0.39 – 0.85, 
P = 0.0055, respectively).  In BLISS-76 there was no difference between groups in time to 
first flare (P = 0.4796) but relative to placebo belimumab somewhat delayed time to first 
severe flare (HR 0.72, 95% CI: 0.50 – 1.05, P = 0.0867).  For the Target population pooled 
across trials, relative to placebo, belimumab significantly delayed time to both first flare (P = 
0.007) and to first severe flare (P = 0.0028). 
SLICC/ACR organ damage 
There was little difference between placebo and belimumab groups in terms of change in 
SLICC/ACR score at week 52; precise values by trial were not submitted.  Data reported 
elsewhere5
 
 were: BLISS-52 score change 0.06 and 0.04 for placebo and belimumab groups 
respectively, P for difference 0.4222; BLISS-76 score change 0.05 and 0.03 for placebo and 
belimumab groups respectively, P for difference 0.3415. 
Fatigue 
At week 52 relative to baseline the belimumab group had greater improvement in FACIT-
Fatigue score than the placebo group (4.8 belimumab and 2.1 placebo in BLISS-52, P < 
0.001; 4.6 and 2.9 in BLISS-76, P = 0.05).  For the Target population at weeks 8 and 12 the 
difference between groups was statistically in favour of belimumab (P < 0.05) however the 
difference between groups then diminished and at week 52 the difference no longer reached 
conventional statistical significance. 
Modified SRI response 
The results for a non-pre-specified secondary outcome, the “modified SRI” at week 52, were 
submitted.  In the “modified SRI” serological improvements (2 points each for anti-dsDNA 
antibodies and for complement) were not allowed to contribute toward a ≥4 points redu ction 
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in SLEDAI score.  In BLISS-52 belimumab delivered a greater percentage of responders than 
did placebo (P = 0.0038); in BLISS-76 the difference in favour of belimumab failed to reach 
the conventional level of statistical significance (P = 0.064).  
1.2.3 Safety 
The submission pooled results from three randomised controlled trials (RCTs): BLISS-52, 
BLISS-76 and LBSL02, providing information on 675 patients who received placebo and 
1458 who were exposed to belimumab.  LBSL02 lasted 52 weeks, preceded the BLISS trials, 
was conducted in North America (98% patients from the USA) randomised 449 patients to 
one of four treatments: SoC + placebo, SoC + 1mg/kg belimumab, SoC + 4mg/kg belimumab, 
and SoC + 10mg/kg belimumab.  Although all patients had a history of auto-immunity, at 
recruitment 30% currently lacked anti-nuclear antibodies.  This trial did not employ the SRI 
composite outcome.  
Deaths 
There were 15 deaths during the controlled phase of the three trials; 3 in the placebo group 
(n=675), and 12 in the belimumab groups (n=1458) with 6 each in the 10mg/kg and 1mg/kg 
groups respectively.  One death in the 1mg/kg belimumab group followed 15 weeks after the 
patient stopped belimumab treatment.  The causes of death were various.  
 
Adverse events 
In all treatment groups > 90% of patients experienced at least 1 adverse event (AE).  The most 
commonly occurring AEs were headache, upper respiratory tract infection, arthralgia, nausea, 
urinary tract infection (UTI), diarrhoea and fatigue.  
 
The percentage of patients experiencing at least one serious AE and at least one serious AE 
was very similar between placebo and belimumab groups ranging from13.5% to 18.6%, with 
a very slight numerical excess in the belimumab group.  The most frequent serious AEs (≥ 1% 
in any treatment group) were pneumonia, pyrexia, UTI, cholelithiasis, and cellulitis.  The 
percentage of patients experiencing at least one severe AE was 15.4% for the placebo group 
and 16% across the belimumab groups; the most common severe adverse events were not 
identified. 
 
Occurrence of infusion plus hypersensitivity reactions was similar between belimumab and 
placebo-treated patients (17% and 14.7%, respectively).  
 
 
18 
 
Infections 
Infections occurred slightly more often in patients treated with belimumab compared to 
placebo.  The most frequent infections were upper respiratory tract infection (URTI), UTI, 
nasopharyngitis, sinusitis, and bronchitis. 
 
Malignancy 
Five solid organ malignancies were reported across the trials: a stomach carcinoid (placebo 
group, day 202); a breast cancer (belimumab 1mg/kg, day 102); a cervical cancer (belimumab 
1mg/kg, day 439); an ovarian cancer (belimumab 1mg/kg, day 21, patient died); and a thyroid 
cancer (belimumab 1mg/kg, day 378).  There were four non-melanoma skin cancers: two 
basal cell carcinomas, and two squamous cell carcinomas (1 in the placebo group, 3 in the 
belimumab 1mg/kg group).  
1.3 Summary of the ERG’s critique of clinical effectiveness evidence submitted 
The submission omitted results for the 1mg/kg groups from the two pivotal trials.  Therefore 
from information in the manufactures submission (MS) alone, the consistency of results 
across the whole data set could not be fully assessed and it was not possible to gauge the 
evidence for a dose response relationship.  However, data for the 1mg/kg groups is available 
in the public domain (FDA documents pertaining to the Human Genome Sciences (HGS) 
Briefing Document to the FDA3,5
 
) and the ERG have considered this information in critiquing 
the submitted evidence.  
Even without the 1mg/kg group results the MS provided clinical evidence for a large number 
of outcomes reported for six separate populations (whole population from  BLISS-52, whole 
population from BLISS-76, pooled whole populations from BLISS-52 plus BLISS-76, pooled 
Target populations from BLISS-52 plus BLISS-76, and after the clarification process Target 
population from BLISS-52 and Target population from BLISS-76.  Additionally, AEs for 
LBSL02 were included.6
 
 
The most noticeable aspect of the submitted results was the relative lack of evidence for 
clinical effectiveness of belimumab seen in the BLISS-76 trial.  Although at week 52 for the 
pre-specified primary outcome measure the percent responders (SRI) reached statistical 
significance in favour of belimumab (P = 0.027), at no other time point did this outcome reach 
significance.  Furthermore, all major and non-major secondary outcome results submitted, 
except for a ≥ 4 point SLEDAI improvement at week 52 which is a subcomponent of the SRI 
response, likewise failed to reach statistical significance including: PGA change at week 24 
and 52, SRI responders at week 76, reduction in use of steroids week 40 to 52, SF-36 change 
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at week 24, time to first flare, time to first severe flare, change in SLICC/ACR organ damage 
score at week 52, fatigue status (FACIT change from baseline), and quality of life (EQ-5D 
change). 
 
The SLE population in BLISS-76 is more likely to resemble that in the UK than that in the 
BLISS-52; therefore the BLISS-76 results are probably more relevant to the decision problem 
than those from BLISS-52.  The results favourable for belimumab submitted for the whole 
population pooled across trials were largely driven by BLISS-52 results.  For the Target 
population the results from the BLISS-52 trial were again more favourable to belimumab than 
those from BLISS-76 and additionally BLISS-52 provided more patients to the pooled Target 
population than BLISS-76 (55% vs. 45%), therefore results favourable to belimumab for the 
pooled Target population were again more strongly driven by the contribution from the 
BLISS-52 Target population. 
 
Results in the public domain3,5
1.4 Summary of cost effectiveness submitted evidence by the manufacturer 
for the 1mg/kg and 10mg/kg dose regimens in the BLISS-76 
trial were not supportive of a dose response relationship.  For many outcomes the results were 
as favourable for the low dose group as for the high dose group.  These outcomes included: 
percentage of SRI responders across trial follow up, percentage of patients with no worsening 
in PGA at week 52, percentage of patients with no worsening in BILAG index at week 52, 
mean change in PGA score from baseline at week 52, reduction in steroid use weeks 40 to 52, 
time to first flare, time to first severe flare, and mean change in FACIT fatigue score at week 
52. 
No published relevant economic evaluations were identified in the submission.  The search 
strategy was poor but it appears unlikely that economic studies were missed.  
The submitted cost-effectiveness work focuses entirely on a new model and economic 
evaluation undertaken by the manufacturer.  This de novo individual patient micro-simulation 
model examined the cost-effectiveness of belimumab plus SoC versus SoC.  This employed 
an annual cycle over a lifetime horizon and conformed to the NICE reference case. 
In brief, the model was constructed using three main sources of data: 
• The BLISS trials 
• The John Hopkins University cohort 
• Additional data drawn from the wider literature 
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The trial data determined distribution of patient characteristics at baseline. Regression 
analysis was also used to model patients’ SLEDAI score at week 52.  Those in the belimumab 
arm who responded at week 24 were modelled as remaining on belimumab and maintaining 
the modelled SLEDAI score at week 52.  Those in the belimumab arm who did not respond at 
week 24 were assumed to stop treatment and were modelled as having the average SoC 
SLEDAI score at week 52.  Discontinuation rates from week 24 were also drawn from the 
trial data. 
Regression analysis from the trial data was also used to derive HRQoL and cost functions 
related to a patient’s SLEDAI score. 
Given these inputs, the bulk of the remainder of the model was derived from the Johns 
Hopkins University (JHU) cohort data.  The survival function and the risks of developing 
each of the 12 organ involvements within the SLICC index were modelled on a range of 
covariates, these including the adjusted mean SLEDAI score to date and the average 
cumulative prednisolone dose. Steroid use was not drawn from trial data but was rather 
modelled using a function estimated from the JHU cohort relating steroid use to a patient’s 
SLEDAI score.  The evolution of the SLEDAI score subsequent to week 52 was also 
estimated from the JHU cohort data, with the manufacturer adjusting the constant of the 
functional form to better fit the belimumab phase II trial data.  
The survival function estimated from the JHU cohort was amended by SMRs drawn from a 
paper within the literature. Additional data drawn from the literature was used to inform the 
HRQoL and cost impacts arising from involvement of the individual 12 organ involvements 
within the SLICC index. 
Base case deterministic results were submitted by the manufacturer for three patient 
populations: 
• The All BLISS patient population; 
• The patient population within the BLISS trials that relates to the anticipated license of 
Anti-dsDNA+ve and low (C3 or C4); 
• The Target population which restricts the patient population to the licensed patient 
population with an SS score at baseline of at least 10. 
 
For the All BLISS population the central survival estimate was an additional 1.50 years 
survival from use of belimumab.  The discounted net gains and costs were 0.43 QALYs at a 
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net cost of £35,584 to yield a cost effectiveness estimate of £82,909 per QALY. With the PAS 
the net cost fell to £*****  to yield a cost effectiveness estimate of £***** per QALY. 
Only the base case deterministic results were presented for the anticipated license population.  
The central survival estimate was an additional 2.13 years survival from use of belimumab. 
The discounted net gains and costs were 0.61 QALYs at a net cost of £40,303 to yield a cost 
effectiveness estimate of £66,170 per QALY. With the PAS the net cost fell to £***** to 
yield a cost effectiveness estimate of £***** per QALY. 
For the Target population the central survival estimate was an additional 2.93 years survival 
from use of belimumab. The discounted net gains and costs were 0.81 QALYs at a net cost of 
£51,925, to yield a cost effectiveness estimate of £64,410 per QALY. With the PAS the net 
cost fell to £***** to yield a cost effectiveness estimate of £***** per QALY. The direct 
costs of belimumab and its administration accounted for 90% and 17% respectively of the 
total net costs. Lower costs from pulmonary involvement and from renal involvement 
provided costs offsets of around 6% and 4% respectively. 
An ERG cross-check of the probabilistic modelling for the Target population resulted in a 
central estimate of £65,530 per QALY. Due in part to the results being reasonably linear and 
also the time inherent in running the model probabilistically all other results presented are 
from the deterministic model. 
A range of sensitivity analyses were presented for the All BLISS patient population and the 
Target population. Restricting attention to the Target population, results were sensitive to the 
initial changes in the SLEDAI score that were modelled, the manufacturer adjustment to the 
long term SLEDAI score function, the impact of the adjusted mean SLEDAI score upon 
mortality and the natural history models for pulmonary and renal involvement. 
 
1.5 Summary of the ERG’s critique of cost effectiveness evidence submitted 
Assuming that belimumab week 24 non-responders will experience the average SLEDAI 
score within the SoC arm is likely to have over-estimated the average impact upon SS scores 
within the belimumab arm.  The SLEDAI score drives the analysis and any error in its 
calculation will have a major impact on results.  There may also be errors in the calculation of 
the adjusted mean SLEDAI score from not taking into account a patient’s probable prior 
history, with this concern also applying to the calculation of the cumulative average steroid 
dose. 
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The maintenance through time of the absolute gain in SLEDAI score among those remaining 
on treatment compared to those on SoC may be optimistic, and at a minimum should have 
been explored in a scenario analysis.  However, ERG expert opinion indicates that it may in 
some sense be possible to “reset” the immune system which may negate this concern. 
Whether it is reasonable to extrapolate the 8% annual discontinuation rate for the Target 
population beyond the trial period is also unclear given the lack of detail around the figures 
underlying this rate. A high discontinuation rate from week 24 improves the cost effectiveness 
of belimumab. 
Adjusting the JHU cohort survival model by SMRs from the literature may not be justified. 
The SMRs applied may also not be representative of the overall literature.  This may have 
tended to exaggerate the impacts of the covariates within the JHU cohort survival model. 
Costs as a function of the SLEDAI score may have been exaggerated by analysing the data on 
a six monthly basis rather than the annual basis on which the model is constructed.  There are 
also some concerns that the separate estimation of costs for each organ involvement may have 
tended to double count the cost impacts of SLE. 
There appear to be some discrepancies in the reported model outputs between the average 
durations of organ involvement, the annual costs of these and the discounted total costs of 
these organ involvements.  There are as a consequence concerns around the calculation of the 
cost offsets from reduced organ involvement arising from belimumab. 
With the exception of the last point the effects of which are currently ambiguous, the above 
suggest that the model may have tended to overestimate the impact of belimumab on the 
SLEDAI score and to have overestimated the likely impact of the SLEDAI score on the 
model outputs.  There are few immediately obvious biases pulling in the opposite direction. 
 
1.6 ERG commentary on the robustness of evidence submitted by the 
manufacturer 
The submitted evidence concerned the clinical and cost effectiveness of 10mg/kg belimumab, 
used as an add-on to standard of care, compared to standard of care alone.  Several SLE 
populations were considered.  Evidence for clinical effectiveness came from two placebo-
controlled phase III trials: BLISS-527 was conducted at 90 centres located in Pacific-Asia, 
South America and Eastern Europe (11 centres); BLISS-76 was conducted in 136 centres in 
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North America and Europe.  As such the results from BLISS-76 are more likely to be 
generalisable to the UK. 
Total populations in the BLISS trials (auto-antibody positive patients with active SLE disease 
sufficient to score ≥ 6 points on the SLEDAI scale) conformed to that in the NICE scope ,but 
the effectiveness of belimumab in the two trials was disproportionately greater in BLISS-52 
than BLISS-76 and the evidence for effectiveness from BLISS-76 was not convincing.  The 
manufacturer pooled data from the two BLISS trials, but the pooled analyses that favoured 
belimumab were almost exclusively driven by the effectiveness results from BLISS-52 and 
are arguably less applicable to the UK than the BLISS-76 results alone.  The results for PGA 
of disease activity were noticeably disparate between trials.  The ERG considered that 
inadequate allocation concealment of outcome assessors (physicians) in BLISS-52 might 
explain this discrepancy and may be a cause for concern since PGA is a component of the 
composite primary outcome. 
The manufacturer submitted evidence for a high disease activity sub-population from the 
BLISS trials; this was called the “Target population”.  The Target population was not a pre-
specified subgroup in the trial protocols; it was identified using post hoc analyses to seek out 
a more strongly responding subgroup of patients.  The Target population was defined 
according to baseline disease activity score (≥ 10 SLEDAI points), l evel of antibodies to 
dsDNA, and low level of complement.  Each of these three criteria defined a pre-specified 
subgroup from the BLISS trials, but the combination of all three was not pre-specified.  The 
Target population represents a subpopulation of the proposed licensed population which in 
turn is a subpopulation of the total BLISS trial population.  For the Target population only 
outcome results pooled across the trials were submitted and it was impossible to check for 
consistency of results between trials.  This was a cause for concern because of the lack of 
convincing evidence of effectiveness for the whole population in BLISS-76 (see above). 
Both BLISS trials had three randomised groups: placebo, 1mg/kg belimumab and 10mg/kg 
belimumab.  The submission did not include results for the 1mg/kg arms of the trials; 
however these results are available in the public domain (FDA documents3,5).  Results for the 
1mg/kg dose regimen are relevant for checking consistency between trial results and in 
determining whether a dose response relationship exists.  In this respect the most noticeable 
result was that in BLISS-76 there was essentially no evidence of any dose response 
relationship across the time span of the trial and no difference between the proportions of SRI 
responders to 1mg/kg and to 10mg/kg.  For the SRI subcomponents PGA and BILAG in 
BLISS-76, the 1mg/kg regimen was more effective than 10mg/mg; similarly the 1mg/kg dose 
regimen appeared as effective as 10mg/kg in suppressing flares. 
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1.6.1  Strengths 
The main strengths of the clinical effectiveness evidence were: 
• The significant result (P < 0.05) for the pre-specified primary end point (52 week 
SRI) in both the two phase III RCTs; 
• The fact that this primary outcome had been developed in consultation with a 
licensing authority (the FDA) and guarded against the possibility that improvement in 
some particular SLE manifestation or manifestations might mask deterioration in 
overall disease activity or involvement of new organ damage. 
The main strengths of the cost effectiveness submission were:  
• Provision of a well constructed model which conforms to the NICE reference case; 
• An impressive attempt at modelling the longer term effects of SLE using extensive 
modelling of the JHU SLE cohort; 
• The presentation of a simple and transparent PAS that allows easy implementation 
within the economic model. 
 
1.6.2 Weaknesses and areas of uncertainty  
There were a number of weaknesses and uncertainties; these include: 
• The lack of convincing evidence from BLISS-76 that belimumab is superior to 
placebo in the total population.  Only at week 52 did the proportion of SRI responders 
reach statistical significance in favour of belimumab. At other monitoring times 
significance was not reached and results for 1mg/kg (available from FDA reports3,5) 
and 10mg/kg belimumab are indistinguishable.  Furthermore, of the five pre-specified 
major secondary end points in only one was belimumab favoured at a level that might 
not reasonably be accounted for by chance; MC this outcome, a reduction in the 
SLEDAI score of ≥ 4 points at week 52, represents the smallest disease activity 
improvement that can be considered clinically significant.  None of the other major 
secondary outcomes in the BLISS-76 trial favoured belimumab at a level that strongly 
excluded the possibility of a chance result, including: PGA change at week 24 and 52, 
SRI responders at week 76, reduction in use of steroids week 40 to 52, SF-36 change 
at week 24.  Furthermore, none of the other submitted secondary outcomes strongly 
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excluded chance from accounting for results in favour of belimumab, including: time 
to first flare, time to first severe flare, change in SLICC/ACR organ damage score at 
week 52, fatigue status (FACIT change from baseline), and quality of life (EQ-5D 
change).  For some of these outcomes there was little distinction in effectiveness 
between 1mg/g and 10mg/kg belimumab dose regimens. 
• There were considerable (and significant) geographical and racial differences between 
the BLISS trials (which may indicate potential differences in practice and in standard 
of care).  The BLISS-76 population is more closely comparable to that of the UK than 
the BLISS-52 as also are the likely underlying care patterns.  The submission pooled 
the two BLISS trials (52 and 76).  The pooled results favourable for belimumab were 
almost exclusively driven by BLISS-52.  The relevance of the pooled results for 
England and Wales is therefore uncertain.  Similarly subgroup analysis 
(Manufacturer’s clarification document) of the primary outcome according to 
geographical region (USA/Canada, Western Europe, Eastern Europe, America-
excluding USA/Canada, Asia) indicated that response was strongest in America-
excluding-USA/Canada and weakest in USA/Canada and Western Europe. 
• The submission excluded results for the 1mg/kg arms of the two BLISS trials.  The 
trial results available from the FDA indicated a lack of convincing evidence for an 
expected dose response relationship, with no consistent additional benefit from 
10mg/kg compared to a 1mg/kg dose. 
• The original submission only presented pooled effectiveness results for the Target 
population.  The NICE submission template specifically requests separate results by 
trial when more than one trial is available.  In the light of the relative lack of 
effectiveness displayed in BLISS-76 for the whole trial population, the lack of trial 
specific data for the Target population weakened the submission’s case.  Trial 
specific results for some outcomes for the Target population were made available 
during the clarification process.  No data is available for the effectiveness of the 
1mg/kg dose in the Target population. 
• The ERG found outcome data common to BLISS and rituximab trials which was not 
explicit in the MS, so that the existence of data for an indirect comparison of 
interventions was not acknowledged.  NICE request a rationale for not conducting 
meta-analysis when more than two RCTs are available.  No rationale was provided in 
the MS. 
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• The BLISS populations exhibited a narrow range of SLE manifestations (mainly 
restricted to musculoskeletal and cutaneous problems).  The BLISS trials were 
underpowered to estimate the effectiveness of belimumab with respect to 
manifestations in other domains.  Also there was a lack of controlled evidence on the 
effectiveness of belimumab relative to SoC in the longer term beyond 76 weeks.  Yet, 
in the economic analysis, effectiveness data from the pooled BLISS populations have 
been used in modelling belimumab’s effect on a wide range of organ systems in SLE 
over a life-time horizon. 
• The economic model generated a survival benefit for belimumab over SoC: an 
additional 2.93 undiscounted year’s survival from belimumab within the Target 
population.  There is no direct clinical evidence to support this.  Actually, during the 
randomised phases of the belimumab trials, there were a greater number of deaths 
associated with belimumab than with placebo. 
• The economic model generates better survival for patients with high disease activity 
than for those with low disease activity.  This counterintuitive result appears to reflect 
the larger proportion of young patients in the Target population from the pooled 
BLISS trials.  As such this will merely reflect the exigencies of trial recruitment and it 
is very uncertain whether this population is representative of high disease activity 
patients in England and Wales. 
• In the economic model there may be an element of double counting in estimating the 
costs of complications, these costs being a function of the SLEDAI score with further 
costs being added for the individual components of the SLICC index. 
• The economic model data from the JHU cohort to estimate a number of functions 
within the model: the long term evolution of the SLEDAI score, steroid use, mortality 
risks and the risk of developing organ involvement. The level of disease activity in 
this cohort is very much lower than that of the Target population and as a 
consequence the manufacturer made an informal adjustment to the SLEDAI score 
evolution function. This adjustment improved the estimate of the cost effectiveness of 
belimumab. Some informal justification for this adjustment has been provided within 
manufacturer responses to ERG clarification questions, but uncertainty remains 
because the reliability and validity of the adopted adjustment was not fully explored 
or robustly defended.   
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• The submission did not provide data about maintenance of response at the patient 
level. The SRI outcome was reported as a group response; the graph line showing 
percentage of responders across the duration of the trials rose and fell at various 
follow up times, thus an individual non-responder could later improve sufficiently to 
be classified as a responder. 
• The economic model overestimated health benefit in the belimumab arm between 
weeks 24 and 52.  This was because the estimate (i.e. the decrease in SLEDAI score) 
for non-responders in the belimumab arm (33% of patients in the belimumab arm) 
was calculated from observed changes in the whole SoC arm which included 
responders as well non-responders.  In the pooled Target population the SoC arm 
consisted of 52% responders and 48% non-responders with average SLEDAI 
improvement of 6.9 points for responders and 1.1 points for non-responders; thus the 
improvement for the SoC arm as a whole was heavily weighted by the SoC 
responders.  A more appropriate procedure would be to base the estimate of the health 
benefits for non-responders in the belimumab arm on the SLEDAI change observed 
for non-responders in the SoC arm (i.e. assuming that the two sets of non-responders 
experience similar disease trajectories as a result of their SLE).  This weakness 
extends beyond week 52 because the manufacturer’s model for the belimumab arm 
non-responders after week 52 continues to make an estimate of disease activity based 
on the whole SoC arm ( made up of a mix of both responders and non-responders).   
1.7 Summary of additional work undertaken by the ERG  
The ERG undertook substantial additional work in the following areas:  
1. Supplementing the MS with data in the public domain e.g. as available from the 
FDA. 
2. Extensive clarifications required to understand the anticipated effectiveness in the 
different relevant sub-populations: Target; high disease activity and license. 
3. Re-running the search strategies. 
4. Running a probabilistic sensitivity analysis (PSA) to cross check the model. 
1.8 Key issues  
The proposed licensed population and the high disease activity “Target” population, the focus 
of the clinical effectiveness and economic submissions, were subgroups identified from post 
hoc analyses aimed at identifying patients with the greatest response to belimumab in the 
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pooled phase III trial populations.  Although important as subgroup analyses, the results 
should be viewed with some caution and not assumed to represent the outcome of an 
independent randomised investigation of pre-defined “Target” populations. 
The MS and clarification document presented results for multiple populations (whole 
population from two RCTs, pooled whole populations, pooled Target populations and Target 
population separately by trial).  The results from the BLISS-76 trial, which were less 
supportive of belimumab than those from BLISS-52, are those more generalisable to the UK; 
the economic model employed results pooled across both trials and therefore may somewhat 
overestimate the cost effectiveness of belimumab for the UK population.  
The submission did not present results for the 1mg/kg groups in the two pivotal trials.  Data in 
the public domain,3,5
The manufacturer’s estimate of the number of Target population patients in the UK was based 
on the proportion of such patients at baseline in the BLISS trials; this will probably be an 
underestimate because SLE is a relapsing and remitting disease and the number of patients 
likely to reach Target population status at some stage in their disease will accumulate through 
time. 
 although not formally tested statistically, indicated that for several 
outcomes, including the primary outcome in the BLISS-76 trial, there was little difference 
between the effect of belimumab in 1mg/kg and 10mg/kg groups. 
The manufacturer’s economic model relied heavily on time to event analyses of the JHU SLE 
cohort.  Based on SELENA SLEDAI scores there was a gross mismatch between JHU cohort 
patients and the populations modelled, the former had far less severe disease, especially in 
comparison to the Target population.  To allow for this mismatch a major adjustment was 
required in modelling; the manufacturer’s justification for the type of adjustment adopted was 
that a similar procedure had been explored in cardiovascular studies for the prevention of 
cardiovascular disease (CVD).8
Participants in the 52 and 76 week pivotal RCTs experienced a relatively narrow range of 
SLE manifestations, predominantly in musculoskeletal, cutaneous and serological domains.  
The economic analysis used trial changes in SELENA SLEDAI scores for these patients in 
order to model long term accumulation of organ damage in many other systems.  The 
reliability of this procedure is again difficult to gauge and was referenced in the MS with a 
single analysis published in 1999.
  The robustness of the manufacturer’s approach in this respect 
is difficult to gauge.  
9 
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2 BACKGROUND 
2.1 Critique of manufacture’s description of underlying health problem 
 
The manufacturer provides an adequate description of the treatment pathways for patients 
with SLE.  These are presented MS section 2 (Page 39).  
The ERG is of the opinion that the manufacturer’s summary of the disease context and 
available treatments for patients with SLE is reasonable. 
2.2 Critique of manufacturer’s overview of current service provision 
The MS executive summary and MS section 2 adequately describe the aims and modes of 
treatment (Pages 17 to 18).  The key points, taken from the MS, are as follows: 
 
Treatments aim to: match treatment to an accurate diagnosis of the extent of organ 
involvement; maintain an appropriate level of therapy to control or halt the inflammatory 
disease activity while minimising side-effects and risk of infection; prevent further organ 
damage; maintain a patient’s daily function and quality of life. 
 
Currently a range of treatments (including NSAIDs, corticosteroids, immunosuppressants and 
antimalarials) are variously used either alone or in different combinations, constituting 
standard of care (SoC).  The MS documents that current SoC may be associated with 
undesirable effects e.g. from chronic use of steroids or side effects associated with 
immunosuppressants.  The MS points out that many treatments are not licensed for use in 
SLE and that a significant number of patients with advanced SLE do not respond to current 
treatments even at high doses”.  Patients with more severe, highly active SLE are usually 
managed in tertiary centres and may routinely receive rituximab.  
 
Currently there is no accepted SLE treatment algorithm and no relevant NICE guideline 
exists. Agreeing on best practice poses a significant challenge owing to the heterogeneous 
nature of SLE. 
 
The manufacturer has estimated the number of patients presenting with SLE in England and 
Wales who would be eligible for treatment with belimumab (see MS Table 2.2).  Taking 
13,198 as the number of patients with active SLE in England and Wales, the MS calculated 
that 92.5% of these are adults.  The estimated number eligible for belimumab according to the 
“proposed license indication” was then based on the proportion of patients (52%) in the 
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pivotal phase III trials who fitted the criteria defining the “proposed license population” 
giving a total of 6,348 (i.e. 0.925 * 0.52 * 13,198).  This proposed license population 
exhibited a higher level of serological disease than the total Phase III populations.  However 
the MS further submitted that NICE should actually consider belimumab for a subgroup of the 
“proposed licence population”.  This population was a narrower population of high disease 
activity patients termed the “Target population”, representing 34% of the patients in the Phase 
III trials, giving an estimated number of 4,151 patients in England and Wales (i.e. 0.925 * 
0.34 * 13,198).   
 
The manufacturer’s calculations should be viewed with some caution because the Phase III 
trials upon which they are based were international studies in which UK patients were a very 
small minority, and because the actual proportions of “proposed license population” and 
“Target population” patients in these trials will reflect the vagaries of trial recruitment rather 
than the distribution of these patients in the countries from which they were selected. 
 
The manufacturer’s estimate of the cost to the NHS of treating the “Target population” in year 
one assumed 50% usage of belimumab (i.e. 2,075 patients) and came to ********* under the 
manufacturer’s proposed patient access scheme (PAS).  The manufacturer’s estimate of the 
number of eligible patients rose by 346 in year two, and then by 137 for each of the next three 
years to year five in which the estimated cost to NHS was **********. 
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3 CRITIQUE OF MANUFACTURER’S DEFINITION OF 
DECISION PROBLEM  
Table 1 shows the MS decision problem with rationale for deviations from the NICE scope.  
Table 1: Manufacturer’s indicated scope (from MS Table 4.1) 
 Final scope issued 
by NICE 
Decision problem addressed in 
the submission 
Manufacturer’s Rationale if different 
from the scope 
Population  Adults with active 
autoantibody-positive 
systemic lupus 
erythematosus 
Phase 3 Trial Population 
Adults with active autoantibody-
positive systemic lupus 
erythematosus. 
High Disease Activity Subgroup 
Adults with active autoantibody-
positive systemic lupus 
erythematosus with evidence for 
serological disease activity (low 
complement, positive anti-dsDNA) 
and SELENA-SLEDAI ≥ 10. 
 
Mindful of NHS resources, the proposed 
population of interest to this decision problem 
is a subgroup of the Phase 3 trial population 
which applies the additional criteria of 
evidence for serological disease activity (low 
complement, positive anti-dsDNA) and 
SELENA-SLEDAI disease activity score of ≥ 
10 
This subgroup experienced an additional 
treatment effect to belimumab over and above 
the Phase 3 trial population and is aimed at 
identifying SLE patients at the greatest risk of 
experiencing long-term organ damage.  
Intervention Belimumab as an add 
on to standard 
therapy 
Belimumab 10mg/kg administered 
as an intravenous infusion over a 
one hour period on days 0, 14 and 
28, and at 4 week intervals 
thereafter in addition to standard 
therapy. 
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 Final scope issued 
by NICE 
Decision problem addressed in 
the submission 
Manufacturer’s Rationale if different 
from the scope 
Comparator(s) • Standard therapy 
alone 
For people in whom 
it is considered 
appropriate: 
• Rituximab plus 
standard therapy 
• Cyclophosphamide 
plus standard therapy 
• Standard therapy which comprises 
(alone or in combination): 
antimalarials, NSAIDs, 
corticosteroids, or other 
immunosuppressants 
(azathioprine, methotrexate, and 
mycophenolate mofetil) 
• Rituximab plus standard therapy 
for the more severe SLE sub-
population 
Despite failing to meet primary or secondary 
outcomes in a Phase 2/3 SLE trial, rituximab, 
is used in the more severe patient population 
in addition to standard therapy. Therefore, 
rituximab plus standard therapy is a relevant 
comparator. The patient population and 
outcomes measured are not comparable to 
those in the belimumab trials. Therefore, 
conducting indirect comparisons of efficacy 
are problematic and have not been 
incorporated into the cost-effectiveness model. 
However, the benefits of belimumab 
compared with rituximab will be discussed in 
the written submission. 
Cyclophosphamide, whilst used in the more 
severe patient population, is largely reserved 
for the treatment of lupus nephritis. This is not 
the proposed Target population for 
belimumab, therefore, cyclophosphamide plus 
standard therapy is not a relevant comparator. 
In addition, adverse effects associated with 
long-term exposure to cyclophosphamide 
including bladder cancer, bone marrow 
suppression, haematologic malignancies, 
infections, myelodysplasia, and infertility 
limit the appropriateness of cyclophosphamide 
given that a high proportion of patients are 
women of childbearing age. 
33 
 
 Final scope issued 
by NICE 
Decision problem addressed in 
the submission 
Manufacturer’s Rationale if different 
from the scope 
Outcomes The outcome 
measures to be 
considered include:  
• disease activity 
• incidence and 
severity of flares 
• mortality 
• health-related 
quality of life, 
including fatigue 
• adverse effects of 
treatment 
The outcome measures included in 
the cost-effectiveness model are: 
• Disease activity  
• Incidence and severity of flares 
• Mortality  
• Health-related quality of life 
• Disease progression in terms of 
long-term organ damage – As 
discussed at the scoping workshop, 
although not collected in the 
clinical trials, long-term organ 
damage will be considered in the 
assessment of cost-effectiveness 
based on modelled data from the 
Johns Hopkins Lupus Cohort 
Additional endpoints discussed in 
the written submission and not 
included in the health economic 
model are:  
• Fatigue - In the Phase 3 trials this 
was measured using the FACIT-
Fatigue instrument and was 
reported as the mean change in 
scale score at Weeks 12, 24, 52 and 
76 (BLISS-76 only) 
• Adverse events of treatment  
Adverse effects of treatment have not been 
included in the base case economic model as 
significant differences between treatments 
were not noted from the two pivotal Phase 3 
trials. The side effect profile of belimumab 
will be discussed in the clinical section of the 
submission. 
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 Final scope issued 
by NICE 
Decision problem addressed in 
the submission 
Manufacturer’s Rationale if different 
from the scope 
Economic 
analysis 
The reference case 
stipulates that the 
cost effectiveness of 
treatments should be 
expressed in terms of 
incremental cost per 
quality-adjusted life 
year. 
The reference case 
stipulates that the 
time horizon for 
estimating clinical 
and cost effectiveness 
should be sufficiently 
long to reflect any 
differences in costs or 
outcomes between 
the technologies 
being compared. 
Costs will be 
considered from an 
NHS and Personal 
Social Services 
perspective. 
• Cost effectiveness will be 
expressed in terms of incremental 
cost per quality-adjusted life year 
• The time horizon for the model 
will be lifetime 
• Costs will be considered from an 
NHS and Personal Social Services 
perspective 
Not applicable. 
Subgroups to 
be considered 
None outlined in 
scope. 
See population section above. See population section above. 
Special 
considerations, 
including issues 
related to 
equity or 
equality  
None outlined in 
scope. 
It will be important to acknowledge 
the innovative nature of belimumab 
in the treatment of SLE.  
There is a limitation with the 
current cost per QALY 
methodology not able to capture all 
the benefits of belimumab (i.e. 
avoidance of corticosteroids, impact 
of fatigue and loss of productivity). 
SLE has a significantly greater 
impact on certain ethnic groups and 
is most prevalent in woman of 
childbearing age. 
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3.1 Population  
 
The manufacturer’s scope specified two populations: the Phase III trial population (adults 
with active autoantibody-positive SLE), and a High Disease Activity Subgroup (HDAS). 
The submitted clinical effectiveness evidence came from two multicentre international Phase 
III RCTs (BLISS-52 and BLISS-76).  The geographical location of study centres differed 
considerably between trials.  In BLISS-52 there were 90 centres: in 13 countries in Latin 
America there were 38 centres (Argentina, Brazil, Chile, Colombia and Peru), in Asia-Pacific 
there were 41 centres (Australia, Hong Kong, India, Korea, Philippines and Taiwan) and in 
Eastern Europe there were eleven centres (Romania and Russia).  In BLISS-76 there were 136 
centres in 19 countries in North America (Canada, Costa Rica, Mexico, Puerto Rico and 
USA) and Europe (Austria, Belgium, Czech Republic, France, Germany, Israel, Italy, The 
Netherlands, Poland, Romania, Slovakia, Spain, Sweden and UK); North America (65 
centres) and Europe (62 centres) contributed 93% of the centres in BLISS-76.  These 
geographical differences were reflected in racial differences between the populations in the 
two trials.  Although both trials included adults with auto-antibody positive active SLE it 
appears clear that the population in BLISS-76 is more likely to be similar to that in England 
and Wales than that from BLISS-52.  It is reasonable to assume that the results from BLISS-
76 will be more generalisable to the UK.  This would be of little consequence if the clinical 
results were consistent between trials; however this was not so for some outcomes and in 
general very little clinical benefit was observed in BLISS-76 compared to some benefits in 
BLISS-52. 
The manufacturer’s scope also specified a HDAS termed the “Target” population and 
described as the focus of the submission.  The identification of the Target population, and the 
evidence for clinical effectiveness of belimumab in the Target population, arose from post hoc 
analyses of the two BLISS trials.  The rationale for this deviation from NICE scope was 
largely on economic grounds in that cost effectiveness was more favourable.  Because the 
BLISS-76 trial subpopulation is more likely to match high disease activity patients in the UK 
than the BLISS-52 subpopulation, it is arguable that the BLISS-76 Target population is the 
most appropriate.  
The Target population was defined as: “Adults with active autoantibody-positive systemic 
lupus erythematosus with evidence for serological disease activity (low complement, positive 
anti-dsDNA) and SELENA-SLEDAI ≥ 10” [MS Page 53].  There are undoubtedly patients in 
the UK who correspond to the Target population; however, according to expert clinical 
opinion, the SELENA SLEDAI is not commonly used to define high disease activity and it 
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may be difficult to estimate the number of patients in the UK who fit this definition.  The 
manufacturer’s estimate of 4,150 patients across England and Wales is presented on Page 310 
of the submission.  
The population proposed in the license application is a high disease activity subgroup, termed 
“population A” in the submission, and defined in the Summary of Product Characteristics 
(SPC) in Box 2. 
Box 2: Proposed license population 
“...adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with 
a high degree of disease activity (e.g. positive for anti dsDNA, low complement) despite 
standard therapy.” 
 
The submission presented very little evidence about the effectiveness of belimumab in the 
proposed licensed population (only one Figure was given (MS Figure 5.3; Page 96).  The 
submission estimated that there are 6,348 “population A” patients in England and Wales.  The 
Target population represents a subpopulation (~64.5%) of population A patients. 
3.2 Intervention 
The intervention described in the submission matches that in the NICE final scope 
Belimumab is a human IgG1λ monoclonal antibody, expressed in a murine cell line that binds 
to soluble human B-lymphocyte stimulator (BLyS) and inhibits its biological activity.  BLyS 
influences differentiation, survival and activation of B lymphocytes.  In the proposed license 
Belimumab is delivered at 10mg/Kg by a one hour IV infusion.  It is an add-on therapy to 
standard of care that commonly consists of a range of treatments (NSAIDs, corticosteroids, 
immunosuppressants and antimalarials) used alone or in various combinations. 
Belimumab awaits marketing approval in Europe.  Application was filed with the European 
Medicines Agency (EMA) on 4th June 2010 and is now under review via the Centralised 
procedure.  CHMP opinion was  expected in May 2011 followed by a Commission decision 
on European marketing authorisation in July 2011.  ************************** 
******************* **************************************. 
In March 2011 the USA FDA approved belimumab for reducing disease activity in adult 
patients with autoantibody positive SLE.  This is a wider population than that encompassed in 
the European license application according to the SPC document submitted by the 
manufacturer. 
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3.3 Comparators 
Three comparators were identified in the NICE final scope: standard of care (SoC), rituximab, 
and cyclophosphamide.  The clinical effectiveness and economic sections of the submission 
did not quantitatively consider rituximab or cyclophosphamide as comparators, only SoC was 
formally assessed. 
The MS justifies the exclusion of rituximab as a comparator on the following grounds:  
• There has been no head to head trial of rituximab versus belimumab; 
• Outcome measures used in rituximab and belimumab trials have differed to the extent that 
there is little possibility of undertaking meaningful indirect comparison meta-analysis; 
• Rituximab has not been shown to be effective versus SoC whereas belimumab has, 
therefore by implication belimumab is unlikely to be less effective than rituximab; 
• ************************************************************************
************************************************************************
************************************************************************
******** 
Regarding effectiveness, although the primary end point was not reached in the Phase II/III 
rituximab RCT (EXPLORER)10
A literature search undertaken by ERG revealed published information on SLEDAI and SF 36 
changes in the EXPLORER trial which might have been used for comparison with the BLISS 
trials.  Furthermore, RCTs for both drugs recorded BILAG changes thus offering the potential 
for an indirect comparison to be undertaken
 the ERG’s clinical expert indicated that the EXPLORER end 
point was more stringent than that in the BLISS trials because it registered a sustained 
response (once a patient was classified as a non-responder they remained so classified for the 
remainder of the trial), whereas the primary end point in BLISS was a group response in 
which a non-responder could later become classified as a responder for the primary end point 
at week 52.   
10,11
The manufacturer responded with further justification as shown in 
. For these reasons the ERG requested 
clarification regarding the manufacturer’s justification for not considering rituximab as a 
comparator. 
Box 3. 
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Box 3: Justification for no formal comparison of belimumab and rituximab 
The main reason for this decision relates to important differences in patient selection and 
consequently the treatment management protocols employed in the studies, ……………..   
The patients in the rituximab Phase 2/3 trial had significant and acute disease activity at entry 
to the study; 53% had at least one BILAG A score (severe disease activity) and a further 28% 
had at least 3 BILAG B scores (please note that although a BILAG B score represents 
moderate disease activity, the presence of 3 BILAG B scores in some organs indicates more 
severe disease activity).  Initially, patients were receiving very high daily doses of prednisone 
(mean 45.9 mg ±16.4mg) to treat the significant level of disease activity and this dose was to 
be tapered where possible during the trial.  In addition, all patients were receiving one 
immunosuppressant at study entry.  In contrast, the patients in the BLISS studies were a 
broader population and not all patients were experiencing major disease flares at study entry 
requiring the very high doses of steroids seen in the rituximab trial.  Even in the high disease 
activity subgroup (Target population), only 19.3% had at least one BILAG A score at 
baseline, the average prednisone or equivalent dose was 12.3 mg ± 9.6mg and 53% were on 
an immunosuppressant.  In particular, we believe that the differences in the use of steroids 
and immunosuppressants to manage disease activity between the rituximab and BLISS trials 
and consequently the differences in the type of response observed in the placebo arms render 
the studies incomparable. 
 
Justification for excluding cyclophosphamide as a comparator was stated as shown in Box 4.  
Box 4: Justification for no formal comparison of belimumab and cyclophosphamide 
Cyclophosphamide, whilst used in the more severe patient population, is largely reserved for 
the treatment of lupus nephritis.  This is not the proposed Target population for belimumab”. 
 
The submitted SPC is shown in Box 5. 
Box 5: From the submitted SPC document  
There are no or insufficient data available on the effects of Benlysta in patients with severe 
active lupus nephritis or severe active central nervous system lupus.  Therefore, Benlysta 
cannot be recommended to treat these conditions. 
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3.4 Outcomes  
The NICE and manufacturer’s scopes state that the outcome measures to be considered 
include: disease activity, incidence and severity of flares, mortality, HRQoL including 
fatigue, and adverse effects of treatment.  All these are reported in the MS. 
The primary outcome in the BLISS trials was the proportion of responders at week 52.  To 
estimate the proportion of responders a novel composite outcome measure, the SLE 
Responder Index (SRI) was introduced.  The SRI was developed in conjunction with the FDA 
to be used in the BLISS trials.  The SRI outcome aims to detect improvement in disease 
activity in terms of resolution of an SLE manifestation or manifestations (estimated using the  
SELENA SLEDAI instrument) while guarding against the possibility that this improvement 
might mask detrimental involvement of new organ systems (estimated using the BILAG) 
index) or an overall deterioration in well being (estimated using a PGA). 
These three components, SELENA SLEDAI and BILAG and PGA had to be satisfied 
according to pre-specified requirements before a patient could be classified as a responder.  
These requirements were as follows:  
• A ≥ 4 point reduction in the SELENA-SLEDAI score compared to baseline; 
• No worsening (an increase of no more than 0.3 points) in PGA score compared to 
baseline; 
• No new BILAG A organ domain scores or no 2 new BILAG B organ domain scores 
at time of assessment compared to baseline.  
 
The SELENA SLEDAI instrument detects the presence of a manifestation of SLE disease.  It 
encompasses 24 individual SLE manifestations, each with a weighted score from 1 to 8 
points.  Assessment relates to the preceding 10 days.  Each manifestation must be related to 
lupus.  A summed score of ≥ 6 across manifestations is considered active disease.  A decrease 
of 4 points relative to previous assessment is thought to equate to a clinically meaningful 
improvement.  For most manifestations there is no intermediate score, the item is registered as 
presence or absent so that a SELENA SLEDAI item generally can only improve by its 
resolution.  The tool is therefore a measure of improvement and is not designed to assess 
worsening of a manifestation once present.  The SRI uses the BILAG and PGA as measures 
of worsening.   
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The BILAG CLASSIC instrument includes 86 items grouped into 8 organ systems, general (5 
items), mucocutaneous (18 items), neurological (15 items), musculoskeletal (9 items), 
cardiorespiratory (12 items), vasculitis (8 items), renal (11 items), and hematological (8 
items)2
3.5 Economic analysis  
.  A score is calculated for each system depending on the SLE clinical manifestations 
(or signs and symptoms) present and whether they are new, worse, the same, improving, or 
not present in the last 4 weeks compared with the previous 4 weeks.  A BILAG A score is 
given for a disease manifestation considered sufficiently severe to normally require high-dose 
steroids (prednisolone > 20 mg/day or equivalent) and/or immunosuppressive / cytotoxic 
agents under normal circumstances.  A more moderate manifestation, which it would be 
considered appropriate to treat with lower dose steroids, antimalarial drugs or NSAIDs, 
constitutes a BILAG B score.  A mild symptomatic manifestation that would require only 
symptomatic therapy (e.g. analgesics and NSAIDs) constitutes a BILAG C score.  If there are 
no current symptoms, but the system has previously been involved, then a BILAG D score is 
recorded, while if the system has never been involved, a BILAG E score is assigned. 
The manufacturer’s economic analysis is in line with that stipulated in the NICE scope.  The 
MS presented its economic assessment in terms of incremental cost per QALY and has 
modelled outcomes using a lifetime horizon. Costs are considered from an NHS and PSS 
perspective. 
3.6 Other relevant factors  
Special considerations and issues raised in the manufacturer’s scope include: 1) the innovative 
nature of belimumab for SLE; 2) the inability of the utility method to capture the QoL of SLE 
patients sufficiently sensitively; and 3) the impact of SLE on particular ethnic groups and on 
women of childbearing age.  The proposed SPC specifies that belimumab should not be 
administered to pregnant women or to those planning pregnancy and therefore the special 
consideration relating to women of childbearing age appears to be of marginal relevance. 
There were no issues identified in the NICE scope. 
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4 CLINICAL EFFECTIVENESS 
4.1 Critique of manufacturer’s systematic review 
The objective of the manufacturer’s systematic review was stated in Box 6 (MS Page 60). 
Box 6: Objective of systematic review 
A systematic review of the published literature was conducted to identify all relevant 
published randomised controlled trials (RCTs) for belimumab and relevant comparators in 
SLE. 
4.1.1 Description of manufactures search strategy  
Two clinical literature searches are reported in the MS; one to identify RCTs and one to 
identify observational studies (MS Appendix 2).  The purpose of the latter search was not 
explicitly stated.  The search strategies were of good quality (a summary of the ERG’s 
assessment is in Appendix 2).  The ERG considers it unlikely that the search would have been 
missed relevant studies. 
The searches undertaken by the manufacturer to identify all relevant RCTs were conducted on 
8th December 2010.  Four electronic databases were searched (Embase, Medline, Medline In-
Process, The Cochrane Library).  The search strategy utilised an appropriate combination of 
free-text and thesaurus terms to identify the patient group (systemic lupus erythematosus), the 
intervention (belimumab) and the comparators.  A date limit and a search filter were applied 
to the Embase and Medline searches to limit them to studies published after 1970 and to a 
particular type of evidence (RCTs), which was appropriate.  The search filter used in Medline 
closely resembles the SIGN RCT filter12
The searches undertaken by the manufacturer to identify non-RCT evidence were conducted 
on 3rd March 2011.  Four electronic databases were searched (Embase, Medline, Medline In-
Process, The Cochrane Library).  The search strategy utilised an appropriate combination of 
free-text and thesaurus terms to identify the patient group (systemic lupus erythematosus) and 
the intervention (belimumab).  Terms to identify comparators were not included.  A search 
filter was applied to the Embase and Medline searches to limit them to a particular type of 
evidence (observational studies), which was not appropriate in Medline in light of the small 
, but misses several lines relating to publication type 
indicating that an old version may have been used.  No language restrictions appear to have 
been applied.  In addition to database searches, hand searching was undertaken of reference 
lists; the proceedings of three relevant conferences between 2006-2010 and four clinical trial 
registers (Clinical Trials, International Standard Randomised Controlled Trial Number 
(ISRCTN) Register, UK Clinical Trials Gateway, metaRegister of Controlled Trials).   
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number of studies retrieved before the filter was applied (66).  The search filter used was the 
SIGN observational study filter12
The database search alone yielded 3774 references (MS Fig 5.1).  It was not possible for the 
ERG to attempt to reproduce the manufacturer’s study selection procedure because of the 
large number if publications retrieved and because the description of the manufacturer’s 
selection procedure was unclear (see below).  An independent selection of studies by the 
ERG, effectively a separate systematic review, was not within the ERG remit or feasible 
within time constraints for such a large number of references.   
 No date restrictions appear to have been applied in the 
search strategies themselves, although this is unclear as MS Appendix 6 states that the date 
span of the search is “Medline & Medline In-Process: 1950 to present day and Embase: 1980 
to present day”.  In addition to database searches, hand searching was undertaken of reference 
lists; the proceedings of three relevant conferences between 2006-2010 and two clinical trial 
registers (Clinical Trials, UK Clinical Trials Gateway).  Whilst the ERG was not able to 
check the search results, the search strategies were of adequate quality. 
4.1.2 Inclusion and exclusion criteria used for study selection  
MS Figure 5.1 provides a flow diagram for the selection of studies.  With regard to selection 
of studies for inclusion, the MS Page 60 states as shown in Box 7. 
Box 7: MS Page 60  
The inclusion and exclusion criteria were chosen to identify all relevant RCTs 
 
Details of these criteria were not clear; they may be those in MS Table 5.1 entitled “Eligibility 
criteria used in search strategy” and shown in Table 2.  However, since ERG could find little 
relationship between the criteria listed and the studies listed as included studies, the ERG 
considers it is possible that MS Table 5.1 (see Table 2) actually represents a summary of the 
search strategy, in which case a formal statement of inclusion criteria was not submitted.  
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Table 2: MS Table 5.1 Page 61 Eligibility criteria used in search strategy  
 Clinical effectiveness 
Inclusion criteria Population 
- Adults (≥ 18 years) with systemic lupus erythematosus (SLE); 
studies were also included for SLE patients with kidney 
involvement 
- Interventions 
o Belimumab 
o Rituximab 
o Mycophenolate mofetil 
o Prednisolone and other steroids 
o Hydroxychloroquine and other antimalarials 
o Azathioprine 
o Cyclophosphamide 
o Methotrexate 
Outcomes 
- Change in SELENA-SLEDAI score (Safety of Estrogens in Lupus 
Erythematosus National Assessment Systemic Lupus Erythematosus 
Disease Activity Index) 
- Change in BILAG score (British Isles Lupus Assessment Group) 
- Change in PGA (physician global assessment scale) 
- Change in SLICC score (Systemic Lupus International 
Collaborating Clinics) 
- Change in number/frequency of flares 
- Quality of life 
- Reduction in steroid use  
- Medical resource utilisation 
- Fatigue (e.g. FACIT, Functional Assessment of Chronic Illness 
Therapy score) 
- Adverse events including: 
o Incidence and severity (grade) of all adverse events (AEs) 
reported 
o Withdrawals due to AEs 
o Mortality 
o SAEs 
Study design 
- RCT, both cross-over and parallel, blinded and open-label designs 
Language restrictions 
- Only English publications (if only the abstract was in English, this 
would be included) 
Exclusion criteria Population 
- Studies enrolling patients with only active lupus nephritis were 
excluded 
Interventions 
- Non-specified 
Outcomes 
- Non-specified 
Study design 
- Designs other than RCT 
Language restrictions 
- Publications in languages other than English 
 
Thus the MS was unclear about how or if the criteria listed in Table 5.1 were actually applied 
to the publications retrieved from searching; for example, although a search for uncontrolled 
studies was undertaken one of the exclusion criteria stated in Table 5.1 is that non-RCT study 
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designs were to be excluded.  After seeking clarification the ERG remain doubtful that the 
criteria from Table 5.1 were systematically applied because many studies were excluded on 
the basis that they lacked a requirement for patients to have active autoantibody-positive SLE 
or because patients were receiving azathioprine, yet active autoantibody disease is not a 
specified inclusion criterion in Table 5.1 and azathioprine is listed as an included intervention 
rather than an excluded one 
In short the MS and the manufacturer’s response to request for clarification fail to indicate 
clearly the criteria used for study inclusion and exclusion. 
4.1.3 Studies included 
The MS systematic review provided confusing information regarding which studies were 
included and which were excluded.  MS Figure 5.1 and Page 62 of the submission state that 
43 publications were included. These are presented in Box 8. 
Box 8: Statement of the number of publications included 
The number of included publications was 43 (36 full publications plus seven abstracts), 
including eight publications (of four trials) of belimumab and 35 publications of other 
interventions. 
 
The MS provided details of only 11 publications, rather than 43, (submission Tables 5.2, 5.3 
and 5.4).  The ERG sought clarification and a full list of the 43 identified publications was 
supplied together with reasons for exclusion of excluded studies.  This list is reproduced in 
Appendix 3.  The clarification implies that of the 43 publications identified nine were classed 
as “included”. Eight of these were publications on four industry sponsored belimumab studies 
(RCTs: LBSL02, BLISS-52, BLISS-76; and Phase I study LBSL01), while the ninth 
described an RCT of rituximab conducted in adults with moderate-to-severe active SLE10
The clarification list of 43 publications was unclear on the status of the two 
hydroxychloroquine publications shown in MS Table 5.3 and described therein as “linked 
publications of competitor drugs that were also included in the systematic review.”  In the 
clarification list as “Reason for exclusion” the entry for both studies reads “Withdrawal study 
in patients with stable SLE”; this may represent a reason for exclusion.  The ERG searched 
the MS text for any further reference to these two hydroxychloroquine publications but could 
find none. 
 
which was not listed in the MS as an included study.   
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A publication describing the industry phase I study LBSL01 was listed as “included” but this 
study was not discussed in the MS.  The manufacturer’s stated reason for this is reproduced in 
Box 9. 
Box 9: Reasons for not including study LBS01 
As this was a small (n=70) exploratory study of limited duration, designed primarily to 
demonstrate safety and tolerability in humans, it does not reflect the proposed clinical use of 
belimumab and therefore will be excluded from further discussion. 
 
4.1.3.1 Important included studies 
No RCTs were found that compared belimumab with an alternative active intervention.  The 
most important belimumab studies identified were three industry-sponsored RCTs conducted 
in adults comparing belimumab plus standard care with placebo plus standard care (trials:  
LBSL0213, BLISS-527, and BLISS-76) together with an uncontrolled extension (LBSL99) of 
LBSL02.  One rituximab RCT (EXPLORER trial10
Table 3
) was included in narrative discussion of 
potential comparators.  Brief details of these studies are shown in .   
Table 3: Important studies included in manufacturer’s submission 
ID 
Year ψ 
Study type Study  
duration 
Patient 
Age, yr 
Treatment   
Groups ¥  
N  
(ITT) 
Countries 
(% enrolled) 
LBSL02 
2006 
Phase 2  
Efficacy and 
Safety  
52 wk 20 - 75 Bel 1mg/kg IV**  
Bel 4mg/kg IV*  
Bel 10mg/kg IV*  
Placebo**  
114  
111  
111  
113  
USA (98%) 
Canada (2%)  
BLISS-76 
2009 
Phase 3  
Efficacy and 
Safety  
76 wk 18 - 73 Bel 1mg/kg IV*  
Bel 10mg/kg IV*  
Placebo** 
271 
273 
275 
USA and Canada (53%)  
West Europe (25%) 
East Europe (11%)  
Latin America (11%) 
BLISS-52 
2009 
Phase 3  
Efficacy and 
Safety  
52 wk 18 - 71 Bel 1mg/kg IV*  
Bel 10mg/kg IV*  
Placebo** 
288 
290 
287 
Latin America (50%) 
Asia (38%) 
East Europe and Australia 
(13%) 
LBSL99 
2006 
Safety  
extension of 
L02  
  Bel 10mg/kg IV* 296 USA and Canada (100%) 
       
EXPLORER Phase 2/3  
Efficacy and 
Safety 
52 wk 16 - 75 Rit 1000mg# 
Placebo*** 
169 
88 
North America (100%) 
ψ Year study subject enrolment ended 
¥  All treatments were additional to standard care 
*  Bel = Belimumab 1, 4, or 10mg/kg administration by IV infusion on days 0, 14, 28, and every 28 days thereafter 
** Placebo by IV infusion on days 0, 14, 28, and every 28 days thereafter 
***  Placebo by IV infusion on days 0, 14, 167 and181 
#  Rit = Rituximab on days 0 and 14   
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4.1.4 Details of any relevant studies that were not included  
The ERG conducted a systematic search for randomised controlled trials of belimumab and of 
rituximab; no relevant studies additional to those included in the MS were identified. 
4.1.5 Summary statement on MS systematic review  
The manufacturer’s systematic review was confused.  Although the search strategy was of 
good quality the use of the retrieved references to identify relevant studies for inclusion was 
not well described.  The ERG remains unclear regarding the methods used and the list of 
included studies both in the MS, and the response to request for clarification was ambiguous.  
Despite these non-systematic aspects, studies relevant to the decision problem have been 
identified and the studies presenting evidence on belimumab appears complete, although a 
rigorous check would require a separate and independent systematic review. 
4.2 Submitted clinical evidence results  
4.2.1 Scope and synopsis of the studies providing clinical evidence  
Belimumab was administered as additional therapy to “standard of care” and was compared to 
placebo plus “standard of care”.  No formal comparison of belimumab vs any other active 
intervention (rituximab) was attempted. 
Four belimumab studies provided clinical evidence: three RCTs: LBSL02, BLISS-52, and 
BLISS-76, and an uncontrolled study (LBSL99) that was an extension of LBSL02.  MS 
Tables 5.4 and 5.5 provide full details of these studies.   
• A phase II RCT (LBSL02) with four patient groups receiving infusions of placebo 
(n=113), or 1mg (n=114) or 4mg (n=111) or 10mg (n=111) belimumab/kg.  A peer 
reviewed full publication of trial LBSL02 appeared in 2009.13
• Two phase III RCTs, BLISS-52 (n=865) and BLISS-76 (n=819), conducted 
simultaneously each with three randomised groups receiving placebo or 1mg/kg or 
10mg/kg belimumab infusions. A peer reviewed full publication of the BLISS-52 trial 
appeared in 2011,
  
7
• LBSL99, a Phase II Continuation Study of the phase II RCT LBSL02. 
 BLISS-76 has yet to appear as a peer reviewed full publication. 
Table: 4 summarises the main features of the four studies.  Further details of study design and 
patient demography are discussed in the following section of this report. 
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Table: 4 Belimumab studies for safety and effectiveness evidence  
ID 
Year* 
Study type Study  
duration 
Patient 
Age, yr 
Treatment   
Groups ¥ # 
N  
(ITT) 
Countries 
(% enrolled) 
LBSL02 Phase 2 
Efficacy and 
Safety  
52 wk 20-75 Bel 1mg/kg IV  
Bel 4mg/kg IV  
Bel 10mg/kg IV  
Placebo  
114  
111  
111  
113  
USA (98%) 
Canada (2%)  
BLISS-76 Phase 3 
Efficacy and 
Safety  
76 wk 18 - 73 Bel 1mg/kg IV  
Bel 10mg/kg IV  
Placebo 
271 
273 
275 
US and Canada (53%) 
West Europe (25%) 
East Europe, (11%)  
Latin America (11%) 
BLISS-52 Phase 3 
Efficacy and 
Safety  
52 wk 18 - 71 Bel 1mg/kg IV  
Bel 10mg/kg IV  
Placebo 
288 
290 
287 
Latin America (50%) 
Asia (38%) 
East Europe and 
Australia (13%) 
LBSL99 Safety extension 
of  LBSL02  
   Bel 10mg/kg IV 296 USA and Canada (100%) 
*  Year study subject enrolment ended 
¥  All treatments were additional to standard care 
#  Bel = Belimumab 1, 4, or 10mg/kg administration by IV infusion on days 0, 14, 28, and every 28 days 
thereafter 
For the assessment of safety, the submission pooled data from all belimumab arms of the 
three RCTs (LBSL02, BLISS-76, and BLISS-52 providing data for1458 patients) and from all 
placebo arms (providing 675 patients).   
Although all patients in study LSBL02 had a history of anti DNA-antibodies, approximately 
30% lacked positive auto-antibody status at recruitment.  Consequently the MS excluded this 
study from the clinical effectiveness analyses and it was only included for assessment of 
safety.  For the assessment of clinical effectiveness the submission presented results from 
BLISS-52 and BLISS-76 phase III trials for the placebo and 10mg/kg belimumab arms only.  
The explanation for excluding results for the 1mg/kg dose regimen was stated in Box 10 (MS 
Page 102). 
Box 10: Manufacturer’s reason for not including results for the BLISS 1mg/kg groups 
Whilst a 1mg/kg dose was examined in the Phase III studies, we will only present results for 
the 10mg/kg belimumab dose as this is the dose submitted for Marketing Authorisation. 
 
Since results for the 1mg/kg arms of the trials can provide information about consistency of 
response and the existence of a dose response relationship, when considered relevant the ERG 
have made use of public domain data provided in FDA documents pertaining to the USA 
licensing application for belimumab3,5
The submission compared clinical effectiveness of 10mg/kg belimumab vs placebo for the 
following populations:  
. 
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• BLISS-52 alone 
• BLISS-76 alone  
• BLISS-52 plus BLISS-76 populations pooled across trials  
• A HDAS (the “Target population”) pooled across BLISS-52 and BLISS-76 trials 
As results for the Target population in BLISS-52 and BLISS-76 were not supplied separately 
in the original submission, these results were requested and supplied during the clarification 
process.  Results for Target population patients who received the 1mg/kg regimen are not in 
the public domain and the manufacturer stated that they were unable to supply these results 
within the time constraints of the clarification process because of the large amount of other 
information that was requested. 
4.2.2 Description and critique of manufacturers approach to validity assessment  
In the main text of the MS, validity assessment of the BLISS trials consisted only of a 
tabulated quality assessment checklist (MS Table 5.14 page 100); this is reproduced in the 
two left hand columns in Table 5 below.  Further details were provided in MS Appendix 3 
(BLISS trials) and in MS Appendix 9 (adverse event studies).  The MS was not clear about 
how their assessment was conducted, or by who, or whether it was based upon the full HGS 
clinical trial reports or on other information.   
A single ERG reviewer undertook an independent quality assessment of the Phase III trials.  
The MS provided insufficient information for full quality assessment and so additional 
information in FDA documents3,5and in the Navarra publication14
Table 5
 of the BLISS-52 trial was 
also utilised.  The assessment is summarised in  below.  
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Table 5: Quality assessment and ERG critique of BLISS-52 and BLISS-76 trials 
Question MS 
rating  
ERG 
rating 
ERG comment 
Was randomisation carried out 
appropriately? 
Yes Yes MS states randomisation was stratified and MS and 
Navarra14state that a computer generated randomisation 
schedule was created. 
Was the concealment of 
treatment allocation adequate? 
Yes Yes Unmasked pharmacist prepared unmarked treatment 
infusion bags; but MS not explicit whether the creation 
and ownership of the randomisation schedule was handled 
by a separate group who had no direct involvement in the 
study.  
Were the groups similar at the 
outset of the study in terms of 
prognostic factors?  
Yes Yes Agree 
Were the care providers, 
participants and outcome 
assessors blind to treatment 
allocation? 
Yes Yes MS states:  patients, investigators, study coordinators, 
and sponsors were masked to treatment assignment 
during intravenous administration of the drug and 
assessment of the patients every 4 weeks during the 52-
week trial. But methods not described and adherence to 
blinding not investigated. 
Were there any unexpected 
imbalances in drop-outs between 
groups? 
No No Table 9 of the FDA briefing package3provides the relevant 
information 
Is there any evidence to suggest 
that the authors measured more 
outcomes than they reported? 
No No The submission did not report outcome results for the 1 
mg/kg treatment arms of the trials.  For the total 
population these are available in the public domain. 
Did the analysis include an 
intention-to-treat analysis? If so, 
was this appropriate and were 
appropriate methods used to 
account for missing data? 
Yes No Analysis was done in a modified intention-to-treat (mITT) 
population of all randomly assigned patients who received 
a dose of belimumab.  The mITT analysis was performed 
according to the treatment that a subject was randomized 
to receive, regardless of actual treatment received. This 
was appropriate. 
Adapted from Centre for Reviews and Dissemination (2008) Systematic reviews. CRD’s guidance for undertaking 
reviews in health care. York: Centre for Reviews and Dissemination 
 
Trial conduct 
The BLISS trials were large, international, multi-centre, double-blind, placebo-controlled 
studies with three parallel groups, that employed a novel primary outcome measure which 
required proficiency training for assessors.  According to the HGS FDA briefing document.5
 “they were conducted under Special Protocol Assessment agreement with the FDA with 
special agreement with respect to selected patient population, primary end point, sample size, 
stratification factors, statistical methods and concomitant medication controls”. 
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Randomisation 
The MS Appendix 3 provided the following description of randomisation:  
“Patients who underwent all screening procedures and met the entry criteria were enrolled in 
the study and assigned to treatment by use of a central interactive voice response system. 
Patients were randomised in a 1:1:1 ratio to placebo, or belimumab 1 mg/kg or 10 mg/kg. 
Randomisation was stratified according to the SELENA-SLEDAI score (6–9 vs ≥10), 
proteinuria concentration (<2 g/24 h vs ≥2 g/24 h) at screening, and ethnic origin (African 
descent or indigenous American [Alaska Native or American Indian from North, South, or 
Central America] vs other).” 
ERG note that in the BLISS-52 trial 867 patients were randomised, and that 142 screened-
patients who met inclusion criteria were not randomised; the corresponding numbers for 
BLISS-76 were: 826 randomised and 135 not randomised (data from MS Figures 5.4 and 5.5). 
Allocation concealment 
MS Appendix 3 states:  
“An unmasked pharmacist prepared unmarked infusion bags for administration. Belimumab 
and placebo were both prepared as sterile and lyophilised vials (5 mL for belimumab 1 
mg/kg; 20 mL for belimumab 10 mg/kg and placebo), and contained the same formulations, 
except without the active drug for placebo.”  
The ERG considers that the above provides some assurance that allocation concealment was 
maintained but notes the difficulties of maintaining concealment across large multi-centred 
studies. 
Baseline balance between treatment groups 
Data provided in the MS and in FDA documents3,5
Blinding of treatment allocation 
 indicates that within each trial there was a 
reasonable balance between known and putative prognostic factor. 
MS Appendix 3 states: 
“Patients, investigators, study coordinators, and sponsors were masked to treatment 
assignment during intravenous administration of the drug and assessment of the patients 
every 4 weeks during the 52-week trial until the database was locked.” 
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The above gives the manufacturer’s description of blinding of care providers, patients and 
outcome assessors to treatment allocation.  There is no mention of methods employed (e.g. all 
potential flares should be adjudicated by a data monitoring board blinded to treatment).  The 
methods for, extent of, and any problems with, blinding were not described.  In the ERG’s 
opinion it is possible that BLISS-52 physician outcomes assessors might have been 
unblinded, thus explaining a more positive PGA in the intervention group in this study as 
compared to the PGA in the BLISS-76 study. 
Imbalance of drop outs between groups 
MS appendices 3 and 7 and state respectively: 
“There were no differences among groups in discontinuation rates”  “The three groups did 
not differ in reasons for discontinuation of treatment.”  and “Withdrawals and dropouts were 
adequately reported”. 
Drop outs were reasonably balanced between treatment arms.  Infringement of concomitant 
medication rules was one reason for discontinuation of treatment, and this differed between 
treatment arms.  According the FDA3
The MS did not provide relevant information about adherence of study medication (e.g. 
missed infusion due to missed clinic visits). 
 analysis:  “ unlike dropouts, ‘medication failures’ are 
not balanced across treatment groups (17%, 9%, and 10% for placebo, 1 mg/kg belimumab, 
and 10 mg/kg belimumab respectively in BLISS-76 study, and 11%, 7%, and 6% for  BLISS-
52”.  
Intention to treat analysis 
MS Appendix 3 states:  
“Analysis was done in a modified intention-to-treat population, defined as all randomly 
assigned patients who received a dose of the study drug. This was appropriate and 
appropriate methods for handling missing data were outlined in the clinical study report.” 
The trials were analysed according to a modified intention treat (mITT) procedure.  In BLISS-
52 and in BLISS-76 respectively two of 867 randomised patients and 7 of 826 randomised 
patients withdrew before receiving medication.  Outcome analyses were based on the 
remaining 865 and 819 patients according to their randomisation group.  Thus the results of 
mITT analyses were unlikely to differ substantially from a full ITT.  
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Pooling of trials 
The pooling of trial data across trials is considered in sections 4.2.4 and 4.2.6 in the current 
report. 
Applicability to the UK and UK clinical practice 
It is unclear how many of the 1684 patients recruited to the BLISS-52 and BLISS-76 trials 
were from UK centres.  The ERG notes that patients in the trials were derived from other EU 
countries.  The MS is unclear whether similar care pathways to the UK occur across all 
centres included in the trials.   
4.2.3 Description and critique of manufactures outcome selection  
 
The primary efficacy endpoint in both Phase III studies was the percentage of responders at 
week 52 estimated using the SRI.  The SRI is a novel composite outcome which was 
developed in consultation with the FDA during protocol planning for the BLISS-52 and 
BLISS-76 trials.  The manufacturer’s submission to the FDA states that assessors received 
proficiency training in SRI outcome assessment at all the centres involved in the trials.  SRI 
and other outcomes selected for reporting in the MS are listed in Table 6. The ERG considers 
these outcomes to be appropriate for the decision problem. 
Table 6: Outcomes reported in MA 
Outcome Measure Outcome specification 
SLE Responder Index (SRI*) % responders at wk 52 Specified primary outcome 
Reduction in SLEDAI score by ≥ 4 points % responders at wk 52 Specified major secondary outcome 
Change in PGA score from baseline Mean change at wk 24 Specified major secondary outcome 
Steroid reduction weeks 40 to 52 % responders Specified major secondary outcome 
SF-36 Physical component summary score Mean change at wk 24 Specified major secondary outcome 
SLE Responder Index % responders at week 76 Specified major secondary outcome 
SLICC/ACR damage index  Mean change at wk 52 Specified secondary outcome 
FACIT-fatigue scale mean change from baseline Mean change at clinic visits Specified secondary outcome 
EQ-5D score Mean change at clinic visits Specified secondary outcome 
Change in PGA score from baseline Mean change at wk 52 Specified secondary outcome 
SF-36 Physical component summary score Mean change at wk 52 Specified secondary outcome 
SLEDAI SLE flare index over 52 wks Time to first flare Specified secondary outcome 
SLE Responder Index (SRI) % responders at timed clinic visits  Other outcome reported 
Modified SLE responder index % responders at wk 52 Other outcome reported 
No worsening in PGA score by ≥ 0.3 % responders at wk 52 Other outcome reported 
No new BILAG 1A/2B domain scores % responders at wk 52 Other outcome reported 
Change in SLEDAI score from baseline Mean change at week 52 Other outcome reported 
* Composite outcome measure consisting of ≥ 4 points improvement in SLEDAI score, no worsening in PGA by ≥ 0.3 points and no new BILAG 1A or 
2B domain scores 
FACIT= Functional Assessment of Chronic Illness Therapy 
EQ-5D = EuroQoL 5 dimensions   
BILAG = British Isles Lupus Assessment Group   
SLEDAI = Systemic Lupus Erythematosus Disease Activity Index 
SF-36 = Short Form 36-Item Health Survey 
SLICC = Systemic Lupus International Collaborating Clinics   
ACR = American College of Rheumatology 
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4.2.4 Description and critique of the statistical approach used 
 
The manufacturer’s approach is described in Table 5.13 of the MS (Page 91). 
Binary efficacy variables were assessed with a logistic regression model, continuous variables 
were analysed with an analysis of covariance model, and time-to-flare variables were 
analysed by use of a Cox proportional hazards model.  All analyses were adjusted for baseline 
randomisation factors. In addition, the JHU observational cohort of patients was used to 
generate the analysis that was used in an SLE patient simulation. 
The ERG reviewed the statistical approach submitted in the main report and notes that in 
general, the statistical methodologies proposed are suitable to these types of data.  However, 
the ERG identified a number of concerns as shown below:   
In order to identify baseline factors that were predictive of response at Week 52 irrespective 
of treatment received and to evaluate belimumab treatment effect adjusted for the predictive 
factors, a logistic regression main effects model was developed by the manufacturer based on 
the pooled data from the Phase III studies (BLISS-52 and BLISS-76). 
The ERG notes that while the pooling of the two data sets might be considered appropriate, 
given that the trials were essentially identical in design and in the analysis of the primary 
endpoint, the approach used to account for potential between-study variability in the estimate 
of the baseline response or the uncertainty in the estimate of the population sampling variation 
was not appropriate (i.e. treatment-by-study interaction). It is not surprising that the P-values 
for the treatment-by-study interaction were not significant (interaction P-values > 0.5).  This 
insignificant P-value is a reflection of the similarity between the two trials in terms of the 
primary endpoint and would not capture a real difference that might exist between the two 
trials. 
A mixed model logistic regression would have been appropriate to account for the correlation 
structure between the two trials and any population sampling variation. Furthermore, a 
sensitivity analysis of the choice of correlation structure should have been conducted. Without 
taking into account the unobserved uncertainty or variability between the two trials, the ERG 
believes that the validity of pooling of data may have been overestimated.  
The ERG also note that results of in the manufacturer’s submission analysing time-to-flare 
variables did not take into account the time-varying effects of some of the covariates. A 
generalized mixed model with time-varying effects could have been considered to deal with 
the time-varying effect of covariates. 
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Sub-group analysis 
The main submission indicates that a series of pre-specified and post-hoc subgroup analyses 
for efficacy data were conducted. A comparison between each belimumab treated group and 
the placebo group was performed by major subgroups which were pre-specified in each Phase 
III analytical plan. 
With reference to the decision problem and the manufacturer’s intention to explicitly identify 
patients who benefit the most, the ERG notes that some additional exploratory subgroup 
analyses which were not pre-specified in the individual analytical plans were evaluated using 
the pooled Phase III population Target or high disease activity sub-group.  The subgroup of 
patients with evidence for serological disease activity (low complement and positive anti-
dsDNA) and who additionally have a SELENA-SLEDAI disease activity score ≥ 10 at 
baseline.  However, even though patients in this subgroup experienced the greatest treatment 
effect over and above the total pooled population, the ERG notes that this sub-group analysis 
was not pre-specified in the analytical plan. Therefore, the results of this sub-group analysis 
should not be regarded as definitive since the two trials were not powered to conduct this sub-
group analysis. 
The ERG notes that there was no attempt to summarise the studies by performing a meta-
analysis or by conducting an incremental analysis. 
4.2.5 Results from pivotal trials  
The clinical effectiveness results in the MS are derived from the two BLISS trials. 
4.2.5.1 BLISS trial study design and patient eligibility  
Methodological details of the BLISS-52 and BLISS-76 trials were presented in Table 5.6 of 
the MS which is reproduced in Table 7. 
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Table 7: MS summary of BLISS trial methodology (from MS Table 5.6)  
 
COMMENT 
The two pivotal trials, BLISS-52 and BLISS-76, were international multicentre RCTs 
undertaken in different largely non-overlapping geographical regions.  The geographical 
location of study centres differed considerably between trials.  In BLISS-52 there were 90 
Trial no.  
(acronym)  
C1057 
(BLISS-52) 
C1056 
(BLISS-76) 
Location 90 centres in 13 countries in Latin America (Argentina, Brazil, Chile, 
Colombia and Peru), Asia-Pacific (Australia, Hong Kong, India, Korea, 
Philippines and Taiwan) and eastern Europe (Romania and Russia). 
136 centres in 19 countries in North America (Canada, 
Costa Rica, Mexico, Puerto Rico and US) and Europe 
(Austria, Belgium, Czech Republic, France, Germany, 
Israel, Italy, The Netherlands, Poland, Romania, 
Slovakia, Spain, Sweden and UK). 
Design  Randomised, double-blind, placebo-controlled, parallel-group study. As per BLISS-52. 
Duration of study 52 weeks 76 weeks (primary end point at 52 weeks) 
Method of 
randomisation 
Patients who underwent all screening procedures and met the entry 
criteria were enrolled in the study and assigned to treatment by use of a 
central interactive voice response system. Patients were randomised in 
a 1:1:1 ratio to placebo, or belimumab 1 mg/kg or 10 mg/kg. 
Randomisation was stratified according to the SELENA-SLEDAI score 
(6–9 vs ≥10), proteinuria concentration 
(<2 g/24 h vs ≥2 g/24 h) at screening, and ethnic origin (African 
descent or indigenous American [Alaska Native or American Indian 
from North, South, or Central America] vs other). 
As per BLISS-52. 
Method of blinding 
(care provider, 
patient and outcome 
assessor) 
Patients, investigators, study coordinators, and sponsors were masked 
to treatment assignment during intravenous administration of the drug 
and assessment of the patients every 4 weeks during the trial until the 
database was locked. An unmasked pharmacist prepared unmarked 
infusion bags for administration. Belimumab and placebo were both 
prepared as sterile and lyophilised vials (5 mL for belimumab 1 mg/kg; 
20 mL for belimumab 10 mg/kg and placebo), and contained the same 
formulations, except without the active drug for placebo. 
As per BLISS-52. 
Intervention(s) (n=) 
and comparator(s) 
(n=) 
Standard of care plus belimumab 1mg/kg (n=288) or belimumab 
10mg/kg (n=290) or placebo (n=287) administered by IV infusion on 
Days 0, 14 and 28 and every 28 days thereafter for 48 weeks. Standard 
of care consisted of the following (alone or in combination): 
antimalarials, NSAIDs, corticosteroids or other immunosuppressants 
(azathioprine, methotrexate, and mycophenolate mofetil). 
Standard of care plus belimumab 1mg/kg (n=271) or 
belimumab 10mg/kg (n=273) or placebo (n=275) 
administered by IV infusion on Days 0, 14 and 28 and 
every 28 days thereafter for 72 weeks. Standard of care 
consisted of the following (alone or in combination): 
antimalarials, NSAIDs, corticosteroids or other 
immunosuppressants (azathioprine, methotrexate, and 
mycophenolate mofetil). 
Progressive 
restrictions placed on 
standard of care 
In both BLISS-52 and BLISS-76, progressive restrictions were placed on standard of care as the study progressed. These are 
outlined in the Figure 5.2 below. 
(see following box) 
 
Primary outcomes 
(including scoring 
methods and timings 
of assessments)  
The primary efficacy endpoint was the response rate at week 52, 
assessed with SLE Responder Index (SRI). With the SRI criteria, a 
responder was defined as having a reduction of at least 4 points in the 
SELENA-SLEDAI score (defined as clinically meaningful) 15
As per BLISS-52. 
, no new 
BILAG A organ domain score, no more than 1 new BILAG B organ 
domain score, and no worsening in PGA score (increase <0.3) at week 
52 compared with baseline.  
 
Secondary outcomes 
(including scoring 
methods and timings 
of assessments) 
Major secondary endpoints: 
 
• Percent of subjects with ≥ 4-point reduction in SELENA-SLEDAI at 
Week 52. 
 
• Mean change in PGA at Week 24. 
 
• Percent of subjects with prednisone (equivalent) reduction ≥ 25% 
from baseline to ≤ 7.5 mg/day during Weeks 40 – 52 (in subjects 
whose prednisone equivalent dose was > 7.5 mg/day at baseline). 
 
• Mean change in SF-36 PCS at Week 24. 
Major secondary endpoints: 
 
• As per BLISS-52.  
 
• Additionally, response rate (SRI) at Week 76. 
Duration of follow-
up 
52 or 56 weeks dependent on participation in the continuation protocol.  76 or 80 weeks dependent on participation in the 
continuation protocol. 
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centres: in 13 countries in Latin America there were 38 centres (Argentina, Brazil, Chile, 
Colombia and Peru), in Asia-Pacific there were 41 centres (Australia, Hong Kong, India, 
Korea, Philippines and Taiwan) and in Eastern Europe there were eleven centres (Romania 
and Russia).  In BLISS-76 there were 136 centres in 19 countries in North America (Canada, 
Costa Rica, Mexico, Puerto Rico and US) and Europe (Austria, Belgium, Czech Republic, 
France, Germany, Israel, Italy, The Netherlands, Poland, Romania, Slovakia, Spain, Sweden 
and UK).  North America (65 centres) and Europe (62 centres) contributed 93% of the centres 
in BLISS-76.  These geographical differences were reflected in racial differences between the 
populations in the two trials.  Although both trials included adults with auto-antibody positive 
active SLE it is arguable that the population in BLISS-76 is more likely to be similar to that in 
England and Wales than that from BLISS 52.  It is reasonable to assume that the results from 
BLISS-76 are more generalisable to the UK.   
Randomisation was stratified according to SELENA-SLEDAI score (6–9 vs ≥10), proteinuria 
concentration (<2 g/24 h vs ≥2 g/24 h) at screening, and ethnic origin.   
Progressive constraints on standard care medications (immunosuppressives, anti-malarials 
and steroids) (see Figure 1) were imposed during the trials; these were implemented so as to 
increase the possibility of detecting improvement due to belimumab without interference from 
the effects of changing background standard care treatments.  
Figure 1: Constraints on standard of care medications (MS Figure 5.2) 
 
 
 
Patient eligibility for BLISS-52 and BLISS-76 was the same and summarised below in Table 
8. 
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Table 8: Patient eligibility for BLISS-52 and BLISS-76 (From MS Table 5.7) 
Trial no. 
(acronym) 
Inclusion criteria  Exclusion criteria  
C1057 
(BLISS-52) 
Adult patients (aged ≥ 18 years) who met the American 
College of Rheumatology criteria for systemic lupus 
erythematosus and had active disease (score ≥ 6 at 
screening on SELENA-SLEDAI) were eligible for 
enrolment. Other inclusion criteria were unequivocally 
positive ANA (titre ≥ 1:80) or anti-dsDNA antibody (≥ 
30IU/mL), and a stable treatment regimen with fixed doses 
of prednisone (0–40mg/day), or non-steroidal anti-
inflammatory, antimalarial, or immunosuppressant drugs 
for at least 30 days before the first study dose 
The main exclusion criteria were severe 
active lupus nephritis or CNS lupus; 
pregnancy; and previous treatment with 
any B-lymphocyte-targeted drug 
(including rituximab), intravenous 
cyclophosphamide within 6 months of 
enrolment, and intravenous Ig or 
prednisone (>100 mg/day) within 3 
months 
C1056 
(BLISS-76) 
As per BLISS-52 As per BLISS-52 
Adapted from Pharmaceutical Benefits Advisory Committee (2008) Guidelines for preparing submissions to the Pharmaceutical 
Benefits Advisory Committee (Version 4.3). Canberra: Pharmaceutical Benefits Advisory Committee 
 
Relative to the whole trial population imbalance between treatment arms was more 
pronounced for the Target population in both trials, especially in BLISS-76 (see Appendix 4 
of this report).  
4.2.5.2 BLISS trials: demography of patients 
Demographic characteristics of patients in BLISS-52 and BLISS-76 were presented in MS 
Tables 5.8 to 5.11 (see Appendix 4 of this report).  Patients were mostly young females (74% 
≤ 45 years of age; 94% female), a population which is representative of patients with SLE.   
Selected characteristics for placebo and 10mg/kg groups taken from MS Table 5.8 are shown 
below in Table 9.  Amongst all treatment arms pooled across the two studies 47% of patients 
were white, 23% American Indian, 21% Asian, and 8.8% black, however there were large 
differences in the racial makeup between the two studies reflecting the racial distributions in 
the geographic regions in which the trial centres were located.  The substantial differences 
between trials in geographical and in racial distributions seen for the whole population were 
mirrored in the Target population Table 9 (Appendix 4).  
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Table 9: Demographic characteristics in the BLISS trials (adapted from MS Table 5.8) 
Table 5.8. Selected demographic characteristics in Phase 3 trials 
  BLISS-52 BLISS-76 Pooled Total Population 
Race Placebo 1 N = 287 
10mg/kg 
N = 290 
All 
N = 865 
Placebo 
N = 275 
10mg/kg 
N = 273 
All 
N = 819 
Placebo 
N = 562 
10mg/kg 
N = 563 
All 
N = 1684 
White 82 
(28.6%) 
71 
(24.5%) 
229 
(26.5%) 
188 
(68.4%) 
189 
(69.2%) 
569 
(69.5) 
270 
(48.0%) 
260 
(46.2%) 
798 
(47.4%) 
Asian 105 
(36.6%) 
116 
(40.0%) 
327 
(37.8%) 
11 
(4.0%) 
11 
(4.0%) 
28 
(3.4%) 
116 
(20.6%) 
127 
(22.6%) 
355 
(21.1%) 
Black 11 
(3.8%) 
11 
(3.8%) 
30 
(3.5%) 
39 
(14.2%) 
39 
(14.3%) 
118 
(14.4%) 
50 
(8.9%) 
50 
(8.9%) 
148 
(8.8%) 
Alaska Native or 
American Indian 
from 
North/Central/ 
South America 
89 
(31.0%) 
92 
(31.7%) 
279 
(32.3%) 
36 
(13.1%) 
34 
(12.5%) 
103 
(12.6%) 
125 
(22.2%) 
126 
(22.4%) 
382 
(22.7%) 
Hispanic or 
Latino origin 
143 
(49.8%) 
136 
(46.9%) 
420 
(48.6%) 
55 
(20.0%) 
56 
(20.5%) 
173 
(21.1%) 
198 
(35.2%) 
192 
(34.1%) 
593 
(35.2%) 
1  Patients who checked more than 1 race category are counted under individual race category according to the minority rule as well as the multiracial 
category. 
 
 
Differences also existed between studies in that BLISS-76 patients had longer disease 
duration and more organ damage (higher SLICC damage scores), and were using lower 
steroid dosages than BLISS-52 patients. 
Both BLISS-52 and -76 populations presented a restricted range of SLE manifestations.  The 
MS did not provide tabulated information for the frequency of SELENA SLEDAI 
manifestations at baseline, these are shown in Table 10 below based on the FDA discussion 
document3 for the whole BLISS populations, and in Table 11 for the target population.  The 
majority of BLISS-76 participants had musculoskeletal and/or mucocutaneous manifestations 
of SLE as assessed by the SELENA SLEDAI disease activity index.  Baseline disease 
involvement was generally well balanced within trial between the three treatment groups with 
the exception of rash. Higher proportions of placebo patients (68%) and patients in the 
1mg/kg belimumab group (66%) had a rash at study entry as compare to patients in the 
10mg/kg (56%).  A similar pattern of SLE disease involvement at baseline was observed for 
subjects in BLISS-52, however, a lower rate of arthritis (59%) was reported compared to 
BLISS-76 (72%).  
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Table 10: Baseline SELENA SLEDAI involvement: whole population in BLISS trials  
 BLISS-52 BLISS-76 
Condition (weight) Placebo (N=287) 
Belimumab 
1mg/kg 
(N=288) 
Belimumab 
10mg/kg 
(N=290) 
Total 
(N=865) 
Placebo 
(N=275) 
Belimumab 
1mg/kg 
(N=271) 
Belimumab 
10mg/kg 
(N=273) 
Total 
(N=819) 
Organic Brain 
Syndrome (8) 0 2 (1%) 0 2 (1%) 1 (0%) 2 (1%) 3 (1%) 6 (1%) 
Lupus HA (8) 4 (1%) 2 (1%) 4 (1%) 10(1%) 1 (0%) 4 (2%) 9 (3%) 14 (2%) 
Vasculitis (8) 20 (7%) 16 (6%) 28 (10%) 64 (7%) 17 (6%) 20 (7%) 10 (4%) 47 (6%) 
Arthritis (4) 165 (58%) 169 (59%) 173 (60%) 507 (59%) 206 (75% 193 (71%) 191 (70% 590 (72%) 
Hematuria (4) 15 (5%) 16 (6%) 16 (6%) 47(5%) 5 (2%) 7 (3%) 8 (3%) 20 (2%) 
Proteinuria (4) 50 (19%) 54(19%) 41 (14%) 145 (17%) 29 (11%) 23 (9%) 26 (10%) 78 (10%) 
Rash (2) 176 (61%) 176 (61%) 182 (63%) 534 (62%) 87 (68%) 180 (66%) 154 (56%) 521 (64%) 
Alopecia (2) 150 (52%) 138 (48%) 158 (55%) 446 (52%) 30 (47% 137 (51%) 116 (43% 383 (47%) 
Mucosal Ulcers (2) 71 (25%) 52 (18%) 58 (20%) 181 (21%) 74 (27%) 57 (21%) 78 (29%) 209 (26%) 
Low Complement (2) 183 (64%) 186 (65%) 198 (68%) 567 (66%) 160 (58% 149 (55%) 159 (58% 468 (57%) 
Inc. DNA Binding (2) 205 (71%) 220 (76%) 218 (75%) 643 (74%) 175 (64% 168 (62%) 176 (65% 519 (63%) 
Leukopenia (1) 18 (6%) 12 (4%) 9 (3%) 39 (5%) 16 (6%) 22 (8%) 23 (8%) 61 (7%) 
 
Table 11: Baseline SELENA SLEDAI involvement: in the Target population in BLISS 
Trials 
 BLISS-52 BLISS-76 Combined BLISS 
Condition (weight) Placebo (N=107) 
Belimumab 
10mg/kg 
(N=112) 
Placebo 
(N=96) 
Belimumab 
10mg/kg 
(N=96) 
Placebo 
(N=203) 
Belimumab 
10mg/kg 
(N=193) 
Organic Brain Syndrome (8) 0 0 1 (1.0%) 0 1 (0.5%) 0 
Lupus HA (8) 1 (0.9%) 3 (2.7%) 0 2 (2.5%) 1 (0.5%) 5 (2.6%) 
Vasculitis (8) 15 (14.0%) 19 (17.0%) 10 (10.4%) 5 (6.2%) 25 (12.3%) 24 (12.4%) 
Arthritis (4) 65 (60.7%) 76 (67.9%) 83 (86.5%) 63 (77.8%) 148 (72.9%) 139 (72.0%) 
Hematuria (4) 9 (8.4%) 7 (6.3%) 3 (3.1%) 6 (7.4%) 12 (5.9%) 13 (6.7%) 
Proteinuria (4) 31 (29.0%) 28 (25.0%) 17 (17.7%) 21 (25.9%) 48 (23.6%) 49 (25.4%) 
Rash (2) 74 (69.2%) 75 (67.0%) 72 (75.0%) 52 (64.2%) 146 (71.9%) 127 (65.8%) 
Alopecia (2) 66 (61.7%) 69 (61.6%) 50 (52.1%) 38 (46.9%) 116 (57.1%) 107 (55.4%) 
Mucosal Ulcers (2) 28 (26.2%) 20 (17.9%) 30 (31.3%) 22 (27.2%) 58 (28.6%) 42 (21.8%) 
Low Complement (2) 107 (100.0%) 112 (100.0%) 96 (100.0%) 80 (98.8%)* 203 (100.0%) 192 (99.5%) 
Inc. DNA Binding (2) 107 (100.0%) 112 (100.0%) 96 (100.0%) 81 (100.0%) 203 (100.0%) 193 (100.0%) 
Leukopenia (1) 6 (5.6%) 4 (3.6%) 7 (7.3%) 10 (12.3%) 13 (6.4%) 14 (7.3%) 
 
A specified major secondary outcome was the percentage of SRI responders at week 76.  
There was only a small difference between placebo and 10mg/kg belimumab (odds ratio and 
P value not submitted; odds ratio 1.31, 95% CI: 0.92 – 1.87, P = 0.1323 by logistic regression, 
taken from the FDA HGS briefing document.5 
60 
 
Relative to the whole trial population imbalance between treatment arms was more 
pronounced for the Target population in both trials, especially in BLISS-76 (Appendix 4).  
Patients from BLISS-52 contributed more patients to the pooled Target population than did 
patients from BLISS-76 (55% and 45% respectively, and contributed a greater proportion of 
the patients receiving 10mg/kg belimumab (58% and 42% from each trial respectively); 
therefore effectiveness results pooled across trials will tend to reflect BLISS-52 outcomes 
more than BLISS-76. 
4.2.5.3 BLISS trial results by outcome 
 
Primary outcome: SRI at week 52 
The pre-specified primary outcome in the BLISS trials was the proportion of responders at 
week 52 defined according to the composite SRI outcome measure.  The results were 
provided in MS Table 5.15 and clarification Table A6.1 and summarised below in Table: 12. 
Table: 12 Primary efficacy endpoint (SRI) at Week 52 (dropout-failure) 
 BLISS-52 BLISS-76 Pooled Total Population
High Disease 
Activity Subgroup 
Pooled Total 
4 
High Disease 
Activity Subgroup 
BLISS-52 
High Disease 
Activity Subgroup 
BLISS-76 
SRI at 
Week 52 
Placebo 
N = 287 
10mg/kg 
N = 290 
Placebo 
N = 275 
10mg/kg 
N = 273 
Placebo 
N = 562 
10mg/kg 
N = 563 
Placebo 
N = 203 
10mg/kg 
N = 193 
Placebo 
N = 107 
10mg/kg 
N = 112 
Placebo 
N = 96 
10  
mg/kg 
N = 81 
No. (%) 
Response 
125 
(43.6%) 
167 
(57.6%) 
93 
(33.8%) 
118 
(43.2%) 
218 
(38.8%) 
285 
(50.6%) 
77 
(37.9%) 
121 
(62.7%) 
44  
(41.1%) 
75  
(67.0%) 
33  
(34.4%) 
46  
(56.8%) 
Observed 
difference 
vs placebo 
(%) 
- 14.03 - 9.41 - 11.8 - 24.8 
 
- 
 
25.9 
 
- 
 
22.4 
OR (95% 
CI)1 -  vs 
placebo 
1.83  
(1.30, 
2.59) 
- 
1.52  
(1.07, 
2.15) 
- 1.68 (1.3, 2.2) - 
2.7  
(1.8, 4.1) 
- 3.0  
(1.7, 5.2) 
- 2.5  
(1.3, 
4.6) 
P-value - 1 0.0006 - 0.0207 - < 0.0001 - < 0.0001  0.0001 - 0.0045 
1  Odds Ratio (95% confidence interval) and p-values were from logistic regression for the comparison between each belimumab dose and 
placebo with covariates. For individual studies, covariates include baseline SELENA-SLEDAI score (≤ 9 vs ≥ 10), baseline proteinuria level 
(< 2 g/24 hour vs ≥ 2 g/24 hour equivalent) and race (African descent or indigenous-American descent vs other). For pooled data analysis, 
study was also included as an additional covariate. 
 
 
In both trials SoC + 10mg/kg belimumab delivered a greater percentage of responders than  
SoC + placebo.  The difference in percentage of responders in the belimumab group relative 
to placebo group for the whole population was 14% in BLISS-52 and 9.4% in BLISS-76.  The 
corresponding adjusted odds ratios for a response in BLISS-52 and in BLISS-76 were 
respectively 1.83 (95% CI: 1.30, 2.59; P = 0.0006) and 1.52 (95% CI: 1.07, 2.15; P = 0.027).  
For the Target population pooled across trials the difference in percentage of responders in the 
belimumab group relative to placebo group was 24.8% and the adjusted odds ratio was 2.7 
(95% CI: 1.8, 4.1; P < 0.0001).  In BLISS-52 and BLISS-76 Target populations the difference 
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between groups was 25.9% and 22.4% respectively (odds ratio 3.0, 95% CI: 1.7, 5.2; P = 
0.0001 for BLISS-52 and odds ratio 2.5, 95% CI: 1.3, 4.6; P = 0.0045 for BLISS-76).  
Relative to the whole population the Target population generated results that were more 
supportive of belimumab.  For the whole population and for the Target population BLISS-52 
produced results more supportive of belimumab than did BLISS-76, however for the Target 
population the difference between trials was less than for the total population.  
SRI at successive clinic visits and at week 76 
The percentage of SRI responders was also reported at multiple follow up times (MS Figures 
5.6, to 5.9 shown in Figure 2.  
For the Target population pooled across trials and in BLISS-52, at many times, a significantly 
greater response was observed for the belimumab group relative to placebo group 
Figure 2: Percentage of SRI responders during follow up (from MS Figures 5.6 to 5.9) 
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(significance tests uncorrected for multiple testing), however, for BLISS-76 the only time a 
significantly (P < 0.05) greater response was observed for the belimumab group was at week 
52.   
In the HGS/FDA5
A specified major secondary outcome was the percentage of SRI responders at week 76.  
There was only a small difference between placebo and 10mg/kg belimumab (odds ratio and 
P value not submitted; odds ratio 1.31, 95% CI: 0.92 – 1.87, P = 0.1323 by logistic regression, 
taken from the FDA discussion document
analysis there is little difference in response between 1mg/kg and 10mg/kg 
groups for BLISS-52. 
5
The HGS Briefing Document to the FDA
). 
5
Figure 3
 provided graphs for all three randomised groups 
(placebo, 1mg/kg belimumab and 10mg/kg belimumab) for the percentage of SRI responders 
observed at successive clinic visits up to 52 weeks for BLISS-52 and week 76 for BLISS-76.  
These graphs are in .  They indicate that in BLISS-76 there was a minimal difference 
in response between 1mg/kg and 10mg/kg groups.  Baseline characteristics for the three 
groups (HGS Briefing Document Pages 87 to 1005
 
) do not provide an obvious explanation for 
this result.  
Figure 3: SRI percent responders over follow up (from HGS Briefing Document to 
FDA) 
 
The ERG note that the percentage SRI responders observed at various follow up times is a 
group response and does not reflect sustained SRI response at the individual level.  The graph 
line showing percentage of responders across the duration of the trials rose and fell at various 
follow up times, thus an individual non-responder could later improve sufficiently to be 
classified as a responder. 
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Modified SRI 
To be classified as an SRI responder a patient is required to have a SELENA-SLEDAI score 
that is reduced by ≥ 4 points relative to baseline.  A 4 point reduction in SELENA -SLEDAI 
can be achieved by normalisation of serological manifestations only (e.g. anti-dsDNA 
antibodies and complement).  The MS presented an analysis of a modified SRI response in 
which the increased DNA binding and low complement items were removed from the 
SELENA-SLEDAI component of the SRI; the analysis was performed in patients who still 
had a SELENA SLEDAI score ≥ 4 at baseline after points for low complement and increased 
DNA binding were removed from the scale.  During the clarification process the manufacturer 
provided modified SRI results for the Target or high disease activity population; these plus 
the information from the MS Page 111 are summarised in Table 13. 
 
Table 13: Modified SRI response at week 52 
 
 BLISS-523 BLISS-763 Pooled Total Population2 
High Disease 
Activity Subgroup 
Pooled Total 
High Disease 
Activity Subgroup 
BLISS-52 
High Disease 
Activity Subgroup 
BLISS-76 
Change 
from 
Baseline 
at Week 
522 
Placebo 
N = 264 
10 
mg/kg 
N = 259 
Placebo 
N = 255 
10 
mg/kg 
N = 245 
Placebo 
N = 519 
10 
mg/kg 
N = 504 
Placebo 
N = 203 
10 
mg/kg 
N = 193 
Placebo 
N = 107 
10 
mg/kg 
N = 112 
Placebo 
N = 96 
10 
mg/kg 
N = 81 
n(%) 
responders 
127 
(48.1%) 
158 
(61.0%) 
92 
(36.1%) 
109 
(44.5%) 
219 
(42.2%) 
267 
(53.0%) 
42 
(39.3%) 
73 
(65.2%) 
29 
(30.2%) 
43 
(53.1%) 
71 
(35.0%) 
116 
(60.1%) 
OR (95% 
CI) - 1 - - - - - - 
3.0  
(1.7, 
5.2) 
- 
2.5  
(1.4, 
4.8) 
- 
2.8  
(1.8, 
4.2) 
P-value1 - - - - - - - 0.0001 - 0.0036 - <0.0001 
10 mg/kg 
vs placebo 
difference 
- (11.9%) - (8.4%) - (10.8%) - (25.9%) - (25.9%) - (25.1%) 
P-value - 0.0038 - 0.0604 - 0.0006 - - - - - - 
1 ANCOVA model for the comparison between each belimumab dose and placebo, adjusted for baseline SELENA SLEDAI score (≤ 9 vs. ≥ 10), 
baseline proteinuria level (< 2 g/24 hour vs. ≥ 2 g/24 hour equivalent) and race (African descent or indigenous-American descent vs. other). For pooled 
data analysis, study was also included as an additional covariate 
2  Defined as SRI response with serology components (increased DNA binding and low complement items) removed 
3  Information extracted from HGS Briefing Document to FDA Figure 9.51 
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Table 14: Modified SRI response at week 52 
 
 BLISS-52 BLISS-763 Pooled Total Population
3 
High Disease 
Activity Subgroup 
Pooled Total 
2 
High Disease 
Activity Subgroup 
BLISS-52 
High Disease 
Activity Subgroup 
BLISS-76 
Change 
from 
Baseline 
at Week 
52
Placebo 
N = 264 
2 
10 
mg/kg 
N = 259 
Placebo 
N = 255 
10 
mg/kg 
N = 245 
Placebo 
N = 519 
10 
mg/kg 
N = 504 
Placebo 
N = 203 
10 
mg/kg 
N = 193 
Placebo 
N = 107 
10 
mg/kg 
N = 112 
Placebo 
N = 96 
10 
mg/kg 
N = 81 
n(%) 
responders 
127 
(48.1%) 
158 
(61.0%) 
92 
(36.1%) 
109 
(44.5%) 
219 
(42.2%) 
267 
(53.0%) 
42 
(39.3%) 
73 
(65.2%) 
29 
(30.2%) 
43 
(53.1%) 
71 
(35.0%) 
116 
(60.1%) 
OR (95% 
CI) - 1 - - - - - - 
3.0  
(1.7, 
5.2) 
- 
2.5  
(1.4, 
4.8) 
- 
2.8  
(1.8, 
4.2) 
P-value - 1 - - - - - - 0.0001 - 0.0036 - <0.0001 
10 mg/kg 
vs placebo 
difference 
- (11.9%) - (8.4%) - (10.8%) - (25.9%) - (25.9%) - (25.1%) 
P-value - 0.0038 - 0.0604 - 0.0006 - - - - - - 
1 ANCOVA model for the comparison between each belimumab dose and placebo, adjusted for baseline SELENA SLEDAI score (≤ 9 vs. ≥ 10), 
baseline proteinuria level (< 2 g/24 hour vs. ≥ 2 g/24 hour equivalent) and race (African descent or indigenous-American descent vs. other). For pooled 
data analysis, study was also included as an additional covariate 
2  Defined as SRI response with serology components (increased DNA binding and low complement items) removed 
3  Information extracted from HGS Briefing Document to FDA Figure 9.51 
 
The MS did not specify patient numbers for this analysis and so data from the HGS Briefing 
Document to the FDA.5 Figure 4   shows the percentage of modified SR responders (from 
HGS Briefing Document to FDA). 
In the HGS/FDA5
The number of patients at risk was not specified.  A stronger response was observed for the 
Target populations than for the total populations and statistical significance was reached in 
both trials. 
 analysis there is little difference in response between 1mg/kg and 10mg/kg 
groups for BLISS-52.  
 
Figure 4: Modified SR percentage of responders (from HGS Briefing Document to FDA) 
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Subcomponents of the SRI response 
Table: 15 summarises the week 52 results for the three subcomponents of the composite SRI 
response (based on MS Table 5.16 and clarification Table A6.1). 
Table 15: Results for subcomponents of SRI at week 52 (adjusted) 
 BLISS-52 BLISS-76 Pooled Total Population
High Disease 
Activity Subgroup 
Pooled Total 
4 
High Disease 
Activity Subgroup 
BLISS-52 
High Disease 
Activity Subgroup 
BLISS-76 
 Placebo N = 287 
10mg/kg 
N = 290 
Placebo 
N = 275 
10mg/kg 
N = 273 
Placebo 
N = 562 
10mg/kg 
N = 563 
Placebo 
N = 203 
10mg/kg 
N = 193 
Placebo 
N = 107 
10mg/kg 
N = 112 
Placebo 
N = 96 
10mg/kg 
N = 81 
4-point 
reduction in 
SELENA-
SLEDAI 
132 
(46.0%) 
169 
(58.3%) 
98 
(35.6%) 
128 
(46.9%) 
230 
(40.9%) 
297 
(52.8%) 
84  
(41.4%) 
125  
(64.8%) 
47  
(43.9%) 
76  
(67.9%) 
37  
(38.5%) 
49  
(60.5%) 
Observed 
difference vs 
placebo (%) 
- 12.3 - 11.3 - 11.9 - 23.4 - 24.0  22.0 
OR (95% 
CI)1 -  vs 
placebo 
1.71 
(1.21,2.41) - 
1.63 
(1.15,2.32) - 
1.68 
(1.3,2.2) - 
2.6 
(1.7,3.9) - 
2.8  
(1.6,4.8) - 
2.4  
(1.3,4.4) 
P-value  1 0.0024  0.0062 - < 0.0001 - 
< 
0.0001  0.0004 - 0.0063 
No New 
1A/2B 
BILAG 
domain 
scores 
210 
(73.2%) 
236 
(81.4%) 
179 
(65.1%) 
189 
(69.2%) 
389 
(69.2%) 
425 
(75.5%) 
125  
(61.6%) 
145  
(75.1%) 
68  
(63.6%) 
88  
(78.6%) 
57  
(59.4%) 
57  
(70.4%) 
Observed 
difference vs 
placebo (%) 
- 8.2 - 4.1 - 6.3 - 13.6 - 15.0 - 11.0 
OR (95% 
CI)1,2 -  vs 
placebo 
1.62  
(1.09,2.42) - 
1.20 
(0.84,1.73) - 
1.4 
(1.1,1.8) - 
1.9 
(1.2,3.0) - 
2.3  
(1.2,4.2) - 
1.6  
(0.9, 
3.1) 
P-value  1,2 0.0181  0.3193 - 0.0190 - 0.0034 - 0.0099 - 0.1297 
No worsening 
in PGA 
199 
(69.3%) 
231 
(79.7%) 
173 
(62.9%) 
189 
(69.2%) 
372 
(66.2%) 
420 
(74.6%) 
119  
(58.6%) 
142  
(73.6%) 
64  
(59.8%) 
86  
(76.8%) 
55  
(57.3%) 
56  
(69.1%) 
Observed 
difference vs 
placebo (%) 
- 10.4 - 6.3 - 8.4 - 15.0 - 17.0 - 11.8 
OR (95% 
CI)1,3 -  vs 
placebo 
1.74  
(1.18,2.55) - 
1.32 
(0.92,1.90) - 
1.5 
(1.2,2.0) - 
2.0 
(1.3,3.1) - 
2.3  
(1.3,4.2) - 
1.6  
(0.9,3.0) 
P-value - 1,3 0.0048 - 0.1258 - 0.0017 - 0.0015 - 0.0063 - 0.1312 
1  Odds Ratio (95% confidence interval) and p-value were from logistic regression for the comparison between each belimumab dose and placebo with covariates. For individual 
studies, covariates include baseline SELENA-SLEDAI score (≤ 9 vs ≥ 10), baseline proteinuria level (< 2 g/24 hour vs ≥ 2 g/24 hour equivalent) and race (African descent or 
indigenous-American descent vs other). For pooled data analysis, study was also included as an additional covariate  
2  Additional covariate: baseline BILAG domain involvement (at least 1A/2B) 
3  Additional covariate: baseline PGA score 
4
 
  No significant treatment-by-study interactions were observed (all p > 0.287) 
The three subcomponents of the composite SRI outcome were: [i] an improved SELENA SLE 
DAI score by ≥ 4 points; [ii] a BILAG index showing no new grade A organ involvement or 
no two grade B organ involvements (i.e. no worsening by one new A or two new B BILAG 
indices); [iii] a PGA score that has not increased by more than 0.3 points (i.e. no worsening in 
PGA by ≥ 0.3).   
The percentage of patients at week 52 that achieved a SLEDAI score reduction of ≥ 4 points 
was defined as a major secondary outcome.  For the whole population, both trials delivered 
more responders in the belimumab group than the placebo group (P = 0.0024 and P = 0.0062 
for BLISS-52 and BLISS-76, respectively).   
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Results at week 52 for the other two SRI subcomponents (i.e. no worsening in BILAG index 
and no worsening in PGA score) were defined as non-major secondary outcomes.  The 
percentage of patients in the whole population that satisfied the BILAG and PGA criteria in 
BLISS-52 was greater for belimumab relative than placebo (significant at P = 0.0181 and P = 
0.0048 for BILAG and PGA, respectively); however, for BLISS-76 the differences between 
belimumab and placebo were considerably smaller and neither component reached statistical 
significance in favour of belimumab (P = 0.319 and P = 0.1258 for BILAG and PGA, 
respectively).  According to results reported in the HGS Briefing Document to the FDA 
(Table 9.20, Page 102) the 1mg/kg belimumab dose regimen in BLISS-76 performed slightly 
better than 10mg/kg for both the PGA and BILAG subcomponents at week 52. 
The corresponding results for the target population supplied during the clarification process 
are also summarised in Table 15 Pooled across trials, all three SRI components at week 52 
were supportive of belimumab relative to placebo and delivered significant effects.  However, 
for BLISS-76 the PGA and BILAG results at week 52 for the target population were 
considerably weaker (P = 0.1312 and P = 0.1297, respectively) than for BLISS-52 or the 
pooled target population.  
Major secondary outcomes 
The MS identified five pre-specified major secondary outcomes. These included the SRI 
response at week 76 and the percentage of patients with a ≥ 4 point SLEDAI improvement at 
week 52, each of which have been discussed in the preceding sections.  The other three major 
secondary outcomes were: mean change in PGA score at week 24, percentage of patients with 
prednisone reductions ≥ 25% from baseline to ≤  7.5 mg/day during weeks 40 to 52 (in 
subjects whose baseline dose was > 7.5 mg/day); mean change in SF36 PCS at week 24.  
These are discussed in this section. 
 
Change in PGA score at week 24 was presented in MS Table 5.18 and the relevant results 
from this are shown in Table: 16 below.  For the whole population in BLISS-52 the change in 
PGA score (week 24 relative to baseline) for both groups indicated disease improvement and 
was greater in the belimumab group (-0.54) than placebo group (-0.39; P = 0.0003 in support 
of belimumab).  For BLISS-76 the difference between groups was very small and in favour of 
placebo (-0.49 placebo and -0.48 belimumab) and did not reach statistical significance (P = 
0.7987).  For the Target HDAP pooled across trials belimumab delivered a greater reduction 
in PGA score than placebo (P = 0.028 with mean changes of -0.42 and -0.52 for placebo and 
belimumab, respectively).  Target population results by trial are not available. 
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Table 16: Mean change in PGA score at week 24 (taken from MS Table 5.18) 
Major 
secondary 
endpoint at 
Week 24 
BLISS-52 BLISS-76 Pooled Total Population 
High Disease Activity 
Subgroup 
Placebo  
N = 287 
10mg/kg  
N = 290 
Placebo  
N = 275 
10mg/kg  
N = 273 
Placebo 
N = 562 
10mg/kg 
N = 563 
Placebo 
N = 203 
10mg/kg 
N = 193 
Mean ± SE  -0.39 ± 0.03 -0.54 ± 
0.03 
-0.49 ± 0.04 -0.44 ± 
0.03 
-0.44 ± 0.02 -0.49 ± 
0.02 
-0.42 ± 0.04 -0.52 ± 0.04 
LS Mean ± SE -0.35 ± 0.04 1 -0.50 ± 0.04 -0.49 ± 0.05 
-0.48 ± 
0.05 -0.40 ± 0.03 
-0.48 ± 
0.03 -0.41 ± 0.05 -0.53 ± 0.05 
P-value1 -   0.0003 - 0.7987 - 0.0167 - 0.0268 
1  All statistics, including the difference in LSM (least square means), were from ANCOVA model for the comparison between each 
belimumab dose and placebo, adjusted for the baseline PGA score, baseline SELENA-SLEDAI score (≤ 9 vs ≥ 10), baseline proteinuria 
level (< 2 g/24 hour vs ≥ 2 g/24 hour equivalent) and race (African descent or indigenous-American descent vs other). For pooled data 
analysis, study was also included as an additional covariate. 
 
 
The mean change in PGA at week 52 was submitted as an additional secondary outcome.  The 
results are shown in Table 17. 
Table 17: Mean change in PGA score at week 52 (taken from MS Table 5.18) 
Other 
secondary 
endpoints 
Week 52 
BLISS-52 BLISS-76 Pooled Total Population 
High Disease Activity 
Subgroup 
Placebo  
N = 287 
10mg/kg  
N = 290 
Placebo  
N = 275 
10mg/kg  
N = 273 
Placebo 
N = 562 
10mg/kg 
N = 563 
Placebo 
N = 203 
10mg/kg 
N = 193 
Mean ± SE  -0.48 ± 0.04 -0.67 ± 0.04 -0.46 ± 0.04 -0.49 ± 0.04 -0.47 ± 0.03 -0.58 ± 0.03 -0.41 ± 0.05 -0.62 ± 0.05 
LS Mean ± SE -0.38 ± 0.05 1 -0.57 ± 0.05 -0.47 ± 0.06 -0.55 ± 0.06 -0.40 ± 0.04 -0.54 ± 0.04 -0.36 ± 0.06 -0.59 ± 0.06 
P-value1 -   0.0001 - 0.1159 - < 0.0001 - 0.0003 
1  All statistics, including the difference in LSM (least square means), were from ANCOVA model for the comparison between each 
belimumab dose and placebo, adjusted for the baseline PGA score, baseline SELENA-SLEDAI score (≤ 9 vs ≥ 10), baseline proteinuria 
level (< 2 g/24 hour vs ≥ 2 g/24 hour equivalent) and race (African descent indigenous-American descent vs other). For pooled data 
analysis, study was also included as an additional covariate. 
 
In BLISS-52 a larger improvement in PGA score was observed for the 10mg/kg group than 
for placebo (P = 0.0001) whereas in BLISS-76 the difference between treatments was trivial 
(P = 0.115).  For the pooled populations 10mg/kg was superior to placebo (P = 0.0003). 
The HGS Briefing Document to the FDA5
Figure 5
 provided graphed results for mean change in PGA 
through successive clinic visits for all three randomised groups.  These are shown below in 
 for BLISS-76. 
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Across 76 weeks of follow up in BLISS-76 the 1mg/kg dose regimen appeared to outperform 
the 10mg/kg regimen.  Baseline differences (MS Table 5.9) were similar between treatment 
groups. 
The mean change in SF-36 PCS scores at week 24 relative to baseline, a major secondary 
outcome, showed little difference between belimumab and placebo groups in BLISS-52 (P = 
0.8870), or in BLISS-76 (P = 0.6601), or in the Target population pooled across trials (P = 
0.4276).  
Change in SF-36 PCS scores at week 52 was specified as a non-major secondary outcome.  
No significant improvement was observed for BLISS-76 or Target populations (P = 0.5134 
and P = 0.1124, respectively) however in BLISS-52 the difference between belimumab and 
placebo arms (4.18 vs. 2.96) was sufficient to reach statistical significance (P = 0.0247). 
Reduction in steroid use between weeks 40 and 52 for those patients receiving ≥ 7.5 mg/day 
prednisone at baseline was specified as a major secondary outcome.  The results submitted 
summarised in Table 18.  
 
 
 
 
 
 
  
Figure 5: Mean change in PGA score in BLISS-76 
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Table 18: Prednisone reduction Weeks 40 through 52 – Phase 3 trials 
 
 BLISS-52 BLISS-76 Pooled Total Population
High Disease 
Activity Subgroup 
Pooled Total 
4 
High Disease 
Activity Subgroup 
BLISS-52 
High Disease Activity 
Subgroup BLISS-76 
 
Placebo  
N  = 
192 
10 
mg/kg  
N = 
204 
Placebo  
N = 126 
10 
mg/kg  
N = 
120 
Placebo 
N = 318 
10 
mg/kg 
N = 
324 
Placebo 
N = 126 
10 
mg/kg 
N = 126 
Placebo 
N = 76 
10 
mg/kg 
N = 81 
Placebo 
N = 50 
10 
mg/kg 
N = 45 
No.   %1  
Response2
23 
12.0%    
38 
18.6% 
16 
12.7% 
20 
16.7% 
39 
12.3% 
58 
17.9% 
9  
7.1% 
20  
15.9% 
4  
5.3% 
15  
18.5% 
5  
10.0% 
5  
11.1% 
Observed 
difference 
vs Placebo  
- 6.65 - 3.97 - 5.64 - 8.73 - 13.5 - 1.1 
OR (95% 
CI)3 -  vs 
placebo  
1.75  
(0.99, 
3.08) 
- 
1.26  
(0.61, 
2.60) 
- 
1.57 
(1.01, 
2.45) 
- 
2.43 
(1.05, 
5.65) 
- 
4.11  
(1.29, 
13.2) 
- 
0.88  
(0.21, 
3.60) 
P-value3 -   0.0526 - 0.5323 - 0.0451 - 0.0389 - 0.0171 - 0.8586 
1  Includes only subjects with baseline prednisone > 7.5 mg/day 
2  Any subject who withdrew from the study prior to the Day364 (Week 52) visit, missed the Day 364 (Week 52) visit (± 28 day window allowed), 
and/or received a protocol-prohibited medication or a dose of allowable (but protocol-restricted) medication that resulted in treatment failure designation 
prior to the Day 364 (Week  52) visit was considered a treatment failure for prednisone reduction 
3  Odds Ratio (95% confidence interval) and p-value were from logistic regression for the comparison between each belimumab dose and placebo with 
covariates. For individual studies, the covariates include baseline prednisone level, baseline SELENA-SLEDAI score (≤ 9 vs ≥ 10), baseline proteinuria 
level (< 2 g/24 hour vs ≥ 2 g/24 hour equivalent) and race (African descent or indigenous-American descent vs other). For pooled data analysis, study 
was also included as an additional covariate 
4
 
  Obtained from a logistic regression by adding study and the treatment-by-study interaction to the above model 
 
In BLISS-52 and BLISS-76 at baseline 68.6% and 44.9% of patients respectively were 
receiving ≥ 7.5 mg/day prednisone.  The percentage that reduced steroid use in weeks 40 to 
52 by the pre-specified amount was greater in the belimumab arm than the placebo arm in 
both trials, however the difference (belimumab vs. placebo) failed to reach statistical 
significance in either trial: 18.6% vs. 12.0% in BLISS-52 (P = 0.0526 from logistic regression 
including baseline covariates) and 16.7% vs. 12.7% in BLISS-76 (P = 0.5323).  
For the Target or HDAP  pooled across trials 15.9% and 7.1% reduced steroid use in the 
10mg/kg belimumab and placebo groups respectively (P = 0.0389 from logistic regression).  
The results from BLISS-52 supported belimumab (P = 0.171) whereas in BLISS-76 
differences between treatments were trivial (P = 0.8586).  The HGS Briefing Document to the 
FDA5
Figure 6
 provided results for reduction in steroid use for all three treatment arms.  Table 9-16 
from the HGS Briefing Document is shown in . 
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Figure 6: Reduction in steroid use Phase II trials (Taken from HGS Table 9-16) 
 
It is noticeable that again there was little difference in effectiveness between the 1mg/kg and 
10mg/kg dose regimens, in BLISS-76 a better outcome was recorded with 1mg/g than with 
10mg/kg, and that the results from BLISS-52 were more strongly supportive of belimumab 
than those from BLISS-76. 
 
Further secondary outcomes submitted  
Flares 
Time to first flare and to first severe flare was reported in MS Figures 5.9 to 5.13. 
In BLISS-52 the time to first flare was delayed by 10 mg/kg belimumab relative to placebo 
(HR 0.76, 95% CI: 0.63 – 0.91, P = 0.0036) (Figure 7).   
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Figure 7: Time to first flare; BLISS-52 (Taken from MS Figure 5.10) 
In BLISS-76 there was no difference between groups in time to first flare (P = 0.4796; Figure 
8).   
 
Figure 8: Time to first flare; BLISS-76 (Taken from MS Figure 5.11) 
When the whole populations from the BLISS trials were pooled the difference between 
treatments reached statistical significance (P = 0.0120; Figure 9). 
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Figure 9: Time to first flare; pooled whole populations (Taken from MS Figure 5.12) 
 
For the high disease activity Target population pooled across trials, belimumab significantly 
delayed time to first flare relative to placebo (P = 0.007; Figure 10).  
 
Figure 10: Time to first flare; pooled Target populations (Taken from MS Figure 5.13) 
 
In BLISS-52 the time to first severe flare was delayed by 10 mg/kg belimumab relative to 
placebo P = 0.0055; Figure 11).  
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Figure 11: Time to first severe flare; BLISS-52 (Taken from MS Figure 5.10) 
In BLISS-76 belimumab somewhat delayed time to first severe flare in (HR 0.72, 95% CI 
0.50–1.05, P = 0.0867; Figure 12).   
 
Figure 12: Time to first severe flare; BLISS-76 (Taken from MS Figure 5.11)  
When the whole populations from the BLISS trials were pooled the difference between 
treatments for time to first severe reached statistical significance (P = 0.0011; Figure 13). 
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Figure 13: Time to first severe flare; pooled whole population (Taken from MS Figure 
5.12) 
For the high disease activity Target population pooled across trials, belimumab significantly 
delayed time to first severe flare relative to placebo (P = 0.0028; Figure 14).  
 
Figure 14: Time to first severe flare; pooled Target population (Taken from MS Figure 
5.13) 
The HGS Briefing Document to the FDA5 Figure 15 provided the graphs shown in  depicting 
results for all three treatment arms. 
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Figure 15: Time to first flare (taken from HGS Briefing Document to the FDA) 
It is noticeable that in both trials the 1 mg/kg belimumab dose regimen was as effective as the 
10 mg/kg dose regimen in extending time to first flare, and that for BLISS-76 this also applies 
for severe flares.  For both flares and severe flares the results from BLISS-52 were more 
supportive of belimumab than those from BLISS-76. 
SLICC/ACR Damage Index 
There was no meaningful difference between the belimumab and placebo groups in the 
change in SLICC/ACR Damage Index at Week 52 compared with baseline.   
FACIT-fatigue index 
The mean change FACIT fatigue score from baseline was reported in MS Figures 5.14 to 5.17 
shown in Figure 16. 
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Figure 16: Mean change in FACIT-Fatigue score – BLISS-52 (Taken from MS Figure 
5.14) 
At week 52 relative to baseline the belimumab group had greater improvement in FACIT-
Fatigue score than the placebo group (4.8 belimumab and 2.1 placebo in BLISS 52; 4.6 and 
2.9 in BLISS-76).  The difference was significant for BLISS-52 (P < 0.001) but not for 
BLISS-76 (P ≥ 0.05) (Figure 17 and Figure 18).   
 
Figure 17: Mean change in FACIT-Fatigue score – BLISS-76 (Taken from MS Figure 
5.15)  
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For the whole population pooled across trials the difference was statistically in favour of 
belimumab at week 52 (Figure 18). 
 
Figure 18: Mean change in FACIT-Fatigue – Pooled Total Population (Taken from MS 
Figure 5.16) 
While for the target population pooled across trials at weeks 8 and 12 the difference between 
groups was statistically in support of belimumab (P < 0.05) however the difference between 
groups then diminished; at week 52 there was no longer a significant difference (see Figure 
19). 
 
Figure 19: Mean change in FACIT-Fatigue – pooled Target population (Taken from MS 
Figure 5.17) 
The HGS Briefing Document to the FDA provided results for all three treatment arms at week 
52.  In BLISS-52 the 10mg/kg dose was more effective than the 1 mg/kg but for BLISS-76 
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the reverse was the case.  The BLISS-76 result is shown in Figure 20 together the mean 
change in SF-36 Vitality domain score. 
 
Figure 20: Mean change in FACIT and SF-36 vitality score by week 52 (Taken from 
HGS Briefing Document to FDA see Figure 9-35) 
EQ-5D 
There was no significant difference between belimumab and placebo in the absolute change 
of EQ-5D score from baseline in either trial or pooled total populations during clinic visits.  
The results for the 10 mg/kg belimumab and placebo groups in BLISS-76 were 
indistinguishable.  For the pooled target population the difference between 10 mg/kg and 
placebo groups reached statistical significance in favour of belimumab at week 24 (P ≤ 0.01), 
but the difference had almost completely faded by week 52 MS Figure 5.21 Page 135). 
Results for the mean change in SELENA SLEDAI score from baseline at week 52 were 
submitted in MS Table 5.17 (Page 113) and clarification response Table A6.1 and are 
summarised in Table 19.  There was no significant difference between belimumab and 
placebo in the absolute change of EQ-5D score from baseline in either trial or pooled total 
populations during clinic visits.  The results for the 10mg/kg belimumab and placebo groups 
in BLISS-76 were indistinguishable.  For the pooled Target population the difference between 
10mg/kg and placebo groups reached statistical significance in favour of belimumab at week 
24 (P ≤ 0.01), but the difference had almost completely faded by week 52 MS Figure 5.21 
Page 135). 
Results for the mean change in SELENA SLEDAI score from baseline at week 52 were 
submitted in MS Table 5.17 (Page 113) and clarification response Table A6.1 and are 
summarised in Table 19.  
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Table 19: Mean change and mean percent change in SLEDAI score week 52 
 
 BLISS-52 BLISS-76 Pooled Total Population
High Disease 
Activity Subgroup 
Pooled Total 
2 
High Disease 
Activity Subgroup 
BLISS-52 
High Disease 
Activity Subgroup 
BLISS-76 
Change from 
Baseline at 
Week 52 
Placebo 
N = 287 
10mg/kg 
N = 290 
Placebo 
N = 275 
10mg/kg 
N = 273 
Placebo 
N = 562 
10mg/kg 
N = 563 
Placebo 
N = 203 
10mg/kg 
N = 193 
Placebo 
N = 107 
10 
mg/kg 
N = 112  
Placebo 
N = 96 
10 
mg/kg 
N = 81 
Mean change 
from baseline 
(± SE) 
 
-3.57  
± 0.24 
4.97  
± 0.27 
-2.77  
± 0.25 
-3.70  
± 0.27 
-3.18  
± 0.18 
-4.36  
± 0.19 
-4.1  
± 0.3 
-5.8  
± 0.3 
-4.1  
± 0.4 
-6.3  
± 0.5 
-4.0  
± 0.5 
-5.2  
± 0.5 
P-value1
 
  - < 0.0001 - 0.0063 - < 0.0001 - 0.0005 - 0.0008 - 0.1705 
Mean % 
change (± 
SE) 
 
-34.76  
± 2.50 
-45.60  
± 2.45 
-25.97  
± 2.72 
-35.94  
± 2.80 
-30.47  
± 1.85 
-40.93  
± 1.86 
-30.5 
(2.3) 
-45.5 
(2.4) - - - - 
P-value1
 
  - 0.0018 - 0.0073 - < 0.0001 - < 0.0001 - - - - 
1  ANCOVA model for the comparison between each belimumab dose and placebo, adjusted for baseline SELENA SLEDAI score (≤ 9 vs. ≥ 10), baseline 
proteinuria level (< 2 g/24 hour vs. ≥ 2 g/24 hour equivalent) and race (African descent or indigenous-American descent vs. other). For pooled data analysis, 
study was also included as an additional covariate 
2
 
  No treatment-by-study interactions observed (all p-values > 0.367) 
Both absolute SLEDAI score reduction from baseline, and percent reduction relative to 
baseline score, were greater for the 10mg/kg group than for the placebo group; this was 
consistent and significant for the whole BLISS population (separately by trial and for pooled 
populations) and for the pooled Target  or high disease activity population.  For the whole 
population, results favoured belimumab more strongly in BLISS-52 than BLISS-76.  The by-
trial results for the Target population are shown below.  They indicate stronger support for 
belimumab in BLISS-52 in which the difference between groups in absolute reduction in 
SLEDAI score was about double that in BLISS-76 in which the difference between groups 
was not significant (P = 0.1705).   
The HGS Briefing Document to the FDA5 Figure 21 (see ) showed the percentage change in 
SLEDAI score (relative to baseline) throughout the two trials; this is reproduced in Figure 21 
for the mean change in FACIT and SF-36 vitality score by week 52. 
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Figure 21: Percentage change in SLEDAI score according to treatment arm (Taken 
from HGS Briefing Document Figure 9-29) 
 
These results support a dose response relationship in BLISS-52, but the difference between 
1mg/kg and 10mg/kg dose regimens in the BLISS-76 trial is relatively trivial.  
Safety  
The submission pooled results from three RCTs: BLISS-52, BLISS-76 and LBSL02.  
LBSL02 lasted 52 weeks, preceded the BLISS trials, and was conducted in North America 
(98% patients from the USA), and did not employ the SRI composite outcome measure.  The 
LBSL02 trial randomised 449 patients to one of four treatments: SoC + placebo, SoC + 
1mg/kg belimumab, SoC + 4mg/kg belimumab, and SoC + 10mg/kg belimumab.  Although 
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all patients had a history of auto-immunity, at recruitment 30% currently lacked anti-nuclear 
antibodies. 
 
There were 15 deaths during the controlled phase of the three trials; 3 in the placebo group 
(n=675), and 12 in the belimumab groups (n=1458) with 6 each in the 10mg/kg and 1mg/kg 
groups respectively.  One death in the 1mg/kg belimumab group followed 15 weeks after the 
patient stopped belimumab treatment.  The causes of death were various and are listed in 
Table 20 (based on FDA Briefing Package, Table 34).3 When deaths are rated according to 
exposure these results translate to: 0.43/100 patient years for placebo (95% CI: 0.09, 1.27) 
and 0.79/100 patient years for belimumab (95% CI: 0.41, 1.38).3
  
  There were two completed 
suicides in the belimumab groups (none in placebo); a further suicide was observed during the 
LBSL99 extension study.  These were not judged to be associated with belimumab since the 
patients concerned had a history of depression and SLE is associated with an increased risk of 
depression and suicide. 
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Table 20: Deaths occurring during controlled phase of belimumab RCTs  
Study group Age/Sex Cause 
Days from 
1’st 
infusion 
Days 
from last 
infusion 
Pertinent History 
Placebo 45yo/F Myocardial 
Infarction 
328 19 Presented to ER with new onset chest and epigastric pain and had 
a cardiopulmonary arrest. 
Placebo 25yo/F Cardiac 
Arrest, 
secondary to 
sepsis 
70 11 Concomitant Meds: Prednisolone, methotrexate, diclofenac and 
ibuprofen. Developed bacterial gastroenteritis and dehydration 
complicated by vasculitis and became septic (blood culture 
positive for Staph. Saprophyticus) despite antibiotics and 
supportive medical care. 
Placebo 18yo/F Unknown 225 84 Hospitalized 2 months prior to death for acute abdominal pain 
secondary to portal/mesenteric/renal vein and vena cava 
thrombosis and acute pancreatitis. 
Belimumab 1mg/kg 43yo/F Suicide 32 20 H/O Depression on antidepressant (citalopram). Reported to have 
worsening depression prior to committing suicide. 
Belimumab 1mg/kg 46yo/F Unknown 56 28 H/O Asthma, clostridial gastroenteritis, eosinophilia and QT 
prolongation on EKG. Concomitant Meds: ibuprofen, 
hydroxychloroquine, mycophenolate, prednisone and lisinopril. Pt. 
developed nausea, vomiting and weakness while camping and was 
found to be dehydrated due to unspecified gastrointestinal illness 
at local ER where she died despite resuscitative measures. 
Belimumab 1mg/kg  52yo/F Ovarian 
cancer 
21 7 Positive family H/O ovarian cancer. H/O Vaginal bleeding prior to 
study entry that evolved to include left lower abdominal pain, 
vaginal pain, pelvic cramping and diarrhea by the 9th study 
medication that was followed by a diagnosis of advanced ovarian 
cancer on laporotomy. 
Belimumab 1mg/kg 32yo/F Sepsis, 
secondary to 
cellulitis 
13 13 Concomitant Meds: Methylprednisolone, mycophenolate, 
thalidomide, and ibuprofen. Developed cellulitis and died as a 
result of sepsis despite antibiotics and supportive medical care. 
Belimumab 1mg/kg 58yo/F Ischemic 
stroke 
345 34 H/O hypertension. Anti-cardiolipin antibody negative at screening. 
Concomitant meds: Prednisolone, hydroxychloroquine, bioprolol. 
Belimumab 1mg/kg 25yo/F Respiratory 
failure /SLE 
flare 
216 104 Patient died due to respiratory arrest more than 15 weeks after the 
patient discontinued the trial due to acute renal failure. Post study 
withdrawal, the patient was hospitalized and experienced oliguria, 
uremic syndrome, sepsis, polyserositis, ascites, intestinal edema, 
anemia, and alveolar hemorrhage. 
Belimumab 10mg/kg 40yo/F Respiratory 
failure 
secondary to 
sepsis 
257 33 Pt. developed aspiration pneumonia status post seizure, became 
septic and died due to respiratory failure despite antibiotics and 
aggressive supportive medical care (respirator). 
Belimumab 10mg/kg 47yo/F Cardiac arrest 
(SLE flare) 
77 21 H/O Diabetes mellitus, pericardial excision, serositis, 
antiphospholipid syndrome, pulmonary hypertension, and heart 
failure. Concomitant Meds: Azathioprine, methotrexate and 
prednisone. Hospitalized after c/o severe headache with vomiting 
associated with fever, chills and productive cough with bilateral 
pleural effusions and lymphopenia attributed to SLE flare with 
CNS involvement. She was treated with corticosteroids and 
NSAIDs but died due to cardiac arrest. 
Belimumab 10mg/kg 53yo/F Bacterial 
sepsis 
331 25 H/O Obesity, pulmonary fibrosis. Developed septic shock (blood 
cultures positive for MRSA) and multi-organ failure secondary to 
infected herpes zoster lesions despite antibiotics. Concomitant 
meds: Methyplprednisone, azathioprine, chloroquine, salbutamol, 
acenocoumarol, sertraline, and omeprazole. 
Belimumab 10mg/kg 20yo/F Infectious 
diarrhea 
336 28 Had SLE flare with cutaneous vasculitis and hypochromic anemia. 
Started on antibiotics and increased corticosteroids but developed 
infectious diarrhea and died en route to hospital. Concomitant 
meds: Prednisolone, azathioprine, hydroxychloroquine, 
levofloxacin, iron, ciprofloxin/tinidazole, and fluconazole. 
Belimumab 10mg/kg 23yo/F Suicide 272 13 H/O Depressed mood and psychotic disorder; autoimmune 
thyroiditis, and drug-induced hepatitis. Committed suicide 
following conflict with parent. Concomitant meds: 
methylprednisone, azathioprine, hydroxychloroquine, meloxicam, 
levothyroxine, and rebamipide. 
Belimumab 10mg/kg 33yo/F Respiratory 
Failure From 
Presumed 
Pulmonary 
Embolus 
128 8 H/O chronic cholecystitis. Pt. developed dyspnea eight days after 
her last study infusion and died en route to the hospital. (No 
autopsy.) Concomitant meds: Prednisone, levothyroxine, and 
ceftriaxone. 
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Adverse events  
In all treatment groups > 90% of patients experienced at least 1 AE.  The most commonly 
occurring AEs were headache, upper respiratory tract infection, arthralgia, nausea, UTI, 
diarrhoea and fatigue.  
 
The percentage of patients experiencing at least one serious AE and at least one serious AE 
was very similar between placebo and belimumab groups ranging 13.5% to 18.6%, there was 
a very slight numerical excess with belimumab.  The most frequent serious AEs (≥  1% in any 
treatment group) were pneumonia, pyrexia, UTI, cholelithiasis, and cellulitis.  The percentage 
of patients experiencing at least one severe AE was 15.4% for the placebo group and 16% 
across the belimumab groups; the most common severe adverse events were not identified. 
Infections 
Infections occurred slightly more frequently in patients treated with belimumab compared to 
placebo.  The most frequent infections were URTI, UTI, nasopharyngitis, sinusitis, and 
bronchitis.   
Infusion / hypersensitivity reactions  
Occurrence of infusion plus hypersensitivity reactions was similar between belimumab and 
placebo-treated patients (17% and 14.7%, respectively).  Of 1458 belimumab treated patients, 
15 experienced hypersensitivity reactions on the day of infusion compared to one of 675 
placebo-treated patients.3
The most frequent infections were URTI, UTI, nasopharyngitis, sinusitis, and bronchitis.  Of 
these, nasopharyngitis and bronchitis occurred more commonly with belimumab treatment 
compared to placebo.  Two opportunistic infections occurred, both in the belimumab 10mg/kg 
group: disseminated CMV infection on day 62; and an Acinetobacter bacteremia on day 15.  
Four infections were related to deaths: sepsis (placebo group); infectious diarrhea (belimumab 
10mg/kg group); cutaneous infection leading to sepsis (belimumab 10mg/kg group); and 
cellulitis leading to sepsis (belimumab 1mg/kg group).
  Five discontinuations resulted from hypersensitivity reactions 
amongst 1458 belimumab patients and none among 675 patients receiving placebo.  
3
4.2.6 Pooling of trial data 
 
NICE requests that: “For each outcome for each included RCT, the following information 
should be provided” ….“The size of the effect” … “The unit of measurement”. 
The submission pooled results from two trials, both for the whole BLISS populations and for 
the Target populations.  The manufacturer considered that the pooled trial results were most 
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appropriate for the decision problem, and importantly it was pooled results for both 
populations that were entered into the economic model.  The MS stated as shown in Box 11. 
Box 11: Taken from Page 21 and 97 of the MS  
“For the purpose of this submission pooled efficacy from the two pivotal Phase III studies is 
considered most relevant to the decision problem.” Refer to MS Page 21  
 
AND 
 
“Pooling is appropriate given that the trials were essentially identical in design and in the 
analysis of the primary endpoint, the p-values for the treatment-by-study interaction were not 
significant (interaction p-values > 0.5).” Refer to MS Page 97 
 
Comment  
The trials were conducted according to very similar protocols and used the same primary end 
point so the lack of significant treatment-by-study interaction was not surprising; see section 
4.2.4 of this report. 
The submission initially supplied only pooled results for the Target population, therefore the 
ERG requested “by-trial” results and further justification for pooling.  The response to this 
request is shown in Box 12 (for the full response see Appendix 5). 
Box 12: From the manufacturer’s clarification response 
“….one must then determine whether the relative treatment effect is different in one study 
compared with the other study when evaluating whether two studies are similar enough to 
pool.  Each of the Phase 3 studies achieved statistical significance for belimumab 10mg/kg on 
the pre-specified primary endpoint of SRI response at Week 52; therefore, these nearly 
identical, studies provide independent replication of results.” 
 
Comment  
There remain doubts as to whether the pooled trial results are  relevant for patients in England 
and Wales.  The BLISS trials were run globally, recruited 1684 patients in 226 centres across 
32 countries and involved a large number of different investigators.  Although both trials 
achieved statistical significance on the primary end point, they were dissimilar in underlying 
patient groups e.g. by ethnicity and in effect size for almost all outcomes, with BLISS-52 
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providing stronger results than BLISS-76; furthermore there were inconsistencies with regard 
to an expected dose response relationship. 
The ERG is concerned that the pooled results are mainly driven by those from the BLISS-52 
trial (conducted in Pacific-Asia and South America) while results in the BLISS-76 trial, 
conducted in North America and Europe, were only marginally in favour of belimumab 
relative to placebo and reached statistical significance only for two overlapping outcomes 
(SRI responders at week 52, and percentage of patients with ≥ 4point reduction in SLEDAI 
score at week 52 which itself is a component of the SRI).  The extent to which these concerns 
extend to the target population was not possible to gauge from the initial submission because 
only pooled results were presented.  The ERG therefore requested clarification on trial 
specific target populations and the manufacturer’s justification for pooling across trials.   
For the target population there was again a greater contribution from BLISS-52 to the pooled 
results both in terms of number of patients (BLISS-52 contributed 55% of whole target 
population and 58% of those that received belimumab) and in effectiveness (BLISS-52 
provided greater effect sizes compared to BLISS-76 for SRI week 52, modified SRI week 52, 
percentage with SLEDAI reduction by ≥ 4points, SLEDAI mean change by week 52, no new 
BILAG 1A/2B, no worsening in PGA and  reduction in steroid usage weeks 40 to 52).  The 
ERG therefore remain concerned that the pooled trial results dilute the rather less positive 
findings most relevant to the decision problem by including additional data from a less 
relevant population, and that target population results by trial should have been included in 
sensitivity analysis in the economic model. 
Trial baseline SLEDAI scores used in economic model 
The manufacturer’s economic analysis (section 5) made use of data from an SLE cohort 
studied at JHU so as to model cost effectiveness of belimumab for the whole and Target 
populations from the BLISS trials.  The JHU cohort experienced relatively mild disease 
compared to patients in BLISS and particularly compared to the BLISS the high disease 
activity Target population.  During the clarification process the ERG requested the 
distribution of SLEDAI scores at year one and last year of observation for patients in the JHU 
cohort.  The SLEDAI scores shown in Figure 22 illustrates the differences between Target 
and JHU populations, (year one and last year scores are shown for JHU cohort, Figure B17.2 
of the clarification document, the clarification response did not make clear which was year 
one and which last year). 
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Figure 22: SLEDAI scores for Target and JHU populations (from clarification 
document) 
 
The median follow up for the JHU cohort was 6.9 years.  During this time organ damage 
progression was monitored and for economic analysis this was modelled (using parametric 
time event analyses) so as to be able to predict organ damage progression for BLISS patients 
according to their observed SLEDAI changes.  Yet for the JHU cohort the difference between 
year one and last year in average SLEDAI scores is small.  The ERG considers that this 
indicates some inadequacy in using the short term measure of disease activity (i.e. SLEDAI) 
to model how a group of patients will progress to organ damage. 
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4.2.7 Conclusions 
Efficacy evidence came from two multicentre international industry sponsored RCTs (BLISS-
52 and BLISS-76) comparing SoC plus belimumab with SoC plus placebo; each trial had 
three arms: placebo, 1mg/kg belimumab and 10mg/kg belimumab dose regimens.  Data for 
the 1mg/kg arms was excluded from the submission, but results available in the public 
domain were considered in the ERG’s assessment.  Outcomes for six populations were 
presented: whole populations from BLISS trials, whole populations pooled across BLISS 
trials, Target population from BLISS trials and Target populations pooled across BLISS trials.   
The Target population was a high disease activity subgroup identified from post hoc 
exploration of effectiveness of the primary outcome.  There were more noticeable within-trial 
baseline imbalances (10mg/kg vs. placebo) for the Target population than for the whole 
population.  The Target population results are not necessarily equivalent to those that would 
be obtained from a randomised trial in this population.  
The primary outcome was specified as the percentage of responders at week 52 according to a 
novel composite disease activity measure (SRI).  This outcome was statistically in favour of 
belimumab (10mg/kg vs. placebo) in both trials.  For both whole and Target populations, 
results from BLISS-52 were more favourable for belimumab than results from BLISS-52. 
For all secondary outcomes in BLISS-76 effect sizes were insufficient to be confident that 
effects could not be accounted for by chance.  For several outcomes, including percentage 
responders and time to first flare in BLISS-76, although formal statistical tests were not 
performed, it appeared that the 1mg/kg dose regimen was as effective, or more effective, than 
the 10mg/kg dosage.  
Geographical and racial differences between BLISS trials indicate that efficacy results from 
BLISS-76, rather than from BLISS-52 or pooled BLISS populations, are more generalisable 
to the UK. 
On most safety outcomes placebo and belimumab performed equally. There were more deaths 
under belimumab than placebo; on a “per patient year of exposure” basis the rate for 
belimumab was about double that for placebo although this finding could have occurred by 
chance.   Causes of death were various and most were those associated with the condition of 
SLE.  There was insufficient evidence to determine if there was any association between 
belimumab and mortality. 
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5 ECONOMIC EVALUATION  
5.1 Introduction  
Including a one page summary of structure, assumptions and sources, with signposting to 
Tables. 
Patient population and subgroups under consideration 
The submission outlines that there are three groups under consideration: 
• The patient population as observed from pooling the All BLISS patient data; 
• The anticipated license patient population of Anti-dsDNA+ve and low (C3 or C4); 
• The Target population which restricts the patient population to the licensed patient 
population with an SS score at baseline of at least 10. 
 
With the exception of Table 6.49 of MS, the analysis presented within the main body of the 
submission relates to the All BLISS patient population.  Little detail is presented for the 
anticipated license population, though the base case results for this group are presented within 
Table 6.49 of the MS.  The inputs and results for the Target population are presented in 
section 6.9 of the MS. 
 
Given the anticipated license as stated within the submission, the ERG review of the 
economics does not focus upon the All BLISS inputs, though the base case results for this 
group are presented.  The brief summary of the base case results for the anticipated license 
patient population is also presented. But unless otherwise stated the inputs to and results of 
the modelling within the ERG review of the economics relate to the Target population.  
 
Implementation of the electronic model 
The manufacturer model is embedded within Excel, but apart from some very basic pre-
modelling data adjustment the Excel element of this is confined to being a database of input 
values and a store of the model results. The modelling is implemented using Visual Basic 
(VB) programming.   
 
Prior to running the model the user is allowed to change various pre-specified settings within 
the model, such as the subgroup to be analysed.  The model uploads the relevant set of input 
parameters into memory, calculates the model using the VB code and outputs the results to an 
Excel worksheet. 
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The VB programming is well organised and compact with no obviously superfluous code.  
But it is relatively complex and lengthy with little to no explanatory comment, running to 53 
Pages when printed out in Arial 8pt.  This has made it difficult for the ERG to confidently 
explore structural scenarios other than those pre-specified within the model within the STA 
time constraints. 
 
Stopping rule and clinical effectiveness estimates 
Note that the economics applies a stopping rule within the belimumab arm at week 24: those 
not experiencing a change in their SELENA-SLEDAI (SS) score of at least 4 by week 24 are 
assumed to stop belimumab treatment. Conceptually, this gives rise to two groups within each 
arm: 
• Belimumab week 24 responders; 
• Belimumab week 24 non-responders; 
• SoC week 24 responders; 
• SoC week 24 non-responders. 
When reviewing the economics of the submission, it should be borne in mind that the actual 
experience of the belimumab week 24 non-responders at week 52 as reported within the trials 
is not used within the model for these patients. 
5.2 Manufacturer’s submission  
5.2.1 Economic literature search 
The searches undertaken by the manufacturer to identify cost-effectiveness evidence were 
conducted on 18th March 2011. Seven databases were searched (Medline (Pubmed), Medline 
In-Process (Pubmed), Embase, EconLit, CRD databases (HTA database, Database of 
Abstracts of Reviews of Effectiveness (DARE), NHS Economic Evaluation Database (EED).  
In addition, searches were conducted in Research Papers in Economics (RePEc), a clinical 
trials database (ClinicalTrials), the websites of the American College of Rheumatology, the 
USA FDA and EMA. 
The search utilised terms to identify patient group (lupus) and the intervention (belimumab). 
Terms to identify comparators were not included. In the Pubmed search, the restriction to title 
and abstract in the belimumab section of the search strategy has resulted in 7 fewer hits 
compared to the same line in the clinical effectiveness search strategy. In line 1 of the 
Pubmed search, lupus would automatically have been mapped by Pubmed, resulting in the 
inclusion of the wrong MeSH heading Lupus Vulgaris. The MeSH heading Lupus 
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Erythematosus, Systemic was not included.  However, because Pubmed also searched for 
lupus in all fields, papers with this MeSH heading should still have been picked up. 
In the Embase search several lines include major mistakes resulting in it being unclear as to 
how the database would have performed the search.  For example, line 1 starts with “exp 
AND” and includes two database index terms that do not exist: ‘lupus’/exp, ‘sle’/exp.  Testing 
this line of the search by entering it exactly as reported results in 23221 (06/05/11), which is 
far fewer than the 58059 reported in the search strategy.  Many of the lines in Embase that 
should have been searching the EMTREE headings were entered very differently and resulted 
in far fewer hits (e.g. the EMTREE heading in the filter at line 11: exp Economic Evaluation/ 
(which when tested brought back 166263 hits on 06/05/11) was entered as “exp AND 
economic AND (‘evaluation’/exp OR evaluation)” and resulted in only 977 hits, which may 
have led to important studies being missed. 
No date or language limits were applied. A search filter was applied to the Embase and 
Medline searches to limit them to a particular type of evidence (economic studies), which was 
not appropriate in Pubmed in light of the small number of studies retrieved before the filter 
was applied (41).  The manufacturer states that the search filter used was the CRD sensitive 
economics filter.  However, the version the manufacturer uses in Pubmed does not match that 
given in CRD’s NHS Economics Evaluation Database Handbook 200716
Overall, the Pubmed and Embase searches appear to be of a poor quality and may have 
resulted in important studies being missed (see 
 and there are also 
some mistakes in the translation of some elements (e.g. the MeSH heading in the filter exp 
“Costs and Cost analysis”/ was entered as: costs AND “cost analysis”. Fortunately, when this 
was translated by Pubmed the correct MeSH heading was searched, but several unusual 
combinations of free text terms were also searched (e.g. costs"[All Fields] AND "cost"[All 
Fields] AND "analysis"[All Fields]). 
Appendix 2 for further details). 
5.2.2 Manufacturer’s direct drug cost and administration  
 
Belimumab dose and direct drug cost 
To calculate the direct drug cost for belimumab the manufacturer has assumed whole vial use 
that minimises wastage. Belimumab is available in 400mg and 120mg vials, at unit costs of 
£381 and £114 respectively excluding the PAS, these yielding the same cost per mg.  
***************************************************************************
**********************************.  Since 120mg is not a factor of 400mg, the 
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minimum cost dose can in theory use anything up to nine 120mg vials.  Cost minimisation 
suggests that where appropriate multiple vials of 120mg should be used.  For instance, six 
120mg vials provides a total available dose of 720mg whereas one 400mg vial and three 
120mg vials provide a total available dose of 760mg: a 72kg patient is most cheaply dosed 
with six 120mg vials while a 73kg patient is most cheaply dosed with one 400mg vial and 
three 120mg vials. 
The manufacturer applies the above dosing calculations to the distribution of patient weights 
of the pooled trial data to arrive at a weighted average belimumab drug cost.  These are 
differentiated by patient subgroups to yield average drug costs per administration of £671 for 
the belimumab arm pooled for All BLISS, £650 when this is restricted to the anti-dsDNA+ve, 
low (C3 or C4) group and £654 when this is restricted to the Target population.  
***************************************************************************
**********************************.  
Belimumab administration cost 
Belimumab administration is assumed to require 2 hours of dedicated nursing time which is 
costed using 2010 Patient Social Service Research Unit (PSSRU) rates for a senior hospital 
staff nurse at £126 per administration.  There is no specific allowance for any consumables 
within this administration costing 
 
5.2.3 Model Structure  
The model is implemented as a patient level simulation due to the complexity of SLE and the 
large number of health states that this implies.  This inevitably makes it and its electronic 
implementation relatively complex, but an outline of the model and the data sources is 
reasonably simple to present. Within this summary it is simplest to separate the model 
elements by the source of the data feeding into them: 
1. Trial data: 
a. The baseline characteristics for each patient being simulated including SS 
score at baseline and whether there is involvement for each of the 12 SLICC 
organs modelled 
b. The likelihood of response at week 24 in the belimumab arm, defined as a 
change of at least 4 in the SS score from baseline 
c. The change in SS score between baseline and week 52 for belimumab week 
24 responders 
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d. The change in SS score between baseline and week 52 for SoC, this also 
being applied to belimumab week 24 non-responders 
e. The “natural” discontinuation rates for belimumab week 24 responders after 
week 24 
f. The direct effect of the SS score upon quality of life 
g. The direct effect of the SS score upon treatment cost 
2. JHU cohort data: 
a. The evolution of the SS score in the SoC arm after week 52, with belimumab 
week 24 responders being assumed to retain the absolute advantage in SS 
score over the SoC arm while they remain on treatment 
b. Implicit in the above the Adjusted Mean SLEDAI (AMS): the adjusted mean 
SS score since baseline 
c. The relationship between the SS score and steroid use 
d. The main survival model 
e. The likelihood of developing involvement for each of the 12 SLICC organs 
modelled if the organ concerned is not involved at baseline 
3. Other data drawn from the broader literature: 
a. The standardised mortality rate for a given SS score 
b. The quality of life impact of organ involvement 
c. The additional cost for each organ involvement 
 
The baseline characteristics, likelihood of response, week 52 SS scores and discontinuation 
rates are differentiated by subgroup within the model (1.a. - 1.e.).  All other relationships are 
not.  A number of Tables from the manufacturer’s submission are replicated within what 
follows for ease of reference. 
Trial data element 1.a.Baseline patient characteristics  
For each patient level simulation the patient characteristics are randomly sampled from the 
underlying distribution; e.g. for the Target population the likelihood of the patient being 
female is based upon the 94.2% of the pooled trial data and a drawing on a Bernoulli 
distribution (Tables 6.37, 6.38 and 6.39 of the MS for the Target population).  The patient is 
then cloned within the model for running through the SoC arm of the model and the 
belimumab arm of the model. 
 
Trial data element 1.b.Likelihood of response in the belimumab arm 
This is differentiated by the patient baseline SS score and drawn on a Bernoulli distribution 
(Table 6.42 of the submission for the Target population).  
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Trial data element 1.c and 1.d.Change in SS score from baseline to week 52 
Unlike the likelihood of response, this is not drawn from lookup Tables based upon SS score 
at baseline and treatment arm.  The manufacturer pools the trial data and uses regression 
analysis to derive coefficients for the percentage reduction in a patient’s baseline SS score 
dependent upon whether the patient was in the SoC arm, the belimumab arm and if in the 
belimumab arm whether they were a week 24 responder (See Table 21; Adapted from Table 
6.41 of MS for the Target population). 
Table 21: Linear regression of coefficients for SS52=(1+β)SS0: Target population 
 β s.e. P value 
SoC -34.9% 2.2% < 0.01 
Belimumab -34.3% 4.6% < 0.01 
Belimumab week 24 responders -28.0% 5.2% < 0.01 
 
As the model assumes that week 24 non-responders within the belimumab arm cease 
treatment and experience the SoC SS scores at week 52 the central estimates of this are more 
transparently rearranged as shown in Table 22. 
Table 22: Rearranged linear regression of coefficients for SS52=(1+β)SS0: Target 
population 
 β 1+β 
SoC -34.9% 65.1% 
Belimumab week 24 non-responders -34.9% 65.1% 
Belimumab week 24 responders -62.3% 37.7% 
 
For a belimumab week 24 responder, the absolute difference at week 52 in SS scores between 
the belimumab week 24 responder and her SoC arm clone is assumed to be maintained while 
she remains on belimumab treatment; i.e. 27.4% of her baseline SS score up to 
discontinuation. 
Trial data element 1.e. natural discontinuation rates for belimumab week 24 responders  
The written submission is not entirely explicit as to the modelled natural discontinuation rates 
but it appears that for belimumab week 24 responders a daily hazard of discontinuation is 
calculated based upon the overall rate of discontinuations between day 168 and day 532.  A 
six monthly natural discontinuation rate is calculated for the first year; i.e. presumably 
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subsequent to the assessment of response at week 24, with an annual rate being calculated 
thereafter.  The day 168 to day 532 proportion remaining on treatment among belimumab 
week 24 responders is given as 0.891 in the electronic model for the All BLISS data set, and 
as 0.920 for the Target population. 
 
A key aspect of this data is that it must relate to discontinuations between day 168 and day 
532 and not to discontinuations between baseline and day 532, as the latter would cause the 
model to overestimate discontinuation rates among belimumab week 24 responders (Table 
6.41 of the MS for the Target population).  There is some lack of detail within the submission 
around this variable: its source, the period it relates to, any pooling of data between BLISS-52 
and BLISS-76 given their differing duration after day 164; any evidence of difference 
between BLISS-52 and BLISS-76 for this variable; and, the reasons for the observed 
discontinuations.  The latter may be particularly important given that this variable is used to 
extrapolate over the time horizon of the model with the cost effectiveness estimate being quite 
sensitive to it. 
 
Within the model the impact of these continuation/discontinuation rates are graphed below, as 
submitted by the manufacturer in response to ERG clarification question B24.  The upper 
curve is the Target population.  Note that Figure 23 shows the effect of both discontinuations 
and mortality on those remaining on belimumab treatment. 
Figure 23: Continuation rates among belimumab week 24 responders 
 
As explored later, a high discontinuation rate improves the estimated cost effectiveness of 
belimumab; i.e. it is more cost effective if belimumab has an initial effect and high response 
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rate but that patients experiencing a response rapidly discontinue belimumab treatment 
thereafter. 
 
Trial data element 1.f. SS score direct impact upon QoL 
Within the BLISS trials EQ-5D data was collected and transformed to HRQoL values using 
the Dolan algorithm17
“Clean” QoL = 1.297 – 0.145 * ln(Age) – 0.054 * ethnicity – 0.009 * SS score 
.  Regression analysis then related these values to patients’ SS scores, 
age, sex, ethnicity and organ damage.  The statistically significant organ damage parameters 
were retained in order to control for their impact within the regression analysis, but organ 
damage was then set to be zero to generate the “clean” utility function for a patient with no 
organ damage: 
where ethnicity is 1 if black and 0 if not.  Note that the above corresponds with the clean 
utility function as in Table 6.20 of the submission and the electronic model, not with the 
function given in the text of the submission which appears to be incorrect. 
Trial data element 1.g. SS score direct impact upon costs:  
Limited detail is provided within the submission on the resource use questionnaire 
administered during the LBSL02 phase II trial.  This was apparently a retrospective data 
collection administered at baseline, day 168 and day 365. 2006 PSSRU and NHS reference 
costs18
Table 23
 were applied to this data, and the aggregate six monthly costs from baseline to day 168 
and day 168 to day 365 were regressed on patients’ SS score severity class during this period.  
The SS score severity class took a value of 0 to 3, this being determined by a patient’s 
maximum observed SS score during the relevant 6 month period: 0 for a maximum SS score 
of 0; 1 for a maximum SS score of between 1 and 4; 2 for a maximum SS score of between 5 
and 12; and, 3 for a maximum SS score of over 12.  This regression analysis based on SS 
score severity class was then mapped back onto SS scores as outlined in Figure 6.16 of the 
submission, with the CPI being used to inflate the figures to 2010 prices and the six monthly 
costs being doubled to yield an annual cost.  This yields the final direct cost function of Table 
6.25 of the MS ( ).  Within this, it should be noted that while both constant and 
derived coefficient were estimated as being significant, the regression had an R2 
 
of only 0.01. 
Table 23: Manufacturer estimated SS direct annual cost function table 
SS score Cost SS score Cost SS score Cost 
0 £1,152 5 £1,625 10 £1,931 
1 £1,286 6 £1,681 11 £2,005 
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2 £1,419 7 £1,736 12 £2,079 
3 £1,514 8 £1,792 13+ £2,153 
4 £1,569 9 £1,857   
 
 
JHU cohort data elements 2.a.and 2.b. Evolution of SS and AMS scores after week 52 
For the evolution of the SS score beyond week 52 the manufacturer originally estimated the 
regression equation: 
 
But the manufacturer views this as providing a relatively poor fit to the data from the 
belimumab phase II trial, as shown in Figure 24.  For the modelling the manufacturer adjusts 
the constant and applies the equation: 
 
on the grounds of it better reflecting the phase II trial data. 
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The AMS score was developed to measure disease severity over time as opposed to the SS 
score which only reflects disease activity over the preceding 10 days.  AMS is calculated as 
the area under the curve of disease activity measurements between two time-points.  The area 
under the curve is then divided by time of follow-up to provide an average score over the 
period of interest.  In Figure 24 above the ERG assume that the area under the curves shown 
can be used to represent AMS. However, the MS references to AMS score may refer to either 
the “AMS over lifetime” or the “average mean SLEDAI up to current time” which are 
presumably calculated in the same manner: the area under the SS score curve divided by time 
elapsed. 
The AMS is calculated as the area under the SS score curve between two time points divided 
by the time of follow-up to provide an average score over the period of interest.  
The AMS score refers to either the “AMS over lifetime” or the “average mean SLEDAI up to 
current time” which are presumably the samea
The SS curve determines the AMS, with it being the AMS that is used within the survival 
model and the organ damage natural history model. 
: the area under the SS score curve divided by 
time elapsed. 
JHU cohort data element 2.c. Steroid use: 
                                                          
a Note that within the written there seems to be some occasional looseness of wording around SS and 
AMS, with there being some instances of the AMS referring to an annual AMS score; i.e. the average 
SS score over one year rather than from baseline. 
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Figure 24: Medium term SS natural history model  
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The manufacturer argues that the steroid doses and changes to these as seen in the BLISS 
trials are not representative of the likely steroid dose reductions that would be possible with 
belimumab.  Given this, the manufacturer fits a random effects model to the JHU data which 
estimates the steroid dose as a function of the average SS score within the year being 
simulated. 
 
Table 24: Steroid use as a function of SS score Table 6.11 
 Coef (95% CI) P-value 
Constant 3.410 (0.617-0.823) < 0.001 
SS score within year average 0.720 (3.073-3.747) < 0.001 
 
Note that despite the arguments around the representativeness of the JHU cohort for the All 
BLISS population and modelling as outlined in the previous section, no alternative forms for 
the steroid use equation were explored.  In response to ERG clarification question C2 the 
manufacturer justifies this on the basis of there being little difference in the baseline steroid 
doses between the JHU cohort, 9.95mg/day, and the pooled All BLISS 10.78mg/day. 
JHU cohort data element 2.d. Survival model 
Initial univariate survival analysis within an exponential regression model framework found a 
range of variables within the JHU cohort data to be predictors of mortality, including age and 
duration of disease which were each statistically significant. Through a process of 
multivariate stepwise covariate selection a sensitivity analysis around the proper distribution 
(Exponential and Weibull) the range of variables included in the survival model were 
reduced.  Within this process age was not included due to concerns around it having a high 
positive correlation with disease duration.  Age at diagnosis and disease duration was chosen 
instead for this selection process.  Within the multivariate stepwise covariate selection disease 
duration was further eliminated, leaving only age at diagnosis [Table 6.12 and Table 5 of 
Appendix 21b
 
].  
Note that both the AMS and the Cumulative Average Prednisone Dose (CAPD) up to current 
time are explanatory variables within the JHU cohort survival model.  As outlined above, 
these are determined by a patient’s SS curve. 
                                                          
b Table 5 of appendix 21 outlines that the model adopted, model 5, has the second highest AIC of the 
four models this is reported for. 
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Since age and disease duration have been eliminated from the JHU cohort survival model, the 
manufacturer reintroduces age to the calculation of mortality risk using an SLE Standard 
Mortality Ratio (SMR) differentiated by age group drawn from the Bernatsky 200619
 
 
reference coupled with general population mortality rates as outlined below. 
JHU cohort data element 2.e.Risk of developing organ involvement 
Through a similar analysis to the survival model, the manufacturer estimates individual risk 
equations for the development of individual SLICC item organ involvement [Table 6.14 and 
for more detail Appendix 21 of the MS].  These individual models are described within the 
model as “JHU – AMS forced in, involvement removed”. 
 
The AMS is an explanatory variable within the models of the risk of: CVD, gastrointestinal, 
musculoskeletal, neuropsychiatric, ocular, peripheral vascular, pulmonary, renal and skin 
involvement.  But is not an explanatory variable within the models of the risk of: diabetes, 
malignancy or gonadal failure involvement. 
The CAPD is an explanatory variable within the models of the risk of: CVD, diabetes, 
gastrointestinal, musculoskeletal, ocular, gonadal failure and skin involvement.  But is not an 
explanatory variable within the models of the risk of: malignancy, neuropsychiatric, 
peripheral vascular, pulmonary or renal involvement. 
Any new involvement of an organ is assumed to occur at the average SLICC score for that 
organ observed as observed across the JHU cohort.  As the manufacturer notes, this will tend 
to overestimate the SLICC score for that organ when involvement occurs, but this bias is 
likely to wane as time and the model progresses.  The net overall impact of the assumption of 
a constant SLICC score at the average of that observed in the JHU cohort for newly incident 
organ involvement is consequently ambiguous. 
Literature element 3.a.SLE SMR by age group 
Due to age not being within the JHU cohort derived survival model, the manufacturer uses a 
set of age dependent SMRs for SLE patients relative to the general population as derived from 
the Bernatsky 200619
 
 reference: 19.2 age 16-24, 8.0 age 25-39, 3.7 age 40-59 and 1.4 age 60+. 
To calculate the likelihood of a patient dying during a cycle the model first derives the 
probability of death for this patient from the JHU survival model.  The probability of death 
from the JHU survival model for a patient at the average value of the covariates observed 
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within the JHU cohort is then calculated. Dividing the first by the second yields the patient’s 
hazard of death compared to the “average” JHU cohort patient.  
 
This hazard is then multiplied by the age dependent SLE SMR as drawn from the Bernatsky 
200619
Literature element 3.b HRQoL impact of organ involvement 
 reference and the age dependent general population risk of mortality, with the derived 
mortality rate then being adjusted back to being a probability [see MS Table 6.13 and untitled 
Table immediately after for a worked example]. 
Utility values for each SLICC element were drawn where possible by the manufacturer from 
HTAs available on the NICE website.  
 
Paralleling the assumption that the average SLICC score for new organ involvement would be 
the average observed across the JHU cohort, the weights attached to each SLICC element 
utility value are the proportion of those elements observed within the JHU cohort.  The 
resulting weighted average is raised to the power of the average SLICC score for those with 
that organ involvement within the JHU cohort as given in Table 6.16 of the MS. 
For instance, for the calculation of the pulmonary involvement HRQoL based upon the text of 
the submission is 0.70 in Table 16.19 of the MS (refer to Table 25). 
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Table 25: HRQoL calculation pulmonary involvement from Table 16.19 
SLICC Element 
HRQoL JHU % Weighted JHU 
SLICC 
Final 
Pulmonary hypertension 0.61 33% 0.20   
Pulmonary fibrosis 0.73 42% 0.31   
Shrinking lung (Chest XRay) 1.00 2% 0.02   
Pleural fibrosis (Chest XRay) 1.00 20% 0.20   
Pulmonary infarction/resection 0.94 4% 0.04   
Average across pulmonary   0.77 1.31 0.70 
 
These organ involvement HRQoL values are applied multiplicatively.  For a patient having 
developed more than one SLICC organ involvement, only the lowest HRQoL multiplier is 
applied to the “clean” utility. 
Literature element 3.c Cost impact of organ involvement 
A similar approach is undertaken for the cost impacts of organ involvement as for the QoL 
impacts, only with the number of patients in the JHU cohort experiencing the individual 
elements among those having had an event within the organ class giving rise to the weight to 
apply.  These weights can sum to more than one due to a patient being able to experience 
more than one event.  As with the calculation of the quality of life impacts this will tend to 
overestimate costs in the incident year and early years after incidence. 
 
As these cost elements are less well documented in the submission than the HRQoL elements 
the full set is outlined below, with more detail being available in Appendix 28 of the 
submission.  There are some minor discrepancies between the figures in Table 26 and those 
given in Table 6.26 of the MS for reasons that are unclear, but these will not affect results. 
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Table 26: Average costs for organ involvement 
 
Unit Costs 
 
Average total 
 
Year 1 Year 2+ Weight Year 1 Year 2+ 
Ocular 
   
£1,518 £17 
Cataract £1,553  96%   
Retinal damage / optic atrophy £103 £64 27%   
Neuropsychiatric    £3,659 £1,131 
Cognitive impairment 
  
24%   
OR major psychosis £1,122 £1,122 8%   
Seizures requiring therapy for 6 months £826  19%   
Cerebral vascular accident ever or resection excl mal. £8,066 £2,266 38%   
Cerebral vascular accident ever or resection >1 £8,066 £2,266 2%   
Cranial or peripheral neuropathy   43%   
Transverse myelitis £4,772 £2,386 4%   
Renal    £1,746 £2453 
 
   To max £6479 
Pulmonary    £9,678 £9,603 
Pulmonary hypertension £22,488 £22,488 43%   
Pulmonary fibrosis   55%   
Shrinking lung (on chest radiograph)   3%   
Pleural fibrosis (on chest radiograph)   26%   
Pulmonary infarction or resection £1,539  5%   
Cardiovascular    £3,402 £500 
Angina or Coronary Artery Bypass Graft £4,196 £368 31%   
Myocardial infarction  £4,322 £368 36%   
Cardiomyopathy  £724 £724 35%   
Valvular disease (dias/sys murmur)   25%   
Pericarditis x 6 mth or pericardiectomy £2,079  14%   
Peripheral vascular    £2,955 £591 
Significant tissue loss ever  £10,375 £368 21%   
Significant tissue loss > 1 site   0%   
Venous thrombosis with swelling £1,501 £936 55%   
Gastrointestinal     £2678 £0 
Infarction or resection of bowel  £2,848  93%   
Resection > 1 site £2,848  1%   
Pancreatic insufficiency enzyme replacement    3%   
Musculoskeletal    £5,372 £1,903 
 
   To min £1,514 
Muscle atrophy / weakness   11%   
Deforming or erosive arthritis  £3,112 £3,112 26%   
Osteoporosis with fracture or vert. collapse  £8,118 £1,148 49%   
Avascular necrosis £1,359  37%   
Avascular necrosis 2 £1,359  3%   
Osteomyelitis    2%   
Ruptured tendon   12%   
Diabetes     £2,313 £2,313 
Diabetes mellitus sufficient for some intervention £2,313 £2,313 100%   
Malignancy    £6,056 £0 
Malignant tumours  £6,056  100%   
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5.2.4 Base case deterministic results 
The base case deterministic results are presented below in Table 27, Table 28, Table 29, Table 
30 and Table 31. 
Both Table 5 and 6 of the MS and also the default belimumab costs in the electronic model, 
suggest that the ********************* ************************* ************** 
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
******************************************************  
Table 27: Base case deterministic results: All BLISS 
  
Without PAS With PAS 
 
SoC Belimumab Net Belimumab Net 
Undiscounted survival Life Years 30.47 31.97 1.50 31.97 1.50 
Discounted quantities 
Belimumab direct drug cost .. £31,687 £31,687 ******* ******* 
Total cost £97,583 £133,167 £35,584 ******* ******* 
QALYs 9.55 9.98 0.43 9.98 0.43 
Base Case ICER 
  
£82,909 
 
******* 
Table 28: Base case deterministic results: Anticipated license population 
  
Without PAS With PAS 
 
SoC Belimumab Net Belimumab Net 
Undiscounted survival Life Years 32.82 34.96 2.13 34.96 2.13 
Discounted quantities 
Belimumab direct drug cost  £36,796 £36,796 ******* ******* 
Total cost £103,591 £143,895 £40,303 ******* ******* 
QALYs 10.11 10.72 0.61 10.72 0.61 
Base Case ICER   £66,170  ******* 
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Table 29: Base case deterministic results: Target population 
  
Without PAS With PAS 
 
SoC Belimumab Net Belimumab Net 
Undiscounted survival Life Years 31.93 34.87 2.93 34.87 2.93 
Discounted quantities 
Belimumab direct drug cost 0 £47,008 £47,008 ******* ******* 
Total cost £105,366 £157,291 £51,925 ******* ******* 
QALYs 9.81 10.61 0.81 10.61 0.81 
Base Case ICER   £64,410  ******* 
 
From the above the difference between the estimates of cost effectiveness for the anticipated 
license population and the Target population are relatively minor. Given this, from an 
economic point of view it is unclear why the manufacturer niches belimumab to only those 
with an SS score of at least 10 at baseline: around 67% (n=396) of the anticipated license 
population (n=592) within the trials. 
Table 30: Base case organ involvement to death MS Table 6.43: Target population 
 SoC Belimumab Net 
Cardiovascular 23.9% 21.3% -2.6% 
Diabetes 17.9% 19.2% 1.3% 
Gastrointestinal 22.1% 25.0% 3.0% 
Malignancy 32.0% 34.1% 2.2% 
Musculoskeletal 48.5% 48.9% 0.4% 
Neuropsychiatric 44.7% 45.8% 1.1% 
Ocular 35.1% 36.0% 0.8% 
Peripheral vascular 21.5% 20.8% -0.7% 
Premature gonadal failure 7.2% 7.2% 0.0% 
Pulmonary 39.9% 36.8% -3.1% 
Renal 24.3% 19.2% -5.1% 
Skin 7.9% 7.9% 0.0% 
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Table 31: Base case discounted costs: Target population 
 
SoC Belimumab Net 
Belimumab therapy .. £47,008 £47,008 
Belimumab administration .. £9,059 £9,059 
Belimumab total costs .. £56,067 £56,067 
Other Costs 
   SS score related costs £27,882 £28,130 £248 
Organ damage costs 
      Cardiovascular £1,838 £1,633 -£205 
   Diabetes £2,493 £2,731 £238 
   Gastrointestinal £359 £399 £40 
   Malignancy £998 £1,031 £33 
   Musculoskeletal £9,758 £10,114 £356 
   Neuropsychiatric £6,434 £6,719 £286 
   Ocular £392 £391 -£1 
   Peripheral vascular £1,380 £1,339 -£41 
   Premature gonadal failure £0 £0 £0 
   Pulmonary £42,692 £39,652 -£3,040 
   Renal £11,139 £9,083 -£2,056 
   Skin £0 £0 £0 
Total other costs £105,366 £101,224 -£4,142 
Total costs £105,366 £157,291 £51,925 
 
As outlined in Table 31 the direct drug costs of belimumab account for around 90% of the 
total net costs with the administration costs of belimumab accounting for another 17% of the 
total net costs: taken together roughly 108% of the total net cost.  Administration costs are a 
significant proportion of the total direct cost of belimumab: 16% without the PAS and 
approximately *** with the PAS. 
The main anticipated cost savings arise from reduced rates of pulmonary disease and renal 
involvement, which generate cost offsets of around -6% and -4% of the total net costs 
respectively. Some additional costs are associated with belimumab due to the anticipated 
undiscounted survival gain of 2.93 life years causing some complications to occur in a higher 
proportion of patients and to be experienced for longer. 
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5.2.5 Base case probabilistic results  
The base case probabilistic results do not appear to be presented within the written 
submission, with only the CEACs being presented.  Refer to Figure 25, Figure 26 and Figure 
27. 
 
 
 
Figure 25: CEAC without PAS (MS Fig 6.27) All BLISS 
Figure 26: CEAC without PAS (MS Fig 6.41) Target population 
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Figure 27: CEAC with PAS, corrected in response to clarification question: Target 
population 
 
***************************************************************************
***************************************************************************
***************************************************************************
**********************************  
Manufacturer’s sensitivity and scenario analysis  
The presentation of the sensitivity analyses within the submission and the responses to ERG 
clarification questions are mainly limited to those for the Target population.  The results of 
sensitivity analyses presented by the manufacturer for other groups are only presented here 
when that for the Target population is not supplied by the manufacturer. 
As outlined in the summary of the model structure for the evolution of SS scores the 
manufacturer estimated a regression from the JHU cohort that related the change in the SS 
score to the average SS score in the previous period, and to gender, ethnicity and age.  The 
constant estimated from this regression was 2.0577.  The modelling applied a value of 3.0 on 
the basis of 2.0577 providing a poor fit to the evolution of SS scores within the All BLISS 
data.  The effect of this upon the cost effectiveness for the All BLISS group is as in Table 32. 
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Table 32: Varying the constant in the SS change regression: All BLISS 
Regression constant ICER 
2.0577 £93,654 
2.5 £85,394 
3.0 £82,909 
3.5 £80,988 
 
The univariate sensitivity analyses undertaken by the manufacturer are presented graphically 
as a tornado diagram in Figure 6.37 of the MS, with the values underlying this shown in Table 
33.  These values relate to the without PAS scenario for which the base case Incremental 
Cost-Effectiveness Ratio (ICER) is estimated as £64,410 per QALY. 
Table 33: Manufacturer univariate sensitivity analysis – Target population 
 Base Low High 
Variable Value Value ICER Value ICER 
Belimumab wk 24 responders % SS change baseline to 52 weeks -0.28 -0.383 £49,393 -0.173 £103,840 
All belimumab patients % SS change baseline to 52 weeks -0.343 -0.437 £50,335 -0.251 £96,031 
AMS on mortality 0.213 0.085 £85,677 0.333 £50,962 
Annual % belimumab week 24 responders on treatment 0.92 0.863 £54,518 0.981 £85,893 
Ln(age) of the "clean utility" regression -0.145 -0.18 £78,448 -0.103 £53,263 
Constant coefficient in "clean utility" regression 1.297 1.146 £79,243 1.426 £55,493 
SoC patients % SS change baseline to 52 weeks -0.349 -0.394 £77,351 -0.307 £55,581 
AMS of the natural history Pulmonary model 0.139 0.06 £73,044 0.216 £55,216 
Constant of the natural history Neuropsychiatric model -7.396 -9.934 £61,333 -5.117 £76,231 
Ln(age) of natural history Neuropsychiatric model 0.607 0.026 £61,514 1.226 £76,261 
AMS coefficient of the natural history Renal model 0.323 0.228 £69,696 0.412 £56,744 
Constant of the adjusted natural history SS model  3 2.202 £73,226 3.934 £61,871 
Constant coefficient from the natural history PV model -11.69 -16.47 £65,935 -6.81 £55,396 
Ln(age) of natural history Pulmonary model 1.232 0.593 £70,841 1.916 £79,571 
Constant of the natural history Renal model -8.29 -9.01 £67,867 -7.56 £60,057 
 
Many of the key variables within the sensitivity analyses tornado diagram are as would be 
expected: including the changes in SS scores, and the impact of SS scores through the AMS 
upon mortality,  
As for the All BLISS sensitivity analysis the adjustment to the constant for the adjusted 
natural history model of the evolution of the SS score, demonstrates a similar impact as in the 
model for the Target population.  The value of 2.202 (close to the original estimate of 2.0577) 
gives a cost effectiveness estimate of £73,226 per QALY.  The alternative estimate of 3.9 
results in a cost effectiveness estimate of £61,871 per QALY.  One point to note is that this is 
109 
 
non-linear: an increase of 0.934 improves the cost effectiveness estimate by £2,539 per 
QALY while a smaller reduction of 0.798 worsens the cost effectiveness estimate by £8,816 
per QALY. 
Given the cost outputs of the model as previously summarised, the specifications of the 
natural history models for pulmonary and renal disease also have an impact.  Perhaps more 
surprising is the influence of the neuropsychiatric natural history model. 
Note that the manufacturer has presented additional information in Tables B8.2 and B8.3 in 
the response to ERG clarification questions.  These outline the sensitivity of net QALYs and 
net costs to the univariate sensitivity analyses.  The neuropsychiatric natural history model 
mainly impacts upon QALYs.  Within net costs, the renal natural history model also has an 
impact. 
A key variable that has not been particularly explored or explained within the submission is 
the assumed rate of continuation and discontinuations among belimumab week 24 responders.  
The ICERs reported in MS provide insufficient detail.  Table 34 shows that both the net 
QALYs and the net cost are increasing in the annual continuation rate for belimumab week 24 
responders, as would be anticipated.  Note that the longer belimumab week 24 responders are 
estimated to remain on belimumab treatment the worse the estimated cost effectiveness is for 
belimumab.  
Table 34: Sensitivity to continuation rate for belimumab week 24 responders: Target 
population 
 Low value Central value High value 
Annual continuation 
rate 
0.863 0.920 0.981 
Net QALY 0.649 0.806 1.165 
Net Cost £35,386 £51,925 £100,094 
ICER £54,518 £64,410 £85,893 
 
The manufacturer also presented a range of scenario analyses for the Target population for the 
without PAS scenario.  Compared to the base case estimate of £64,410 per QALY: 
• Excluding the continuation rule at week 24 worsens the ICER to £72,207 per QALY 
• Tightening the continuation rule to SS change ≥ 6 improves the ICER to £50,114 per 
QALY 
• A 12% higher belimumab price worsens the cost effectiveness to £71,297 per QALY 
• Vial sharing improves the cost effectiveness to £61,671 per QALY 
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• Using the original natural history model worsens the cost effectiveness to £77,707 per 
QALY 
•  An administration cost of £159 worsens the cost effectiveness to £67,353 per QALY 
5.2.6 Base case deterministic results  
Base case results 
Simulating 50,000 patients within the deterministic model results in mean estimates that cross 
check with those presented within the submission. 
5.2.7 Base case probabilistic results 
Due to the patient level simulations for the base case deterministic results being run across 
50,000 simulations, running the model for a sufficiently large number of iterations for the 
probabilistic modelling to reliably generate a central estimate and associated CEAC takes 
around  one week.  Time constraints have precluded the ERG from running the model 
probabilistically for all the subgroups and for any of the sensitivity analyses. 
The results of an ERG probabilistic run of the model for the Target patient population, 
retaining 50,000 patients over 1,000 iterations, cross check with that of the manufacturer, the 
likelihood of belimumab being cost effective for a given willingness to pay (WTP):  
• 0% at £30,000 per QALY 
• 1% at £40,000 per QALY 
• 11% at £50,000 per QALY 
• 40% at £60,000 per QALY 
In addition, the central estimates from the ERG probabilistic run of the model are an 
additional 0.84 QALYs at an additional cost of £55,166 to yield a central estimate of cost 
effectiveness of £65,530 per QALY.  Both net QALYs and net costs are slightly higher than 
the deterministic run of the model, 0.81 and £51,925 respectively, but both rise in roughly 
equal proportion and the central estimate from the probabilistic modelling of £65,530 per 
QALY is little different from the deterministic estimate of £64,410 per QALY. 
5.2.8 Data inputs  
 
For correspondence between written submission and electronic model related to the Target 
population please refer to Table 35. 
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Table 35: Correspondence between MS and electronic model: Target population 
Written submission Electronic model Correspondence 
Model parameters specific to Target population 
Data Table Worksheet Cells Correspondence 
Baseline 
demographics 
6.37 Baseline Patient 
Characteristics 
Subgroup 
BLISS data 
D9 
Q7:Q62, P64, P78, 
P69, P240 
Yes 
Baseline disease 
activity 
6.38 Baseline Patient 
Characteristics 
Subgroup 
BLISS data 
D21:D32 
Q185:Q215 
P258:Q258 
P260:Q260 
P262:Q262 
P265:Q265 
P267:Q267 
P269:Q269 
P271:Q271 
P273:Q273 
Yes 
Baseline SDI items 6.39 Subgroup 
BLISS data 
P245:T256 Yes 
Discontinuation 
rates 
6.40 Treatment 
Effect 
Baseline Patient 
Characteristics 
Subgroup 
BLISS data 
L33:L34 
AD38 
Q185:Q215 
AR9:AR39 
P276:Q276 
 
Week 52 SS 
regression 
6.41 Treatment 
Effect 
 
D12:E14 
P221:Q223 
Yes 
Week 24 response 
by SS 
6.42 Baseline Patient 
Characteristics 
Subgroup 
BLISS data 
AD7:AD38AR9:AR39 Yes 
Model parameters common to all subgroups 
Data Table Worksheet Cells Correspondence 
Long term SS 
regression 
6.9 Natural  History  
Short 
D11:D16 As per the text of the 
submission, the constant 
within Table 6.9 is 
increased from 2.0577 to 
3.0000. The electronic 
model corresponds with 
the constant being 3.0000 
Steroid use 6.11 PSA Inputs HY7:HZ7 Yes 
Mortality weibull 6.12 Natural  History  
Model data 
AG8:AG52 Yes 
SLE SMR by age 6.13 PSA Inputs IB7:IE7 Yes 
Organ damage tte 6.14 Natural  History  
Model data 
AI8:AT52 Yes 
JHU cohort 
characteristics 
6.15 Hopkins Patient 
Characteristics 
D8:D38 Possibly not. The 
electronic model 
highlights a larger range 
of cells in white than the 
five rows within Table 
6.15: 19 cells in total. 
These cells are described 
within the electronic 
model as “Average 
characteristics imputed to 
simulate non-trial 
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Written submission Electronic model Correspondence 
characteristics that are 
used to determine long 
term outcome risks”. 
Some of these elements of 
the electronic model may 
relate to those given in 
Table 6.16 of the 
submission 
 
Baseline hypertension 
within the electronic 
model is given as 53.1% 
compared to the 15.8% 
annual risk within Table 
6.15. Note that the 
electronic model given the 
annual infection 
probability as 15.8% 
JHU SLICC scores 6.16 Hopkins 
Characteristics 
D8:D38? Possibly not. There is no 
ready read across between 
D8:D38 of Hopkins 
Characteristics and Table 
6.16. For instance, the 
electronic model  give a 
value of 9.7% renal 
damage (mean) while 
Table 6.16 gives a renal 
score of 1.83. Even if the 
renal damage among the 
9.7% had been at the 
maximum SLICC damage 
level of 4 it is difficult to 
see how this can result in a 
renal score of 1.83 
Organ HRQoL 
impact 
6.19 QoL Inputs X9:AI10 Yes 
“Clean” utility 
equation 
6.19 QoL Inputs D10:D13 No. The electronic model 
applies the values given in 
Table 6.20 and not those 
given in Table 6.19 and in 
the body of the text of the 
submission 
“Clean” utility 
equation 
6.20 QoL Inputs D10:D13 Yes 
Cost for a given SS 
score 
6.25 Other cost 
inputs 
D9:D29 Yes 
Organ damage cost 6.26 Other cost 
inputs 
W8:AH9 Partial. The year 1 and 
year 2 costs in the 
electronic model are as per 
Table 6.26 
 
But note that the 
musculoskeletal annual 
cost declines between year 
2 and year 17 from £1,903 
to £1514 
 
Also note that the renal 
annual cost increases 
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Written submission Electronic model Correspondence 
indefinitely from year 2 
onwards from £2,453 to 
£6,749 by year 50 
Belimumab annual 
costs 
6.27 Belimumab cost I23:I38 Yes 
 
5.2.8.1 Model structure 
Belimumab dose and direct drug cost 
There appear to be minor errors in the calculation of the average belimumab drug cost per 
administration.  For instance, for a patient weight of 50kg the manufacturer calculates that this 
is most cheaply administered using five 120mg vials at a cost of £571 per administration.  
This results in a total available dose of 600mg and wastage of 100mg, when a combination of 
one 400mg and one 120mg dose results in a total available dose of 520mg and wastage of 
only 20mg. 
 
Note that if the simpler approach of using 400mg vials being used for the dose up to a 
multiple of 400mg with anything in addition to this being topped up through use of 120mg 
vials, wastage and the average drug cost would increase.  
The drug cost for a patient of the mean patient weight can be calculated on the same basis as 
the manufacturer uses for individual patient drug cost calculations.  Within an individual 
patient simulation model the approach of the manufacturer is correct.  But much of the 
modelling submitted to NICE employs Markov modelling of a cohort of representative 
patients.  This may use a weighted average drug cost, but it is also not unknown for the drug 
cost for the representative patient to be calculated.  See Table 36. 
Table 36: Belimumab average direct cost per administration 
 Manufacturer ERG 400mg Mean Median 
All BLISS £671 £664 £694 67kg £686 63kg £610 
Anti-dsDNA+ve, low 
(C3/C4) 
£650 £642 £671 65kg £686 62kg £610 
Target population £654 £646 £674 65kg £686 63kg £610 
 
Any errors within the manufacturer calculations are slight and will not materially affected the 
estimates of cost effectiveness.  For the most severe subgroup of patients adopting the 
approach of using 400mg and topping up with 120mg rather than minimising waste has a 
similar effect to costing at the mean patient weight, with both increasing the average drug cost 
by a little over 3%. 
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As the belimumab drug costs account for around 90% of the estimated total net cost for both 
the All BLISS population and the most severe subgroup with an SS ≥ 10 at baseline, any 
change in the belimumab drug costs will lead to a roughly proportionate change in the cost 
effectiveness estimate. 
Modelling the evolution of SS scores during the 1st
The likelihood of the patient dying or developing organ involvement is not directly 
determined by the SS score, but this flow through to the AMS score which does determine 
mortality and organ involvement. The SS score has direct impacts upon patient utilities and 
the costs of treatment. The SS score also determines the patient steroid use, which in turn 
further affects the likelihood of mortality and organ involvement. The SS score is the key 
variable within the modelling. 
 year 
 
The manufacturer response to ERG clarification question B3 outlines that the change in the 
SS score from baseline to week 52, SS52-SS0
But calculating SS
, for belimumab week 24 non-responders is 
calculated using the week 52 linear regression for the SoC arm.  The reason for this is that 
belimumab week 24 non-responders cease belimumab treatment at week 24 and as a 
consequence at week 52 are receiving only SoC. 
52 
Table 37
for belimumab week 24 non-responders using the week 52 linear 
regression for the SoC arm is likely to be incorrect.  Both the SoC arm and the belimumab 
arm of the trials had week 24 responders and week 24 non-responders.  For the Target 
population these are shown in  below.c
Table 37: Week 24 response rates – Target population 
 
 BLISS-52 BLISS-76 Pooled 
 Resp NResp Resp NResp Resp NResp 
SoC 59% 41% 44% 56% 52% 48% 
Belimumab 71% 29% 62% 38% 67% 33% 
OR 1.75  2.07  1.93  
 
By definition the 52% of patients within the pooled SoC arm with response at week 24 had a 
change of at least 4 in their SS score at week 24, while the 48% without response at week 24 
had a change of less than 4 in their SS score at week 24.  Similarly by definition, the 33% 
within the pooled belimumab arm without response at week 24 had a change of less than 4 in 
their SS score at week 24.  
                                                          
c Based upon the patient numbers reported in table A7.1 of the manufacturer response to ERG 
clarification question A7. 
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It seems likely to be more appropriate to model SS52
Table 38
 for the belimumab week 24 non-
responders based upon the changes in SS scores among the SoC week 24 non-responders than 
upon changes in SS scores across all SoC patients, the latter being an average across week 24 
responders and week 24 non-responders.  This is underlined by the response of the 
manufacturer to ERG clarification question A7 and associated Table A7.1 outlining the mean 
changes in SS scores at week 24 and week 52 by arm and week 24 responder status.  See 
. 
Table 38: SS changes at week 24 and by week 52 by week 24 status – Target population 
 BLISS-52 BLISS-76 Pooled 
Week 24 status  Resp NResp All Resp NResp All Resp NResp All 
Mean change from baseline at week 24: SS24-SS0 
SoC -6.7 -0.7 -4.2 -7.1 -1.3 -3.9 -6.9 -1.1 -4.1 
Belimumab -7.4 -0.8 -5.5 -7.0 -1.0 -4.7 -7.3 -0.9 -5.2 
Mean change from baseline at week 52: SS52-SS0 
SoC -5.4 -2.3 -4.1 -6.1 -2.3 -4.0 -5.7 -2.3 -4.1 
Belimumab -7.5 -3.3 -6.3 -6.8 -2.5 -5.2 -7.2 -2.9 -5.8 
 
Among week 24 non-responders the average changes in SS score at week 24 were very 
similar between the SoC arms and the belimumab arms: for instance these were -1.1 and -0.9 
respectively within the All BLISS data.  
It could be argued that among week 24 non-responders the average changes in SS score have 
started to slightly divergence between the SoC arms and the belimumab arms by week 52: -
2.3 and -2.9 respectively within the All BLISS data.  But for modelling purposes these figures 
are not particularly relevant.  The stopping rule of the modelling is applied at 24 weeks. As a 
consequence, the evolution of SS scores among week 24 non-responders in the belimumab 
arm between week 24 and week 52 within the trials is of less interest.  It reflects continued 
use of belimumab between week 24 and week 52 during the trials, when the modelling 
assumes that these patients will no longer receive belimumab between week 24 and week 52.  
It is presumably for this reason that SS52 
In the light of the above (see 
has to be modelled for belimumab week 24 non-
responders rather than drawn directly from trial data. 
Table 38), for the belimumab week 24 non-responders it would 
seem to have been more appropriate to base SS52-SS0 upon the parallel change for SoC week 
24 non-responders than that for the SoC arm as a whole: -2.3 rather than -4.1 within the All 
BLISS data.  This is quite a large difference of -1.8 for belimumab week 24 non-responders 
given the overall changes in average SS scores within the trials. Belimumab week 24 non-
responders make up 33% of the belimumab Target population within the trials. 
116 
 
The trial data reported in Table 39 is illustrative of the assumption underlying the 
manufacturer model, with the figures relating to trial data.  The model makes a parallel 
assumption, but estimating SS52-SS0
Table 39
 uses the linear regressions as outlined in Table 6.41 of 
the MS and the manufacturer response to question C6 of the ERG clarification questions (see 
). 
Table 39: Linear regression of SS52-SS0 central parameter estimates – Target 
population 
 BLISS-52 BLISS-76 Pooled 
SS52-SS0 -0.3629  SoC -0.3341 -0.3493 
SS52-SS0 -0.3746  belimumab -0.3153 -0.3435 
SS52-SS0 -0.2626  belimumab week 24 responders -0.2827 -0.2800 
 
Where SS52-SS0 SoC is the average SS change within the SoC arm, SS52-SS0 belimumab is 
the average SS change within the belimumab arm and SS52-SS0 belimumab week 24 is the 
additional average SS change within the belimumab arm among those showing a response at 
week 24.  Note that these are regression coefficients and multiplicative: e.g. from the All 
BLISS data a patient within the SoC arm with, for example, SS0 = 10.00 has a central 
estimate of SS52-SS0 = -0.349*10 = -3.49 hence SS52 
Note that the data in 
= 6.51. 
Table 39 will include any additional treatment effect from belimumab 
between week 24 and week 52 among belimumab week 24 non-responders.  To the extent that 
this effect exists it will tend to lead to an overestimate of the effectiveness of for SS52-SS0 
belimumab within the regression model, but this will tend to net out through a reduction in the 
estimate of SS52-SS0 
As outlined within the manufacturer response to the ERG clarification question B3, SoC 
patients are assumed to have the SoC coefficient applied, belimumab week 24 non-responders 
are assumed to have the SoC coefficient applied and belimumab week 24 responders have the 
sum of the two belimumab coefficients applied.  Given this the model application of the 
results of the regression can be more transparently presented as below.  These are then applied 
to the trial mean of SS
belimumab week 24 responders.  Within the modelling it is only really 
the sum of these two coefficients that it applied.  
0
  
≈12.7 among the Target population to result in a modelled estimate for 
the trial mean which can then be compared with the actual trial mean for some simple 
triangulation and model validation. 
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Table 40: SS52-SS0 model versus trial – Target population 
All BLISS  
Coeff. 
Modelled 
SS0=12.7 
Trial 
mean 
SS52-SS0 -0.349  SoC week 24 non-responders -4.4 -2.3 
SS52-SS0 -0.349  SoC week 24 responders -4.4 -5.7 
SS52-SS0   SoC All (weighted average) -4.4 -4.1 
SS52-SS0 -0.349  belimumab week 24 non-responders -4.4 -2.9 
SS52-SS0 -0.623  belimumab week 24 responders -7.9 -7.2 
SS52-SS0   belimumab All (weighted average) -6.8 -5.8 
 
As anticipated, data shown in Table 40 suggests that assuming that belimumab week 24 non-
responders have the same change in SS scores as the average for the SoC arm systematically 
overestimates the average change in the SS score within belimumab arm.  Note that this also 
does not correct for any impact of belimumab week 24 non-responders being assumed to 
cease treatment at week 24, which may suggest that the -2.9 trial mean will be an 
overestimate of the likely effect in clinical practise and the value that should be applied within 
the modelling.  
Note also that the electronic copy of the model includes the coefficients for the parallel 
regression of the change in SS scores at week 24: SS24-SS
Table 41
0 
 mirrors the week 24 trial data, but appears unduly pessimistic for the belimumab 
week 24 non-responders when coupled with the average baseline of SS0
Table 41: Linear regression of SS
≈12.7. This 
regression is not used within the current model implementation and is not presented within the 
written submission. 
24-SS0 central parameter estimates – Target 
population  
 BLISS-52 BLISS-76 Pooled 
SS24-SS0 n.a.  SoC n.a. -0.3525 
SS24-SS0 n.a.  belimumab n.a. -0.0003 
SS24-SS0 n.a.  belimumab week 24 responders n.a. 0.5755 
 
The manufacturer in response to ERG clarification question C8 confirms that the central 
estimates of the modelled evolution of SS scores for SoC, belimumab week 24 non-
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responders and belimumab week 24 responders for the first 10 yearsd
Table 42
 of the modelling are 
shown in . 
Table 42: Modeled evolution of SS scores – Target population 
Year 
SoC 
 
Bel. week 24 
non-responders 
Bel. week 24 
responders 
0 12.7 12.7 12.7 
1 8.2 8.1 4.9 
2 6.5 6.4 3.4 
3 5.5 5.5 2.6 
4 4.9 4.9 2.3 
5 4.6 4.6 2.2 
6 4.4 4.4 2.2 
7 4.3 4.3 2.2 
8 4.2 4.2 2.3 
9 4.1 4.1 2.4 
10 4.1 4.1 2.5 
 
On the basis of a 67:33 split between belimumab 24 week responders and non-responders, the 
weighted average SS score within the belimumab arm is modelled as being 5.95 at the end of 
year 1: a net gain over SoC of around 2.2.  This compares with a net observed gain from 
belimumab over SoC in the trials of 1.7: the modelled net improvement is around 30% greater 
than that observed in the trials.  If the SoC week 24 non-responder change of -2.3 at week 52 
is assumed to apply to the belimumab week 24 non-responder at week 52 on the grounds that 
these patients are assumed to cease belimumab treatment from week 24 the net “observed” 
gain from belimumab over SoC in the trials falls to 1.5: the modelled net improvement 
consequently increases to around 45% over that “observed” in the trials. 
In short, given the trial data for the average changes in SS scores for SoC and belimumab 
week 24 responders and non-responders, it seems unwarranted to assume that belimumab 
week 24 non-responders will have the same change in SS score at week 52 as the average 
observed across the SoC arm.  This overestimates the impact of belimumab upon SS scores. 
Modelling of AMS scores 
                                                          
d For all the SS and AMS elements only the first 10 years modelling is presented for illustrative 
purposes, while the modelling extends to the patient lifetime. 
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It is not the SS score but the AMS score that directly contributes to the likelihood of a patient 
dying and a patient developing cardiovascular, gastrointestinal, musculoskeletal, 
neuropsychiatric, ocular, peripheral vascular, pulmonary, renal and/or skin involvement. 
Renal involvement further determines the likelihood of cardiovascular involvement.  
 
As explained previously the AMS is calculated as the area under the SS score curve between 
two time points divided by the time of follow-up to provide an average score over the period 
of interest. Within the response to ERG clarification question C8 the manufacturer clarified 
the central estimates of the SS scores and AMS as below in Table 43. 
Table 43: Modeled evolution of AMS scores: manufacturer clarification – Target 
population 
Year SoC 
 
Bel. week 24 
non-responders 
Bel. week 24 
responders 
SS AMS SS AMS SS AMS 
0 12.7 12.7 12.7 12.7 12.7 12.7 
1 8.2 10.4 8.1 10.4 4.9 9.9 
2 6.5 9.1 6.4 9.1 3.4 8.4 
3 5.5 8.2 5.5 8.2 2.6 7.4 
4 4.9 7.6 4.9 7.5 2.3 6.8 
5 4.6 7.1 4.6 7.0 2.2 6.3 
6 4.4 6.7 4.4 6.7 2.2 5.9 
7 4.3 6.4 4.3 6.4 2.2 5.6 
8 4.2 6.1 4.2 6.1 2.3 5.4 
9 4.1 5.9 4.1 5.9 2.4 5.2 
10 4.1 5.8 4.1 5.8 2.5 5.0 
 
Running the model with a 100% probability of response for belimumab and a 0% probability 
of responsee
For both the SoC arm and the belimumab week 24 non-responders, the AMS at time T as 
reported in the response to clarification question C8 cross checks with being the average of 
 for belimumab results in the same SS scores as above for SoC, Belimumab week 
24 non-responders and belimumab week 24 responders. 
                                                          
e Implemented by setting the Baseline Patient Chars worksheet AD7:AD38 = 1 for 100% response and  
= 0 for 0% response and taking the values from the Results worksheet columns BR:BS. 
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the SS values t = 0…..T.  But for the belimumab week 24 responders the AMS at time T as 
reported in the response to clarification question C8 bears no relation to the ERG cross check 
(see Table 44). 
 
Table 44: Modelled evolution of AMS scores: Belimumab week 24 responders – Target 
population 
Year Belimumab week 24 responders 
SS Manufacturer AMS ERG AMS 
0 12.7 12.7 12.7 
1 4.9 9.9 8.8 
2 3.4 8.4 7.0 
3 2.6 7.4 5.9 
4 2.3 6.8 5.2 
5 2.2 6.3 4.7 
6 2.2 5.9 4.3 
7 2.2 5.6 4.1 
8 2.3 5.4 3.9 
9 2.4 5.2 3.7 
10 2.5 5.0 3.6 
 
The values submitted in response to the ERG clarification question are averages across many 
individual patient iterations.  Some non-linearity or rounding approximation may have crept 
into the figures.  But it is difficult to reconcile the ERG cross check of the AMS for SoC and 
belimumab week 24 non-responders with the discrepancies between the ERG cross check and 
the manufacturer reported values of the AMS for belimumab week 24 responders. 
It is unclear whether the above discrepancy is due to an error in the manufacturer response to 
the ERG clarification question, an error in the VB coding of the model or an error in 
interpretation by the ERG.  The manufacturer figures for the AMS may incorporate 
discontinuations within the belimumab week 24 responder figures.  
Ignoring this discrepancy for the moment, by definition the AMS introduces memory of 
previous SS scores to the modelling.  As a consequence of this, even when there is no 
modelled contemporaneous difference in SS scores between the arms at a particular point, the 
AMS scores will retain a memory of previous differences in SS scores between the arms.  
Any errors in the calculation of SS scores within the first year will, even if largely washed out 
over a relatively short period due to a high discontinuation rate within the belimumab arm, 
continue to be carried forward by the AMS.  
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Patients within the JHU cohort were recruited at somewhat lower values in their SS scores 
compared to the BLISS trials, Figure 6.8 of the MS suggesting an average SS score in their 
first year of around 2.8 with the subsequent AMS being reasonably level or declining slightly 
over the 17 years of data presented within Figure 6.8.  At a minimum it seems possible that 
JHU cohort type patients would have a history of lower SS scores prior to being eligible for 
recruitment to the BLISS trials.  Any history of SS scores prior to baseline will tend to 
dampen the impact that changes in SS scores at baseline have upon the AMS.  
As noted by the manufacturer, the AMS tends to smooth out changes in the SS scores.  But by 
not taking into account a patient’s SS score prior to the model baseline, the model effectively 
ignores this smoothing out effect and exaggerates the impact that the changes in SS scores at 
baseline have upon the AMS and upon the net difference in the AMS between the arms.  For 
the AMS at time T from model baseline for belimumab week 24 responders from the written 
submission it seems that the intention of the model is to calculate it as: 
 
With the net difference in the AMS at time T between belimumab week 24 responders and 
SoC as: 
 
But this ignores the previous history of SS scores since diagnosis D years prior to the model 
baseline. Taking this into account results in an AMS at time T for belimumab week 24 
responders of: 
 
 
With the net difference in the AMS at time T between belimumab week 24 responders and 
SoC as: 
 
Which implies that: 
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Manufacturer clarifications on SS scores suggests that SS scores among belimumab week 24 
responders are never worse than the contemporaneous SS score for SoC, and typically appear 
to be modelled as being superiorf
Any overstatement of effect upon the AMS arising because of this will be larger during the 
early years of the modelling, and for those patients with a long prior history of SLE.  The 
average duration of disease at recruitment was 6 -7 years within the Target population.  The 
average duration of disease at recruitment to the JHU cohort was a little over 5 years. 
.  Since (T+D)/T is greater than one this implies that 
modelled superiority in AMS for belimumab week 24 responders over SoC systematically 
overstates the actual superiority in AMS for belimumab week 24 responders over SoC due to 
not having taken into account the previous patient history.  
Calculation of steroid dose 
The ERG expert opinion is that steroid use is variable, but that the tapering allowed within the 
trials was not unrepresentative of UK practice.  In response to ERG clarification question A8 
the manufacturer has clarified that within the BLISS trials the evolution of steroid use in the 
Target population was as shown in Table 45. 
 
Table 45: Average steroid use (mg): BLISS Target population 
 
 BLISS-52 BLISS-76 All BLISS 
 
SoC Belim. SoC Belim. SoC Belim. 
Week 24 responders: n=63 n=80 n=42 n=50 n=105 n=130 
Baseline 12.4 ± 8.6 13.7 ± 10.8 8.9 ± 8.2 10.9 ± 7.6 11.0 ± 8.6 12.6 ± 9.8 
Week 24 14.4 ± 11.7 11.5 ± 8.0 9.1 ± 6.7 11.4 ± 8.4 12.3 ± 10.3 11.5 ± 8.1 
Week 52 10.5 ± 6.3 8.6 ± 5.9 7.5 ± 6.2 11.9 ± 21.9 9.3 ± 6.4 9.8 ± 14.1 
Week 24 non-responders: n=44 n=32 n=54 n=31 n=98 n=63 
Baseline 13.4 ± 8.1 13.6 ± 9.3 11.3 ± 9.2 9.5 ± 8.9 12.2 ± 8.7 11.6 ± 9.3 
Week 24 17.8 ± 30.2 14.1 ± 10.1 20.5 ± 54.8 12.5 ± 8.8 19.2 ± 44.8 13.3 ± 9.4 
Week 52 13.3 ± 7.0 12.1 ± 9.3 9.9 ± 9.2 9.9 ± 8.3 11.4 ± 8.3 11.0 ± 8.8 
Overall: n=107 n=112 n=96 n=81 n=203 n=193 
Baseline 12.8 ± 8.4 13.7 ± 10.4 10.3 ± 8.8 10.4 ± 8.1 11.6 ± 8.6 12.3 ± 9.6 
Week 24 15.7 ± 20.6 12.1 ± 8.6 14.9 ± 39.5 11.8 ± 8.5 15.3 ± 30.6 12.0 ± 8.5 
Week 52 11.4 ± 6.6 9.4 ± 6.9 8.6 ± 7.8 11.2 ± 18.6 10.2 ± 7.3 10.1 ± 12.9 
 
                                                          
f Note that these are average figures across the 50,000 patient simulated. Within the patient level 
modelling clinical effectiveness estimates are treated deterministically, and as a consequence this 
seems likely to apply to each individual belimumab patient and its clone that is modelled within the 
50,000 simulations.  
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Note that the standard deviations associated with these estimates suggests quite strongly 
skewed data. The manufacturer further notes in response to ERG clarification question A8 
that “corticosteroid taper during the study was determined strictly at the investigators’ 
discretion.  There were no protocol mandates regarding dose reduction.  The total dose of 
corticosteroids could be adjusted as clinically required during the first 24 weeks of the study; 
corticosteroid use beyond pre-specified dose limits resulted in the patient being designated as 
a non-responder.” 
A crude assessment of the above might suggest that steroid use at baseline is typically lower 
within BLISS-76 than within BLISS-52, which may reflect the different geographic 
recruitment for the two trials with BLISS-76 locations being more relevant to the UK. 
The modelling ignores the above steroid use data on the grounds of it being unrepresentative 
of UK practice, choosing instead to use the relationship derived from the JHU cohort.  The 
steroid dose is modelled as a linear function of the AMS score: steroid dose (mg/day) = 3.41 
+ 0.72 * AMST
This links with the trial based linear regression of changes in SS scores SS
 [Table 6.11]. 
52 = (1+β) * SS0 
which implies that AMS52 ≡ (SS52 + SS0 )/2 = (2+β)/2 * SS0 where for SoC β = -0.349 and 
for belimumab week 24 responders β = -0.623.  Given a central baseline of SS0 = 12.7 for the 
Target population this implies AMS52 = 10.5 for SoC and AMS52 
• 12.6mg at baseline 
= 8.7 for belimumab.  For 
the Target population this in turn implies estimated daily steroid doses at the central baseline 
SS scores of: 
• 11.0mg at week 52 for SoC 
• 9.7mg  at week 52 for belimumab week 24 responders 
 
While the trial steroid use data appears to be quite skewed, the average steroid doses for the 
Target population are: 
• For BLISS-52 
o 12.8mg at baseline and 11.4mg at week 52 for SoC 
o 13.7mg at baseline and 8.6mg at week 52 for belimumab week 24 responders 
• For BLISS-76 
o 10.3mg at baseline and 8.6mg at week 52 for SoC 
o 10.9mg at baseline and 11.9mg at week 52 for belimumab week 24 
responders 
• For All BLISS 
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o 11.6mg at baseline and 10.2mg at week 52 for SoC 
o 12.6mg at baseline and 9.8mg at week 52 for belimumab week 24 responders 
 
It can be argued that the trial data as presented, and in particular the trial data from BLISS-76, 
does not triangulate particularly well with the steroid doses estimated within the modelg
Note also that while the absolute difference in SS scores between a belimumab 24 week 
responder and her SoC clone is maintained while the patient remains on belimumab, the SoC 
SS score is modelled as falling over time as shown in Table 6.9 and Figure 6.7 of the MS.  As 
a consequence of this, the absolute difference in steroid dose between a belimumab 24 week 
responder and her SoC clone will be modelled as falling over time. 
.  
Calculation of the CAPD 
There is limited detail within the submission on the calculation of the CAPD.  It seems 
possible that this may be subject to the same source of bias as the calculation of the AMS, if a 
patient’s prior history and CAPD to date at baseline is not taken into account. 
 
Calculation of the mortality probability 
The JHU model survival excludes age and duration of disease on statistical grounds. The SLE 
SMRs from the Bernatsky reference19
 
 are then applied to the ratio of the JHU modelled 
patient specific probability of death with the JHU modelled SLE average probability of death. 
This appears quite convoluted.  A more natural approach might have been to have 
reconsidered the treatment of age within the JHU survival model, and given the age ranges 
within the JHU cohort to assess whether the derived model would be applicable outside a 
certain age range. 
The manufacturer justifies the application of the SLE SMRs as drawn from the Bernatsky 
reference19 on the grounds of the JHU survival model being unrepresentative of older patients 
and so unsuitable for extrapolating into old age.  This may be the case, but the SLE SMRs 
drawn from the Bernatsky reference19
 
 are larger for younger patients than older patients.  
Admittedly in the younger age group these will be being applied to lower general population 
mortality risks.  
                                                          
g Within this it should be borne in mind that the week 52 steroid dose for belimumab week 24 
responders within the BLISS-76 trial has a particularly high standard deviation. 
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There is the concern that the multiplication by the Bernatsky SMRs may tend to exaggerate 
the impact of the covariates within the JHU cohort survival model, and of any differences in 
the values of the covariates as modelled between the arms of the model.  
It can also be noted that the Bernatsky 2006 reference19
Table 46
 provides a number of cuts of the data 
for the SMR estimates unadjusted and from a “multivariate hierarchical regression to 
determine the independent effects of the factors examined (sex, age group, SLE duration, 
calendar year period of SLE diagnosis, country) on the relative SMR estimates among SLE 
patients”.  Refer to . 
Table 46: Bernatsky SLE SMRs 
Unadjusted SMRs by Unadjusted SMR 95% CI Revised SMR 95% CI 
Gender     
  Female 2.5 2.3 – 2.7 1.2 1.0 – 1.4 
  Male 1.9 1.7 – 2.2 1.0 (ref) 
Age     
  16-24 19.2 14.7 – 24.7 .. .. 
  25-40 8.0 7.0 – 9.1 .. .. 
  < 40 (above pooled) 10.7 9.5 – 11.9 6.4 5.5 – 7.5 
  40-59 3.7 3.3 – 4.0 2.6 2.3 – 3.0 
  60+ 1.4 1.3 – 1.5 1.0 (ref) 
Duration SLE years     
  < 1 5.4 4.7 – 6.3 7.7 5.9 – 10.2 
  1 – 4  2.5 2.2 – 2.8 3.2 2.5 – 4.1 
  5 – 9 2.1 1.9 – 2.4 2.4 1.8 – 3.0 
  10 – 19  2.0 1.8 – 2.3 1.8 1.4 – 2.2 
  20+ 2.0 1.7 – 2.0 1.0 (ref) 
 
The manufacturer argument for the need to apply the SLE SMRs to the JHU cohort survival 
model centres on speculation that the JHU cohort survival model does not correctly estimate 
survival probabilities for older SLE patients who were insufficiently represented within the 
JHU cohort.  A possible approach would be to validate the JHU cohort survival model by 
examining to what extent the estimates of survival probabilities conform to the SMR 
estimates given within Bernatsky: both relative to the general population and relative to other 
SLE patients.  If the model results triangulate well with the Bernatsky SMRs it is a good fit, if 
not it is not a good fit and needs revision.  But it would seem sensible to check this first, prior 
to any ad hoc revisions. 
The argument as to why the cohort survival model requires adjustment by the Bernatsky 
SMRs when modelling patients who are of a similar age to those within the JHU cohort is 
unclear. 
There is also some concern around the SMR values applied from Bernatsky.  A recent UK 
based study found somewhat lower SMRs for SLE as shown in Table 47. 
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Table 47: SMRs for cohort of UK SLE patients: Caroline Gordon (22 June 2011, 
personal communication) 
Age SMR CI 
20 - 24 *** ****** 
25 – 34 *** ****** 
35 – 44 *** ****** 
45 – 54 *** ****** 
55 – 64 *** ****** 
65 – 74 *** ****** 
75 – 84 *** ****** 
≥ 85 *** ****** 
 
***************************************************************************
***************************************************************************
***************************************************************************
*********************************************************** 
Calculation of the SS score direct effect upon treatment costs 
The one year observational cost study divided the data into two six month periods and 
examined the relationship between the SS score severity class 0, 1, 2 or 3 and the patient’s 6 
month cost.  The SS score severity class was determined by the maximum SS score observed 
during the relevant 6 month period.  To arrive at an annual cost related to the SS score 
severity class during the six months, the six monthly costs are simply doubled within the 
submission. 
 
Given that annual costs are required for the model, there is the obvious question of why the 
cost data is not analysed on an annual basis. SS scores will have varied over the one year 
observational study, and the maxima are likely to have differed between the two 6 month 
periods for some if not all patients.  It would be anticipated that costs will be highest in the 
period immediately around any peak in SS score, and will tend to fall away either side of this.  
Doubling the six monthly cost will tend to have projected a patient’s high costs during one 
period into what was actually a lower cost period. 
To labour the point, suppose that a flare leads to an SS score of 12 and a hospital admission of 
two weeks duration for a particular patient.  If the observational cost data had been analysed 
on a monthly basis and the patient’s peak in the SS score due to the flare was observed in the 
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data, the SS score of 12 or SS score severity class of 3 would in this instance be associated 
with a hospital admission of two weeks duration.  The corollary of the manufacturer approach 
to annualisation would be to multiply this by 12, leading to the conclusion that in this instance 
an SS severity index of 3 sees the patient spend half the year admitted to hospital. 
While the bias caused by the manufacturer approach will be less than that outlined in the 
hypothetical example above, it seems likely that it will have tended to exaggerate the 
association between the SS score average over the year and annual treatment costs. A simpler 
approach that averages patients’ SS scores over the year and relates these to their annual cost 
would seem to be more in line with the natural history model and probably less likely to lead 
to bias. 
Calculation of HRQoL and Cost impacts of newly incident organ involvement 
It can be noted that the assumption that newly incident organ damage will be at the average 
SLICC score for that SLICC element within the JHU cohort has a possible double impact.  As 
noted by the manufacturer, incident cases will by definition be 1 when incident rather than the 
average SLICC score for that element within the JHU cohort.  But the element being involved 
at incidence may also tend to be a less serious element.  The weighting given to the utility 
values within each SLICC score is also the average prevalence of the elements within the 
organ SLICC score within the JHU cohort. If the more serious elements tend to occur later, 
then not only will the number of elements being involved at incidence be overestimated, their 
seriousness might be as well. 
 
The above applies with equal force to the costs associated with newly incident organ 
involvement. 
Double counting of treatment costs 
Within the manufacturer model there is a direct causal link between the SS score and the 
incidence of new organ involvement.  This is perfectly reasonable.  But the costs associated 
with the SS score are estimated entirely separately from the costs associated with individual 
organ involvement.  Due to the positive association between SS scores and organ 
involvement, adding the cost associated with SS scores and the cost associated with organ 
involvement is likely to have double counted these costs to some degree. 
 
The extent of this bias may be limited if rates of organ involvement within the observational 
cost study conducted during the phase II trial were low.  In some sense, there is a need for the 
corollary of the “clean” utility function on the cost side of the modelling: a “clean” SS score 
cost function stripped of the impact of organ involvement upon costs. 
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5.2.9 ERG reconciliation of durations of organ involvement and undiscounted organ 
costs 
The modelling for the target population results in quite large estimates of the net discounted 
cost savings from reduced pulmonary involvement with belimumab: £3,040 which is around 
6% of the total net discounted cost estimate of £51,925. The model output also outlines that 
the average duration of pulmonary involvement is modelled as 9.87 years within the SoC arm 
and 9.50 years within the belimumab arm, these appearing to be undiscounted figures (see 
Table 48). 
Table 48: ERG cross check of modelled pulmonary costs – Target population 
 
SoC Belimumab Net 
Average survival undiscounted 31.93 34.87 2.93 
Pulmonary involvement 
Baseline 2.5% 2.5% 0.0% 
Final 39.9% 36.8% -3.1% 
Pulmonary costs cross check  
Pulmonary average duration (D) 9.87 9.50 -0.37 
Pulmonary cost year 1 (£Y1) £9,678 £9,678   
Pulmonary cost year 2+ (£Y2) £9,603 £9,603   
Total costs (£Y1 + £Y2*(D-1)) £94,896 £91,308 -£3,587 
Modelled costs 
Undiscounted costs from model £94,852 £91,262 -£3,590 
Discounted costs from model £42,692 £39,652 -£3,040 
Pulmonary involvement duration 
Pulmonary average duration (affected) 24.75 25.82 1.07 
 
Given this, the modelled average duration of pulmonary involvement can be coupled with the 
average costs in year 1 and year 2+ for pulmonary involvement to arrive at the average 
undiscounted costs for pulmonary involvement. This cross check appears to tally very closely 
with the summary of the model output: within the SoC arm average undiscounted costs for 
pulmonary involvement of 94,896 compared  to the £94,852 reported in the model output, and 
£91,308 compared to £91,262 for the belimumab arm. This is in part due to year 1 and year 2 
costs being very similar for pulmonary involvement which means that the mean organ 
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duration is sufficient to characterise the undiscounted mean costs; the distribution of organ 
duration does not have to be taken into account. 
But this cross check is based upon the average duration of pulmonary involvement reported 
within the model output being that applicable across the patient cohort; i.e.  including those 
who are modelled as not developing pulmonary involvement. This implies an average 
duration of pulmonary involvement among those with pulmonary involvement at baseline or 
developing pulmonary involvement over the period of the model of 24.75 years for SoC and 
25.82 years for belimumab. The has been confirmed as correct by the company that developed 
the model for the manufacturer, which in turn imples the following average undiscounted 
durations of organ involvement and average undiscounted organ cost among those having the  
relevant organ  involved at some point during the modelling.  Note that organ involvement at 
baseline was low. These can then be conditioned by the percentages having the  relevant 
organ  involved at some point during the modelling to arrive at the avergage organ cost across 
the cohort as a whole; i.e. including those not having  the  relevant organ  involved at some 
point during the modelling (see Table 49).  
Table 49: Mean undiscounted organ durations and costs – Target population 
 Among those with the organ involved Across the whole patient group 
 Duration Undiscounted cost Involvement Undiscounted cost 
 SoC Belim SoC Belim SoC Belim SoC Belim 
Cardiovascular 23.48 24.53 £14,787 £15,313 24% 21% £3,527 £3,260 
Diabetes 14.72 15.68 £34,408 £36,656 18% 19% £6,173 £7,035 
Gastrointestinal 20.92 22.55 £2,696 £2,697 22% 25% £595 £675 
Malignancy 13.73 14.86 £6,119 £6,120 32% 34% £1,955 £2,089 
Musculoskeletal 23.16 24.83 £40,285 £42,833 49% 49% £19,552 £20,952 
Neuropsychiatric 24.98 26.36 £30,782 £32,349 45% 46% £13,761 £14,826 
Ocular 22.42 23.57 £1,897 £1,917 35% 36% £666 £690 
PV 17.01 18.02 £12,532 £13,130 22% 21% £2,698 £2,729 
Gon. Failure 24.53 25.78 £0 £0 7% 7% £0 £0 
Pulmonary 24.75 25.82 £237,795 £248,049 40% 37% £94,852 £91,262 
Renal 22.16 23.22 £103,220 £108,974 24% 19% £25,060 £20,947 
Skin 31.47 34.11 £0 £0 8% 8% £0 £0 
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5.2.10 Comparison with NICE reference case  
 
Table 50 provides a comparison between the MS basecase submission and the NICE 
reference case. 
Table 50: Comparison with NICE reference case 
Attribute Reference case and TA Methods 
guidance 
Does the de novo economic evaluation 
match the reference case 
Comparator(s)  Therapies routinely used in the NHS, 
including technologies regarded as 
current best practice  
The main comparison is between 
belimumab adjunctive to standard 
therapy and standard therapy alone 
 
The NICE scope also includes rituximab 
as a comparators 
Patient group As per NICE scope The manufacturer niches belimumab to 
those within the anticipated license with 
an SS score of at least 10 
Perspective costs NHS and Personal Social Services 
(PSS)  
Yes 
Perspective benefits  All health effects on individuals Yes 
Form of economic evaluation  Cost-effectiveness analysis  Cost utility analysis 
Time horizon Sufficient to capture differences in costs 
and outcomes  
Yes 
Synthesis of evidence on outcomes  Systematic review As there is no consideration of rituximab 
or cyclophosamide there is no 
requirement for a synthesis of the 
evidence as the comparator is the 
standard care arm of the trials. The only 
synthesis of the trial data is the pooling 
of BLISS-52 with BLISS-76 
Outcome measure  Quality adjusted life years (QALYs)  Yes 
Health states for QALY  Described using a standardised and 
validated instrument  
Yes. The “clean” utility linked to SS 
scores is derived from EQ-5D trial data 
 
The HRQoL impacts from further organ 
involvement are drawn from a range of 
studies within the literature 
Benefit valuation  Time-trade off or standard gamble  Yes. The “clean” utility linked to SS 
scores using EQ-5D trial data applies the 
standard social tariffs from Dolan REFto 
arrive at utility values 
Source of preference data for 
valuation of changes in HRQL  
Representative sample of the public  Yes. The “clean” utility applies the 
standard social tariffs from Dolan to 
arrive at utility values 
Discount rate  An annual rate of 3.5% on both costs 
and health effects  
Yes 
Equity  An additional QALY has the same 
weight regardless of the other 
characteristics of the individuals 
receiving the health benefit  
Yes 
Probabilistic modelling  Probabilistic modelling Probabilistic modelling is presented for 
the base case results 
Sensitivity analysis   A wide range of univariate sensitivity 
analyses and scenario analyses are 
included 
 
5.3 ERG additional scenario and sensitivity analysis  
 
The model runs 50,000 patient simulations for reliable convergence which takes some time.  
***************************************************************************
***************************************************************************
***************************************************************************
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***************************************************************************
***************************************************************************
***************************************************************************
********************************************************* 
Belimumab administration cost 
The £126 per administration for two hours of senior nursing time cross checks with the 2009-
10 PSSRU health care costs, though including qualification costs increases this slightly to 
£140 per administration. 
 
ERG expert opinion is in line with the manufacturer in noting that the administration cost for 
belimumab would be similar to that for tocilizumab which is also a one hour IV infusion. 
Tocilizumab was recently reviewed by NICE for rheumatoid arthritis in TA 198 within which 
there was clearly some debate throughout over the assessment up to the FAD about the 
appropriate administration cost to apply.  The ERG noted the availability of tariffs and 
reference costs for Health Research Group (HRG) codes HD23A to HD23C for Inflammatory 
Spine, Joint or Connective Tissue Disorders.  Refer to Table 51 and Table 52. 
Table 51: 2011 NHS Tariffs 
Combined Daycase / Elective tariff 
HD23A with Major CC £1,730 
HD23B with CC £595 
HD23C without CC £471 
 
Table 52: 2009 - 10 reference costs 
Daycase 
HD23A with Major CC £    455  
HD23B with CC £    412  
HD23C without CC £    432  
 
Within the manufacturer’s assessment of these costs, the £432 day case reference cost is 
adjusted pro rata by the number of hours required to yield an administration cost of £115 
(£432 * 7.5/2.0).  The manufacturer argues that adopting £126 per administration is as a result 
conservative.  Adjusting the reference cost in this manner may be questionable. 
Within TA198 the ERG noted that “The administration cost of each infusion of tocilizumab 
was assumed to be £142.  This originated from the first version of the Birmingham 
Rheumatoid Arthritis Model (BRAM) model calculations using 0.5 day case administration 
cost from the 2001 version of the PSSRU Unit Costs of Health and Social Care.  That 
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administration cost was calculated to be £124… This has then been inflated from 2004 to 
2008 to get £142 which, according to the submission, has since been used in a couple of STAs 
including the Abatacept appraisal (TA141).”  Further correcting this for inflation led to a final 
administration cost of £154 with the Final Appraisal Determination (FAD) indicating that 
while there was uncertainty around this cost £154 was acceptable, with this flowing through 
to the costing template for tocilizumab. 
Since the day case cost taken from the PSSRU is relatively dated, there is an argument for 
adopting a similar approach but taking half of the current reference cost of £432 to yield £216 
rather than the 7.5/2 suggested by the manufacturer.  The most stringent approach would be to 
apply the full day case cost of £432. Applying these costsh
Table 53
 results in the following cost 
effectiveness estimates.  Refer to . 
Table 53: Belimumab administration cost sensitivity analyses – Target population 
  
Without PAS With PAS 
 
SoC Belimumab 
 
Net Belimumab Net 
QALYs 9.81 10.61 0.81 10.61 0.81 
Admin cost @ £126 .. £9,059 £9,059 £9,059 £9,059 
Total cost      
  Admin @ £115 £105,366 £156,500 £51,134 ******** ******** 
  Admin @ £126 £105,366 £157,291 £51,925 ******** ******** 
  Admin @ £154 £105,366 £159,304 £53,938 ******** ******** 
  Admin @ £216 £105,366 £163,761 £58,395 ******** ******** 
  Admin @ £432 £105,366 £179,290 £73,924 ******** ******** 
ICERs      
  Admin @ £115   £63,429   ******** 
  Admin @ £126   £64,410   ******** 
  Admin @ £154   £66,907   ******** 
  Admin @ £216   £72,436   ******** 
  Admin @ £432   £91,699   ******** 
 
Patient age at baseline 
Holding all other variables constant and setting the patient age at baseline to be 30, 40 and 50 
results in cost effectiveness estimates of £65,498 per QALY, £62,695 per QALY and £55,439 
per QALY respectively; i.e. for otherwise identical patients the cost effectiveness of 
belimumab improves as the age at first administration increases. 
 
The manufacturer response to ERG clarification question B2 confirmed that these estimates 
for age 30 and age 50 are correct.  The rationale provided by the manufacturer for this initially 
counter intuitive result lies in the calculated AMS at baseline for a 30 year old and a 50 year 
old being the same within the hypothetical example.  The AMS has the same additive effect 
within the λp
                                                          
h Due to time constraints these estimates are derived by applying a multiplier to the total administration 
costs estimated within the base case run for the Target population. For instance, for the £432 day case 
cost the multiplier applied is £432/£126 = 3.43. 
=X’β for the 30 year old as for the 50 year old, since by assumption all patient 
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variables within X’β are the same for the 30 year old and the 50 year old other than the AMS.  
This rolls through to the patient hazard of death relative to the JHU cohort “average”.  It 
seems that it is at this point that the modelling of the 30 year old and the 50 year old diverge, 
with the age specific Bernatsky SLE SMRs being applied in conjunction with the age specific 
general population mortality rate. 
In the light of what still appears to be counterintuitive result around baseline age, this may 
argue for a review of the modelling of mortality and the application of the Bernatsky SLE 
SMRs to the JHU cohort survival model. 
Linear regression of SS52-SS0
The base case uses the pooled trial data to estimate the linear regression of SS
 central parameter estimates 
52-SS0
 
.  As 
already outlined, the parameter estimates for this regression differ quite considerably between 
the two trials. All parameter estimates have p values of less than 0.1%. 
From Table 54, for BLISS-52 the overall effect for belimumab week 24 responders is a 
central parameter estimate of -0.6372, as compared to -0.5980 for BLISS-76. But this has to 
be read in conjunction with the estimates for SoC which are also larger in BLISS-52 than for 
BLISS-76.  The net difference between the overall effect of belimumab week 24 responders 
over that of SoC is -0.2743 for BLISS-52 and -0.2639 for BLISS-76 which given their 
similarity as naturally close to that estimated from the pooled data: -0.2742. 
Table 54: Linear regression of SS52-SS0 central parameter estimates – Target 
population 
 BLISS-52 BLISS-76 Pooled 
SS52-SS0 -0.3629  SoC -0.3341 -0.3493 
SS52-SS0 -0.3746  belimumab -0.3153 -0.3435 
SS52-SS0 -0.2626  belimumab week 24 responders -0.2827 -0.2800 
 
For the estimated net SS change among belimumab week 24 responders over that of SoC to 
be so similar between the trials is surprising given the absolute mean changes as previously 
reported and repeated in Table 55.  There would appear to be a larger absolute advantage 
within BLISS-52 compared to that within BLISS-76: 3.4 (-7.5 vs. -4.1) compared to 2.8 (-6.8 
vs. -4.0).  
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Table 55: SS changes at week 52 by week 24 responder status and by trial – Target 
population 
 BLISS-52 BLISS-76 Pooled 
Week 24 responder Resp NResp All Resp NResp All Resp NResp All 
Mean change from baseline at week 52: SS52-SS0 
SoC -5.4 -2.3 -4.1 -6.1 -2.3 -4.0 -5.7 -2.3 -4.1 
Belimumab -7.5 -3.3 -6.3 -6.8 -2.5 -5.2 -7.2 -2.9 -5.8 
 
Applying the estimates from the BLISS-52 and BLISS-76 results in economic estimates (see 
Table 56). 
Table 56: Effect upon economic estimates of SS52-SS0 source: Target population 
 
 
Without PAS With PAS 
 SoC Belimumab Net Belimumab Net 
BLISS-52 as source for SS52-SS0 regression 
Total cost £105,195 £157,102 £51,907 ******* ******* 
QALYs 9.84 10.64 0.80 10.64 0.80 
ICER   £64,950  ******* 
BLISS-76 as source for SS52-SS0 regression 
Total cost £105,518 £157,469 £51,951 ******* ******* 
QALYs 9.77 10.55 0.78 10.55 0.78 
ICER   £66,318  ******* 
 
As anticipated, the cost effectiveness estimates are not particularly different between the 
application of the pooled regression coefficients, the BLISS-52 regression coefficients and the 
BLISS-76 regression coefficients. 
Steroid dose use equation 
The trial evidence for a steroid dose effect between the arms may be open to question, 
particularly within BLISS-76.  This effect can be removed through a sensitivity analysis that 
slightly arbitrarily applies constant steroid dose of 10mg/day for all patientsi
                                                          
i Implemented within the PSA Inputs worksheet by setting HY7=0 and HZ7=10 for 10mg and 8 for 
8mg, and HY7=0. 6799 and HZ7=3.197 for the post 1 Jan 2000 JH data 
, together with 
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another that reduces it to 8mg/day.  But note that this not only equalises the steroid dose 
between the arms but also equalises it between patients of differing SS score severity at 
baseline which is likely to be unrealistic. Unfortunately the electronic model is not easily 
amended to permit different steroid dosing based upon the individual patient baseline SS 
score undifferentiated by arm. 
 
Retaining the differentiation of steroid use by arm, in response to ERG clarification question 
B21 the manufacturer re-estimates the steroid dose equation with a dummy for data that was 
pre-2000.  The dummy was statistically significant and of the anticipated sign at 1.433, with 
the regression constant and coefficient for the SS score falling to 0.6799.  These values can be 
used for a third sensitivity analysis.  Refer to Table 57. 
Table 57: Steroid doses: Target population 
 
 
Without PAS With PAS 
 SoC Belimumab Net Belimumab Net 
Constant steroid dose of 10mg/day 
Total cost £103,261 £154,453 £51,192 ******* ******* 
QALYs 9.64 10.38 0.74 10.38 0.74 
ICER     £68,766   ******* 
Constant steroid dose of 8mg/day 
Total cost £104,816 £156,561 £51,745 ******* ******* 
QALYs 9.79 10.55 0.76 10.55 0.76 
ICER     £68,278   ******* 
Post 1 January 2000 JHU data regression 
Total cost £105,692 £157,877 £52,186 ******* ******* 
QALYs 9.84 10.65 0.81 10.65 0.81 
ICER     £64,369   ******* 
 
Arbitrarily equalising the steroid dose between the arms of the model to a constant 10mg/day 
or 8/mg per day does affect the overall patient experience and cost, but the net effect of the 
10mg/day and the 8/mg is similar.  For both, the net costs show limited change from the base 
case but the net benefits fall away slightly faster, resulting in reasonably similar cost 
effectiveness estimates of around £68,500 per QALY without the PAS 
***********************.   The revised post 1 January 2000 regression has no practical 
136 
 
impact upon the results of the model.  This may suggest that the net outcomes of the model 
are not particularly driven by the level of steroid dose, but differentiated by arm it has some 
impact with this mainly affecting the QALY side of the cost effectiveness equation. 
Modelling of mortality and application of SMR  
The requirement to apply the SMRs drawn from the Bernatsky reference within the modelling 
remains unclear to the ERG, particularly for when the patient being modelled is within the age 
range of the JHU cohort.  But if it is reasonable to apply SLE SMRs within the mortality 
modelling, there is an additional concern over whether the SMRs from the Bernatsky 
reference are representative.  ************************************* 
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
******************** 
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
***************************************************************************
********************************************************* 
Table 58: SMRs for sensitivity analysis 
Age Base case Sens. analysis 
16 – 24 19.2 5.3 
25 – 40 8.0 3.7 
40 – 59 3.7 2.6 
60+ 1.4 1.4 
 
The SMRs reported in Table 58 result in the following model outputs (Table 59). 
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Table 59: Sensitivity analysis around SMRs – Target population 
  Without PAS With PAS 
 SoC Belimumab Net Belimumab Net 
Survival LY - undiscounted 35.00 37.58 2.58 37.58 2.58 
Total cost - discounted £116,657 £168,095 £51,438 ******** ******** 
QALYs - discounted 10.53 11.26 0.726 11.26 0.73 
ICER   £70,860  ******** 
 
***************************************************************************
***************************************************************************
************************** 
Given the apparently quite large undiscounted additional survival of 2.93 years within the 
Target population, the contribution of the various coefficients within the JHU cohort survival 
function of Table 6.12 can be explored. This is most simply achieved by sequentially setting  
each of the individual coefficients within Table 6.12 to equal zero with the remainder taking 
the values within Table 6.12 and running the modelj
Ordering results by their impacts upon net undiscounted survival results in the following 
estimates compared to the 2.93 additional life years of the Target population base case: AMS 
0.90 life years; renal 2.59 life years; CAPD 2.68 life years; PVD 2.70 life years; age at 
diagnosis 3.14 life years; diabetes 3.06 life years; gastrointestinal 2.99 life years; malignancy 
2.98 life years; and, infection 2.90 life years.  Musculoskeletal and cholesterol have no impact 
upon the net undiscounted survival.  Refer to 
. It is recognised that , as with the 
stepwise elimination of coefficients that led to the JHU cohort survival model, further 
eliminating coefficients within the JHU cohort survival model would if correctly undertaken 
change the values of the remaining coefficients. 
Table 60. 
  
                                                          
j Implemented within the Nat Hist Model Data worksheet by setting the relevant cell within cells 
AG11:AG52 equal to zero 
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Table 60: Removing the AMS coefficient from JHU cohort survival function - Target 
population 
  Without PAS With PAS 
 SoC Belimumab Net Belimumab Net 
Survival LY - undiscounted 20.20 21.10 0.90 21.10 0.90 
Total cost - discounted £127,598 £174,022 £46,424 ******* ******* 
QALYs - discounted 11.12 11.55 0.43 11.55 0.43 
ICER   £106,912  ******* 
 
The data reported in Table 60 underlines the importance of the AMS coefficient within the 
JHU cohort survival function to the anticipated additional 2.93 life years from belimumab use 
within the Target population. This should be read in conjunction with the concerns around the 
calculation of the SS score and the resultant calculation of the AMS score. It also highlights 
the possible significance of applying the Bernatsky SMRs to the patient mortality hazard as 
drawn from the JHU cohort survival function. 
 
SLICC organ involvement at baseline 
The model through random drawings simulates a range of organ involvements at baseline 
within the 50,000 patient simulated. The central estimate of cost effectiveness average across 
these. Given this it is illustrative to explore the scenarios of: no organ involvement at 
baseline; all organs having a SLICC score of 1 at baseline; and, individual organs having a 
SLICC score of 1 at baseline with no other organ involvementk
Table 61
. The net effects reported 
below relate to the addition of belimumab to SoC.  Refer to . 
  
                                                          
k Implemented within the Subgroup BLISS data worksheet by setting cells P245:P256 equal to cell Q64 
and cells Q245:T256 equal to 0, and for any organ involvement at SLICC score 1 setting the relevant 
cell(s) within cells Q245:Q256 equal to cell Q64 with the corresponding cells within P245:P256 equal 
to 0 
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Table 61: SLICC involvement at baseline – Target population 
SLICC = 1 
involvement 
None All CV Diabetes* GI* Malign* MSK* 
SoC undiscounted 
LYs 
33.45 1.40 33.00 26.05 28.53 22.04 29.84 
Net undiscounted 
LYs 
2.82 0.32 3.05 3.13 3.19 3.35 3.13 
Net disc. QALYs 0.84 0.13 0.67 0.88 0.86 0.95 0.75 
Net disc. Costs ex 
PAS 
£51,018 £16,067 £51,846 £53,135 £51,130 £49,048 £53,094 
ICER ex PAS £60,486 £122,796 £77,635 £60,240 £59,583 £51,759 £71,048 
ICER with PAS ******* ******* ******* ******* ******* ******* ******* 
 
SLICC = 1 
involvement 
NP Ocular PV* GF Pulm Renal* Skin 
SoC undiscounted 
LYs 
33.05 33.02 23.11 32,87 33.06 26.97 32.86 
Net undiscounted 
LYs 
3.08 2.91 3.05 3.00 2.97 2.89 3.11 
Net disc. QALYs 0.63 0.83 0.88 0.84 0.61 0.81 0.82 
Net disc. Costs ex 
PAS 
£53,303 £51,624 £50,449 £52,530 £65,233 £58,222 £51,033 
ICER ex PAS £84,963 £62,420 £57,486 £62,206 £107,729 £71,932 £61,875 
ICER with PAS ******* ******* ******* ******* ******* ******* ******* 
* Within the JHU cohort survival function of Table 6.12 of the submission 
CV – cardiovascular; GI – gastrointestinal; Malign – malignancy; MSK – musculoskeletal; NP – 
neuropsychatric; PV – peripheral vascular; GF – gonodal failure; Pulm – pulmonary 
 
Table 61 illustrates that of the organs not entering the JHU cohort survival function, assuming 
their individual involvement at baseline with no other organ involvement at baseline has a 
similar effect upon the anticipated patient survival as there being no organ involvement at all 
at baseline: an average survival in the SoC arm of a little over 33 years. Belimumab is 
anticipated to provide around an additional 3 life years.  
 
The impact upon net QALYs is more marked. But it must be borne in mind that within the 
model multiple organ involvement only sees the HRQoL multiplier for the worst organ 
involved being applied. Neuropsychiatric involvement or pulmonary involvement are the 
worst, with HRQoL multipliers of 0.71 and 0.69 respectively, and their involvement from 
baseline effectively limits QALY gains to those arising from additional survival. 
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Cardiovascular and musculoskeletal disease with HRQoL multipliers of 0.76 and 0.79 
respectively also have this effect but to a lesser extent, as their involvement at baseline leaves 
open the possibility of the subsequent development of neuropsychiatric involvement and/or 
pulmonary involvement. 
 
Of those organs entering the JHU cohort survival function, assuming the individual 
involvement at baseline of malignany or peripheral vascular has the largest impact upon 
anticipated survival in the SoC arm, the anticipated additional survival from belimumab 
remains fairly constant at around 3 life years. 
 
Given the individual impacts of organ involvement and the JHU cohort survival function, it 
may be slightly surprising for the scenario of all organ systems being involved at baseline to 
result in an average survival within the SoC arm of only 1.40 years. It is only in this 
admittedly extreme scenario that the anticipated additional survival from belimumab drops 
noticeably below 3 life years. 
 
Patients may differ at baseline in terms of their organ involvement. For organs within the JHU 
cohort survival function this is modelled as affecting their anticipated survival under SoC. But 
almost regardless of their anticipated survival under SoC, adding belimumab to SoC appears 
to be modelled as yielding a fairly constant additional 3 years survival. This may again 
highlight the centrality of the modelling of the impact of belimumab on the SS score, and by 
implication the AMS score, upon model outcomes. 
 
Pulmonary involvement costs and HRQoL 
The costs of pulmonary involvement are based upon 90% of patients requiring average direct 
drug costs of £1571 per month plus 100% of patients requiring £316 other resource use to 
give a total monthly cost of £1,730.  Within this the direct drug cost if only sildenafil was 
used would be somewhat less at only £348.  In response to an ERG clarification question the 
manufacturer has run two additional sensitivity analyses: one applying the costs from 
sildenafil and the other excluding all pulmonary costs.  These result in cost effectiveness 
estimates for the Target population of £66,807 per QALY and £68,182 per QALY 
respectively. 
 
The HRQoL impacts are mainly sourced from the same HTA monograph that examines 
pulmonary arterial hypertension, these relating to the pulmonary arterial hypertension 
functional classes II, III and IV.  An additional HRQoL value for functional class I is drawn 
from the Zisman pulmonary fibrosis paper, but as this is assumed to only apply to 1% of 
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pulmonary arterial hypertension patients it has no impact upon the calculations.  This leads to 
the modelling applying an HRQoL multiplier for pulmonary arterial hypertension 
involvement of 0.61 as shown in Table 62. 
Table 62: Pulmonary arterial hypertension average HRQoL 
PAH functional class 
HRQoL % patients 
I 0.73 1% 
II 0.67 24% 
III 0.60 63% 
IV 0.52 12% 
Weighted Average 0.61 
  
As already outlined this can be applied within the overall pulmonary HRQoL calculation as 
shown in Table 63. 
Table 63: HRQoL calculation pulmonary involvement from Table 16.19 
 HRQoL JHU % Weighted JHU SLICC Final 
Pulmonary hypertension 0.61 33% 0.20   
Pulmonary fibrosis 0.73 42% 0.31   
Shrinking lung (Chest XRay) 1.00 2% 0.02   
Pleural fibrosis (Chest XRay) 1.00 20% 0.20   
Pulmonary 
infarction/resection 
0.94 4% 0.04   
Average across pulmonary   0.77 1.31 0.70 
 
Sensitivity analyses around this parameter do not appear to have been conducted.  To explore 
its impact upon model outputs it can in effect be removed from the modelling, due to the 
values being treated as multiplicative by setting it equal to 1.00l
 
.  This results in a central 
estimate of £65,812 per QALY suggesting that results are not particularly sensitive to this 
variable. 
                                                          
l Implemented within the QoL Inputs worksheet by setting cells AG9:AG58=1 
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6 DISCUSSION  
6.1.1 Clinical Effectiveness 
Across many outcomes whilst the pooled data appear promising, the effect size for patients in 
BLISS-52 favoured belimumab to a much greater extent than those in BLISS-76, this applied 
for both the whole and the Target (high disease activity) populations.  The effect sizes in 
favour of belimumab for the whole population in BLISS-76 were modest and for the most 
part showed no significant difference between belimumab and placebo groups. BLISS-76 is 
likely to be more representative of the proposed patient population in England and Wales. 
Drawing on FDA data there appeared to be little difference in effectiveness between 1mg/kg 
and 10mg/kg dose regimens.  The reasons for, and implications of, the differences between 
trials and a lack of dose response between doses for BLISS-76, are worthy of discussion but 
on available evidence cannot be resolved.  The reason BLISS-76 patients were relatively 
unresponsive to belimumab is unlikely to be attributable to recruitment of patients with 
inactive disease because all were auto-immune positive at entry and had a SLEDAI score ≥ 6 
points.   
BLISS-76 patients had longer established disease, had more developed organ damage, were 
older, and were receiving less steroid dosage than those in BLISS-52, and these differences 
may have contributed to differing responses to therapy.  The most obvious differences 
between trials were in the geographical distribution of study centres and in the racial make-up 
of the populations.  These might be reflected in differences in response to therapy and in the 
nature of standard of care practices.  Ninety two percent of BLISS-76 study centres, but none 
of the BLISS-52 centres, were located in North America + West Europe.  The LBSL02 phase 
II RCT (100% of the trial centres located in USA + Canada) preceded the BLISS trials and 
failed to demonstrate effectiveness of belimumab (primary outcomes: percent mean change in 
SLEDAI score at week 24, and median time to first flare).  However, post hoc analysis of 
LBSL02 data did identify a subgroup of patients (~ 70% of the total) who responded better 
and who exhibited auto-immune positive disease at trial entry. This population became the 
focus of the subsequent Phase III BLISS trials.  The failure of the LBSL02 trial to show an 
effect was attributed to the inclusion of inappropriate patients lacking auto-antibodies at 
recruitment. 
Belimumab is an expensive drug and the proposal is that it should be administered at monthly 
intervals at a dose of 10mg/kg.  Because of some doubt regarding the relative effectiveness of 
differing dose regimens it is possible that in practice belimumab may be used at lower than 
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10mg/kg; it seems important that if this should happen that good data on effectiveness of 
reduced dose regimens should be collected.   
Target population and proposed licence population 
The focus of the MS was the high disease activity “Target population” which represents a 
subgroup of the proposed “licence population” (in turn a subpopulation of the pooled BLISS 
population).  The primary end point, which was the percentage of responders at week 52 
according to the novel composite SRI outcome measure, was very similar for pooled Target 
population and pooled “licence population” with respectively 19.8% and 24.8% extra 
responders for belimumab compared to placebo (belimumab vs. placebo odds ratio = 2.7 for 
both populations).  Furthermore the cost-effectiveness of belimumab in each population was 
essentially the same (base case ICER £64,410 and £66,170 / QALY respectively).  Given 
these results, there appear small grounds on which  to distinguish patients in the Target 
population from those in the proposed licence population on the basis of either clinical or 
cost-effectiveness and a  SLEDAI score cut-off of 10 points, appears to be an arbitrary 
criterion that would be difficult to implement in practice.  One effect of selecting the Target 
population in preference to the “licence population” is to considerably reduce the 
manufacturer’s calculation of total budget impact of introducing belimumab across the 
country. (MS section 7). 
 
Belimumab vs. rituximab 
No head-to-head trial comparing belimumab with rituximab has been conducted.  The ERG 
and the manufacturer disagree about the commonality of outcome measures available from 
belimumab and rituximab trials, but concur that a credible indirect comparison is not feasible 
on the grounds of large difference between trial populations.  The ERG note that the primary 
outcome measure in the relevant Rituximab trial may be a more stringent test of therapeutic 
effect than that used in the BLISS trials, and therefore are not convinced by the 
manufacturer’s implication that belimumab is necessarily a more effective drug. 
Efficacy of belimumab for different SLE manifestations 
In the BLISS trials the most commonly involved SLE manifestations were musculoskeletal 
(60%), mucocutaneous (59%), hematologic (16%), general (11%), renal (11%) and vasculitis 
(7%).  Direct evidence for a beneficial effect of belimumab on other manifestations, such as 
pulmonary, renal or central nervous system manifestations, is not available.   
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6.1.2 Cost Effectiveness 
The manufacturer presents a complex and impressive natural history model of the evolution 
of SLE. The visual basic modelling as far as has been assessed to date by the ERG is 
sophisticated and appears correct.  There appear to be some data input discrepancies between 
the written submission and the electronic model. 
It is also unclear from an economic point of view why the manufacturer niches belimumab to 
those with a baseline SLEDAI score of at least 10.  The cost effectiveness estimates for the 
anticipated license population and the Target population are very similar.  Over time it also 
seems possible that those within the anticipated license population may fall within the Target 
population. 
The base case estimates for a patient falling within the Target population are that belimumab 
will: 
• Increase undiscounted survival by 2.93 years 
• Increase discounted patient benefits by 0.81 QALYs 
• Increase discounted costs by £51,925 ************* 
• Cost £64,410 per QALY *********** 
 
There are a number of ERG concerns with the modelling of the submission.  If these concerns 
are justified, addressing them appears more likely to worsen the estimate of the cost 
effectiveness of belimumab than improve it. 
• Assuming that belimumab week 24 non-responders will experience the average SS 
score within the SoC arm seems likely to have over-estimated the average impact 
upon SS scores within the belimumab arm. The SS scores drive the analysis and any 
error in their calculation is likely to have a major impact on results 
• Not taking into account a patient’s history before entry into the trial may further 
exaggerate the impact upon the AMS of belimumab compared to SoC 
• The steroid use data within the trials has been passed over within the modelling. 
• The calculation of the cumulative average steroid dose may be subject to a bias 
similar to that of the calculation of the AMS 
• Maintaining the net gain in SS score for a belimumab week 24 responder compared to 
the parallel patient in the SoC arm while the belimumab week 24 responder remains 
on treatment may be optimistic 
• There is some lack of clarity around the reasons for patients’ discontinuation and the 
derivation of the 8% annual discontinuation rate among belimumab week 24 
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responders, and of the reasonableness of extrapolating using this value. A low 
discontinuation rate worsens the cost effectiveness of belimumab 
• The requirement to adjust the JHU cohort survival model by SMRs from the literature 
is unclear and may have tended to exaggerate the impact of the individual covariates 
within the JHU cohort survival model 
• The analysis of the observational cost data on a six monthly basis in order to relate it 
to the maximum SS score during that period then doubling it to arrive at the annual 
relationship appears peculiar given that the observational cost data was collected over 
a year. It may also lead to bias 
• The separate estimation of a cost per organ involved may have double counted costs 
estimated within the SS score cost function to some degree 
• There appear to be some discrepancies in the reported model outputs for the average 
durations of organ involvement, the annual costs of these and the discounted total 
costs of these organ involvements. There are as a consequence concerns around the 
calculation of the cost offsets from reduced organ involvement arising from 
belimumab  
6.2 Implications for research  
It is unlikely that an industry sponsored trial will be conducted to compare belimumab with 
rituximab or other new biological interventions for SLE.  The cost of a sufficiently powered 
study to discriminate between such treatments is likely to be too great for such studies to be 
undertaken independently of industry sponsorship.  In view of the relative expense of 
belimumab and the lack of clear demonstration of a dose response relationship it is possible 
that in the real world belimumab may be employed at doses less than 10mg/kg.  Useful 
research could be undertaken to monitor such usage and the 24 week response rates elicited.  
Due to the paucity of long-term evidence for the continued benefit of belimumab and its 
safety, monitoring and surveillance of patients who have been treated with belimumab are 
therefore necessary.  Further investigation is needed in patients excluded in the current 
BLISS-52 and BLISS-76 trials who had severe lupus nephritis or central nervous system 
manifestations of the disease.  The two trials were limited in the inclusions of black patients, 
who for example account for approximately 25% of lupus patients in the USA.  These patients 
also tend to have more severe disease than the general lupus population.  In an earlier Phase II 
study of belimumab, black patients did significantly better than non-black patients.  In 
contrast the reported Phase III trials found black patients treated with belimumab performed 
worse than those given placebo.  These discrepancies needed to be considered further. 
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Although BLyS (B-Lymphocyte stimulator) is raised in SLE, reducing its activity with 
belimumab in SLE patients appears to have only a very modest effect.  In RCTs a large 
proportion of patients in the belimumab group responded, but the placebo group response 
indicated that many would have responded irrespective of receiving belimumab.  In a 
Targeted population with higher response rates the effect of belimumab remained relatively 
modest.  On this basis, research should be directed at identifying additional factors that 
independently, or together with BLyS play a role in the pathology of SLE.  Until such factors 
are identified it is probable that the traditional armamentarium of interventions will remain 
core for the treatment of most SLE patients. 
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8 APPENDICES 
8.1 Appendix 1 SLE Flare index   
 
The SLE Flare Index categorizes SLE flare as “mild or moderate” or “severe” based on 6 
variables20,21,22
•  Change in SELENA SLEDAI score from the most recent assessment to current.  
 (check that this is the correct Petri et al, 2005):  
•  Change in signs or symptoms of disease activity.  
•  Change in prednisone dosage.  
•  Use of new medications for disease activity or hospitalization.  
•  Change in PGA score.  
•  Hospitalization for SLE activity (severe flare only).  
Applied as follows (Taken from HGS Briefing Document to the FDA Oct 20105
 
):  
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8.2 Appendix 2  Assessment of manufacturer’s search strategies 
 
Appraised using PRESS CHECKLIST 
Checklist developed by: Sampson M, McGowan J, Lefebvre C, Moher D, Grimshaw J. PRESS: Peer Review of 
Electronic Search Strategies. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. Available 
from: http://www.cadth.ca/media/pdf/477_PRESS-Peer-Review-Electronic-Search-Strategies_tr_Appendices.pdf 
 
worksheet 
Search for non-randomised studies 
1. Translation: Is the search question translated well into search 
concepts? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
2. Operators: Are there any mistakes in the use of Boolean or 
proximity operators? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
3. Subject headings: Are any important subject headings missing or have any 
irrelevant ones been included? 
 Adequate 
Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
4. Natural language: Are any natural language terms or spelling variants missing, or 
have any irrelevant ones been included? Is 
truncation used optimally? 
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 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
5. Spelling & syntax: Does the search strategy have any spelling mistakes, system 
syntax errors, or wrong line numbers? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
6. Limits: Do any of the limits used seem unwarranted or are 
any potentially helpful limits missing? 
 Adequate  
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
Uses SIGN’s Observational study filters for Embase and Medline) 
 
7. Adapted for db: Has the search strategy been adapted for each database to be 
searched? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
 
Other notes: 
Initial number in report is 14. Number in combined total for databases is 14. 
Search doesn’t include comparators, but section 5.1.1 of report implies that their plan was only to 
look for non-RCTs for belimumab. 
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et 
Search for RCTs 
1. Translation: Is the search question translated well into search 
concepts? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
2. Operators: Are there any mistakes in the use of Boolean or 
proximity operators? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
3. Subject headings: Are any important subject headings missing or have any 
irrelevant ones been included? 
 Adequate 
Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
4. Natural language: Are any natural language terms or spelling variants missing, or 
have any irrelevant ones been included? Is 
truncation used optimally? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
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5. Spelling & syntax: Does the search strategy have any spelling mistakes, system 
syntax errors, or wrong line numbers? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
6. Limits: Do any of the limits used seem unwarranted or are 
any potentially helpful limits missing? 
 Adequate  
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
Uses SIGN RCT filter for Embase, Sections of the search for Medline appear exactly the same as 
the SIGN RCT filter for Medline, but several lines are missing covering relevant publication types 
and other small differences are noted. SIGN filter may have been updated and the version used 
here is older? – new publication types) 
 
7. Adapted for db: Has the search strategy been adapted for each database to be 
searched? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
 
Other notes: 
Initial number in flow diagram in section 5.1 of report is 3774. Number in combined total for 
databases in Appendix is 3776 
 
In section 5.1 of the report it is stated that 39 full publications and 4 conference proceedings were 
included, but no details have been given for most of these (only 11 are mentioned in Tables 5.2, 
5.3 and 5.4). Ideally we should see a list of all 43 publications in tabular form with clear reasons 
for exclusion. 
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Search for economic studies 
1. Translation: Is the search question translated well into search 
concepts? 
  Adequate 
 Needs revision Provide an explanation or example 
________________________________________________________________________ 
The searches are not as well done as the searches for the clinical effectiveness section. In 
Pubmed, the use of title/abstract in the belimumab section of the search strategy has resulted in 7 
fewer hits compared to the same sections in the clinical effectiveness search strategy. In Embase 
several lines include major mistakes resulting in it being unclear how the database would have 
performed the search. For example, line #1 starts with “exp AND” and includes two EMTREE 
headings that do not exist: ‘lupus’/exp, ‘sle’/exp. Testing this line of the search by entering it 
exactly as reported results in 23221 (06/05/11), which is far fewer than the 58059 reported in the 
search strategy. There are similar problems in the economic filter section of the search strategy. 
 
The search strategies do not include comparators, but they state in report that they do not intend 
to search for these (is this reasonable?). 
______________________________________________________________________ 
 
2. Operators: Are there any mistakes in the use of Boolean or 
proximity operators? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
3. Subject headings: Are any important subject headings missing or have any 
irrelevant ones been included? 
󲐀 Adequate 
 Needs revision Provide an explanation or example 
________________________________________________________________________ 
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The basic search in Pubmed for lupus was automatically mapped by Pubmed, resulting in the 
inclusion of the MeSH heading Lupus Vulgaris. The MeSH heading Lupus Erythematosus, 
Systemic was not included. However, because Pubmed also searched for lupus in all fields papers 
with this MeSH heading would have been picked up. 
________________________________________________________________________ 
4. Natural language: Are any natural language terms or spelling variants missing, or 
have any irrelevant ones been included? Is 
truncation used optimally? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
5. Spelling & syntax: Does the search strategy have any spelling mistakes, system 
syntax errors, or wrong line numbers? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
6. Limits: Do any of the limits used seem unwarranted or are 
any potentially helpful limits missing? 
  Adequate  
 Needs revision Provide an explanation or example 
________________________________________________________________________ 
As the numbers found in the subject part of the search were so small for Medline (44 in Pubmed), 
the use of a filter was inappropriate. It is stated in section 6.1 of report that the CRD sensitive 
economics filters for Pubmed and Embase were used, but the version used in Pubmed does not 
match that given in CRD’s NHS Economics Evaluation Database Handbook 2007. The versions of 
the filter that used to be on CRD’s website are no longer there after the website restructure so it is 
possible that they have been updated. However, there are some clear discrepancies in the 
translation of some elements (i.e.the MeSH heading in the filter exp “Costs and Cost analysis”/ 
was entered as costs AND “cost analysis”. Fortunately, this was translated by Pubmed correctly, 
but as well as including the correct MeSH heading several odd combinations of free text terms 
were searched, such as (costs"[All Fields] AND "cost"[All Fields] AND "analysis"[All Fields] ). 
Many of the lines in Embase that should have been searching the EMTREE headings were entered 
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very differently and resulted in massively fewer hits (e.g. the EMTREE heading in the filter exp 
Economic Evaluation/ (which when tested brought back 166263 hits on 06/05/11) was entered as 
“exp AND economic AND (‘evaluation’/exp OR evaluation)” and resulted in only 977 hits. 
 
7. Adapted for db: Has the search strategy been adapted for each database to be 
searched? 
 Adequate 
󲐀 Needs revision Provide an explanation or example 
________________________________________________________________________ 
________________________________________________________________________ 
 
Other notes: 
The initial number in the flow diagram tallies with those in the search strategies. 
 
In section 5.1 of the report it is stated that the 14 excluded studies are listed in section 9.1, 
Appendix 10, but only 2 are actually listed in this Appendix. 
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8.3 Appendix 3  List of 43 publications from manufacturer’s clinical study search 
 
Inclusion / exclusion table from manufacturer’s clarification document 
Table A16.1 Summary of publications of RCTs reviewed and their reasons for exclusion 
Publication Reason for exclusion 
1. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, 
double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus 
erythematosus. Arthritis Care and Research. 2009 15;61 (9):1168-78. 
Included (LBSL02). 
2. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based 
systemic lupus erythematosus responder index. Arthritis & Rheumatism. [Research Support, N.I.H., 
Extramural]. 2009 Sep 15;61(9):1143-51. 
Included. Linked to LBSL02. 
3. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, et al. Biologic activity and safety of 
belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in 
patients with systemic lupus erythematosus. Arthritis research & therapy. 2008;10 (5):R109. 
Included (LBSL01). 
4. Navarra S, Ilianova E, Bae SC, Guzman R, et al. Belimumab, a BLYS-specific inhibitor, reduced 
disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): 
BLISS-52 study. EULAR. 2010:Abstract SAT0204. 
Included (BLISS-52). 
5. Tanasescu C, Gallacher A, Garcia M, Littlejohn G, Saaibi D, et al. Belimumab, a BLYS-specific 
inhibitor, significantly improved physical functioning, fatigue, and other health-related quality of life 
(HRQOL) measures in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. 
EULAR. 2010:abstract SAT0206. 
Included (BLISS-52). 
6. D'Cruz D, Tanasescu C, Navarra S, Guzman R, et al. Belimumab, a BLYS-specific inhibitor, reduced 
disease activity, flares and prednisone use in patients with active seropositive SLE: Phase 3 BLISS-52 
study. BSR. 2010: abstract OP3. 
Included (BLISS-52). 
7. Furie R, Zamani O, Wallace D, Tegzova D, et al. Belimumab, a BLyS-Specific Inhibitor, Reduced 
Disease Activity and Severe Flares in Seropositive SLE Patients: BLISS-76 Study Results through Wk 
76 ACR. 2010:Abstract 1454. 
Included (BLISS-76). 
8. Petri M, Van Vollenhoven RF, Zamani O, Furie RA, et al. Belimumab, a BLyS-Specific Inhibitor, 
Reduces Disease Activity and Severe Flares in Seropositive Systemic Lupus Erythematosus (SLE) 
Patients: BLISS-76 Study. International Journal of Rheumatic Diseases; Asia Pacific League of 
Associations of Rheumatology 2010;13:suppl. 1: 110-5, abstract 0281. 
Included (BLISS-76). 
9. Wallace DJ, Kalunian KC, Petri MA, Strand CV, et al. Epratuzumab Demonstrates Clinically 
Meaningful Improvements in Patients with Moderate to severe Systemic Lupus Erythematosus (SLE): 
Results from EMBLEM™, at Phase IIb Study ACR. 2010:Abstract 1452. 
Investigational drug. Not yet available 
in the UK. 
10. Carneiro JRM, Sato EI. Randomized double-blind clinical study with methotrexate in systemic lupus 
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active autoantibody-positive systemic 
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Cyclophosphamide is not a relevant 
comparator. 
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active autoantibody-positive systemic 
lupus erythematosus. 
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comparator. 
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158 
 
18. Dussán KB, Magder L, Brodsky RA, Jones RJ, Petri M. High dose cyclophosphamide performs 
better than monthly dose cyclophosphamide in quality of life measures. Lupus. 2008(12):1079-85. 
Cyclophosphamide is not a relevant 
comparator. 
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Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus 
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8.4 Appendix 4 Demographic details for BLISS total and Target populations (MS Table 5.9) 
  BLISS-52 BLISS-76 Pooled Total Population 
 Placebo 
N = 287 
1mg/kg 
N = 288 
10mg/kg 
N = 290 
All 
N = 865 
Placebo 
N = 275 
1mg/kg 
N = 271 
10mg/kg 
N = 273 
All 
N = 819 
Placebo 
N = 562 
1mg/kg 
N = 559 
10mg/kg 
N = 563 
All 
N = 1684 
SLE Disease duration (yr)1            
 Mean ± SD 5.93 ± 6.17 
4.96 ± 
4.58 
5.03 ± 
5.07 
5.31 ± 
5.32 
7.42 ± 
6.72 
7.93 ± 
7.13 
7.20 ± 
7.45 
7.52 ± 
7.10 
6.66 ± 
6.48 
6.40 ± 
6.13 
6.08 ± 
6.42 
6.38 ± 
6.35 
SELENA SLEDAI score             
  ≥ 10 158 (55.1%) 
139 
(48.3%) 
160 
(55.2%) 
457 
(52.8%) 
141 
(51.3%) 
144 
(53.1%) 
136 
(49.8%) 
421 
(51.4%) 
299 
(53.2%) 
283 
(50.6%) 
296 
(52.6%) 
878 
(52.1%) 
 Mean ± SD 9.70 ± 3.62 
9.56 
± 3.78 
9.97 
± 3.88 
9.75 
± 3.76 
9.80 
± 3.97 
9.70 
± 3.65 
9.52 
± 3.64 
9.67 
± 3.󲐀5 
9.75 
± 3.79 
9.63 
± 3.71 
9.75 
± 3.77 
9.71 
± 3.76 
PGA score             
 < 1 43 (15.0%) 
38 
(13.2%) 
32 
(11.0%) 
113 
(13.1%) 
33 
(12.0%) 
39 
(14.4%) 
51 
(18.7%) 
123 
(15.0%) 
76 
(13.5%) 
77 
(13.8%) 
83 
(14.7%) 
236 
(14.0%) 
 1 - < 2 195 (67.9%) 
207 
(71.9%) 
212 
(73.1%) 
614 
(71.0%) 
196 
(71.3%) 
189 
(69.7%) 
175 
(64.1%) 
560 
(68.4%) 
391 
(69.6%) 
396 
(70.8%) 
387 
(68.7%) 
1174 
(69.7%) 
 ≥ 2 49 (17.1%) 
43 
(14.9%) 
46 
(15.9%) 
138 
(16.0%) 
46 
(16.7%) 
43 
(15.9%) 
47 
(17.2%) 
136 
(16.6%) 
95 
(16.9%) 
86 
(15.4%) 
93 
(16.5%) 
274 
(16.3%) 
BILAG organ domain involvement            
 at least 1A or 2B 166 (57.8%) 
166 
(57.6%) 
172 
(59.3%) 
504 
(58.3%) 
187 
󲐀󲐀8.0%) 
173 
(63.8%) 
160 
(58.6%) 
520 
(63.5%) 
353 
(62.8%) 
339 
(60.6%) 
332 
(59.0%) 
1024 
(60.8%) 
 at least 1A 52 (18.1%) 
58 
(20.1%) 
54 
(18.6%) 
164 
(19.0%) 
37 
(13.5%) 
38 
(14.0%) 
24 
(8.8%) 
99 
(12.1%) 
89 
(15.8%) 
96 
(17.2%) 
78 
(13.9%) 
263 
(15.6%) 
SLICC Damage Index 
score  (Mean ± SD) 
0.55 
± 0.93 
0.60 
± 1.06 
0.55 
± 1.00 
0.57 
± 1.00 
0.99 
± 1.45 
1.04 
± 1.39 
0.94 
± 1.38 
0.99 
± 1.41 
0.77 
± 1.23 
0.81 
± 1.25 
0.74 
± 1.21 
0.77 
± 1.23 
 SLICC Damage Index score = 0 
182 
(63.4%) 
190 
(66.0%) 
193 
(66.6%) 
565 
(65.3%) 
145 
(52.7%) 
125 
(46.1%) 
145 
(53.1%) 
415 
(50.7%) 
327 
(58.2%) 
315 
(56.4%) 
338 
(60.0%) 
980 
(58.2%) 
 SLICC Damage Index score = 1 
70 
(24.4%) 
56 
(19.4%) 
60 
(20.7%) 
186 
(21.5%) 
66 
(24.0%) 
76 
(28.0%) 
62 
(22.7%) 
204 
(24.9%) 
136 
(24.2%) 
132 
(23.6%) 
122 
(21.7%) 
390 
(23.2%) 
 SLICC Damage Index score ≥ 2 
35 
(12.2%) 
42 
(14.6%) 
37 
(12.8%) 
114 
(13.2%) 
64 
(23.3%) 
69 
(25.5%) 
66 
(24.2%) 
199 
(24.3%) 
99 
(17.6%) 
111 
(19.9%) 
103 
(18.3%) 
313 
(18.6%) 
Proteinuria (g/24 hour)             
 ≥ 2 21 (7.3%) 
26 
(9.0%) 
19 
(6.6%) 
66 
(7.6%) 
11 
(4.0󲐀) 
7 
(2.6%) 
15 
(5.5%) 
33 
(4.0%) 
32 
(5.7%) 
33 
(5.9%) 
34 
(6.0%) 
99 
(5.9%) 
 Mean ± SD 0.62 ± 1.15 
0.63 
± 1.13 
0.54 
± 0.91 
0.60 
± 1.07 
0.39 
± 0.81 
0.33 
± 0.65 
0.40 
± 0.73 
0.37 
± 0.74 
0.50 
± 1.00 
0.48 
± 0.94 
0.48 
± 0.83 
0.49 
± 0.93 
1  Time elapsed between date of SLE diagnosis and the date of informed consent. 
 
161 
 
 BLISS whole population serological (MS Tables 5.10) 
 
  BLISS-52 BLISS-76 Pooled Total Population 
 Placebo 
N = 287 
1mg/kg 
N = 288 
10mg/kg 
N = 290 
All 
N = 865 
Placebo 
N = 275 
1mg/kg 
N = 271 
10mg/kg 
N = 273 
All 
N = 819 
Placebo 
N = 562 
1mg/kg 
N = 559 
10mg/kg 
N = 563 
All 
N = 1684 
Anti-dsDNA positive (≥ 30 IU/mL) 205 (71.4󲐀) 
221 
(76.7%) 
218 
(75󲐀2%) 
644 
(74.5%) 
174 
(63.3%) 
171 
(63.1%) 
179 
(65.6%) 
524 
(64.0%) 
379 
(67.4%) 
392 
(70.1%) 
397 
(70.5%) 
1168 
(69.4%) 
Anti-Smith positive (≥ 15 U/mL) 101/287 (35.2%) 
102/288 
(35.4%) 
105/287 
(36.6%) 
308/862 
(35.7%) 
72/269 
(26.8%) 
69/269 
(25.7%) 
75/265 
(28.3%) 
216/803 
󲐀26.9%) 
173/556 
(31.1%) 
171/557 
(30.7%) 
180/552 
(32.6%) 
524/1665 
(31.5%) 
IgG >ULN (16.18 g/L) 146 (50.9% 
140 
(48.6%) 
151 
(52.1%) 
437 
(50.5%) 
108 
(39.3%) 
105 
(38.7%) 
94 
(34.4%) 
307 
(37.5%) 
254 
(45.2%) 
245 
(43.8%) 
245 
(43.5%) 
744 
(44.2%) 
Complement             
 Normal/high C3 and C4 102 (35.5%) 
100 
(34.7%) 
89 
(30.7%) 
291 
(33.6%) 
113 
(41.1%) 
122 
(45.0%) 
112 
(41.0%) 
347 
(42.4%) 
215 
(38.3%) 
222 
(39.7%) 
201 
(35.7%) 
638 
(37.9%) 
 Low C3 or C4, but not both 78 (27.2%) 
55 
(19.1%) 
75 
(25.9%) 
208 
(24.0%) 
65 
(23.6%) 
57 
(21.0%) 
60 
(22.0%) 
182 
(22.2%) 
143 
(25.4%) 
112 
(20.0%) 
135 
(24.0%) 
390 
(23.2%) 
 Low C3 (< 900 mg/L) 132 (46.0%) 
148 
(51.4%) 
147 
(50.7%) 
427 
(49.4%) 
116 
(42.2%) 
100 
(36.9%) 
115 
(42.1%) 
331 
(40.4%) 
248 
(44.1%) 
248 
(44.4%) 
262 
(46.5%) 
758 
(45.0%) 
 Low C4 (< 16 mg/dL) 160 (55.7%) 
173 
(60.1%) 
180 
(62.1%) 
513 
(59.3%) 
143 
(52.0%) 
141 
(52.0%) 
147 
(53.8%) 
431 
(52.6%) 
303 
(53.9%) 
314 
(56.2%) 
327 
(58.1%) 
944 
(56.1%) 
 Low C3 and C4 107 (37.3%) 
133 
(46.2%) 
126 
(43.4%) 
366 
(42.3%) 
97 
(35.3%) 
92 
(33.9%) 
101 
(37.0%) 
290 
(35.4%) 
204 
(36.3%) 
225 
(40.3%) 
227 
(40.3%) 
656 
(39.0%) 
BLyS (above LOQ, ≥ 0.5 ng/mL) 273/283 (96.5%) 
273/285 
(95.8%) 
281/285 
(98.6%) 
827/853 
(97.0%) 
268/271 
(98.9%) 
267/270 
(98.9%) 
263/268 
(98.1%) 
798/809 
(98.6%) 
541/554 
(97.7%) 
540/555 
(97󲐀3%) 
544/553 
(98.4%) 
1625/1662 
(97.8%) 
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BLISS whole population concomitant medications (MS Tables 5.11) 
 
  BLISS-52 BLISS-76 Pooled Total Population 
 Placebo N = 287 
1mg/kg 
N = 288 
10mg/kg 
N = 290 
All 
N = 865 
Placebo 
N = 275 
1mg/kg 
N = 271 
10mg/kg 
N = 273 
All 
N = 819 
Placebo 
N = 562 
1mg/kg 
N = 559 
10mg/kg 
N = 563 
All 
N = 1684 
Total corticosteroid 
use 
276 
(96.2%) 
276 
(95.8%) 
278 
(95.9%) 
830 
(96.0%) 
212 
(77.1%) 
211 
(77.9%) 
200 
(73.3%) 
623 
(76.1%) 
488 
(86.8%) 
487 
(87.1%) 
478 
(84.9%) 
1453 
(86.3%) 
  Prednisone or 
equivalent             
 > 0 to ≤ 7.5 g/day 84 (29.3%) 
72 
(25.0%) 
74 
(25.5%) 
230 
(26.6%) 
86 
(31.3%) 
81 
(29.9%) 
80 
(29.3%) 
247 
(30.2%) 
170 
(30.2%) 
153 
(27.4%) 
154 
(27.4%) 
477 
(28.3%) 
 > 7.5 to < 2 
mg/day 
136 
(47.4%) 
133 
(46.2%) 
131 
(45.2%) 
400 
(46.2%) 
76 
(27.6%) 
96 
(35.4%) 
81 
(󲐀9.7%) 
253 
(30.9%) 
212 
(37.7%) 
229 
(41.0%) 
212 
(37.7%) 
653 
(38.8%) 
 
≥ 20 mg/day 56 (19.5%) 
71 
(24.7%) 
73 
(25.2%) 
200 
(23.1%) 
50 
(18.2%) 
34 
(12.5%) 
39 
(14.3%) 
123 
(15.0%) 
106 
(18.9%) 
105 
(18.8%) 
112 
(19.9%) 
323 
(19.2%) 
Antimalarials 201 (70.0%) 
195 
(67.7% 
185 
(63.8%) 
581 
(67.2%) 
180 
(65.5%) 
171 
(63.1%) 
168 
(61.5%) 
519 
(63.4%) 
381 
(67.8%) 
366 
(65.5%) 
353 
(62.7%) 
1100 
(65.3%) 
Other 
immunosuppressants 
122 
(42.5%) 
120 
(41.7%) 
123 
(42.4%) 
365 
(42.2%) 
154 
(56.0%) 
153 
(56.5%) 
148 
(54.2%) 
455 
(55.6%) 
276 
(49.1%) 
273 
(48.8%) 
271 
(48.1%) 
820 
(48.7%) 
 1 
immunosupressant 
111 
(38.7%) 
116 
(40.3%) 
118 
(40.7%) 
345 
(39.8%) 
140 
(50.9%) 
143 
(52.8%) 
140 
(51.3%) 
423 
(51.6%) 
251 
(44.7%) 
259 
(46.3%) 
258 
(45.8%) 
768 
(45.6%) 
 2 
immunosupressants 
11 
(3.8%) 
4 
(1.4%) 
5 
(1.7%) 
20 
(2.3%) 
13 
(4.7%) 
10 
(3.7%) 
8 
(2.9%) 
31 
(3.8%) 
24 
(4.3%) 
14 
(2.5%) 
13 
(2.3%) 
51 
(3.0%) 
 Azathioprine 67 (23.3%) 
71 
(24.7%) 
84 
(29.0%) 
222 
(25.7%) 
57 
(20.7%) 
52 
(19.2%) 
58 
(21.2%) 
167 
(20.4%) 
124 
(22.1%) 
123 
(22.0%) 
142 
(25.2%) 
389 
(23.1%) 
 Methotrexate 35 (12.2%) 
24 
(8.3%) 
20 
(6.9%) 
79 
(9.1%) 
60 
(21.8%) 
53 
(19.6%) 
39 
(14.3%) 
152 
(18.6%) 
95 
(16.9%) 
77 
(13.8%) 
59 
(10.5%) 
231 
(13.7%) 
 Mycophenolate 19 (6.6%) 
16 
(5.6%) 
17 
(5.9%) 
52 
(6.0%) 
42 
(15.3%) 
45 
(16.6%) 
50 
(18.3%) 
137 
(16.7%) 
61 
(10.9%) 
61 
(10.9%) 
67 
(11.9%) 
189 
(11.2%) 
 Cyclosporin 6 (2.1%) 
5 
(1.7%) 
2 
(0.7%) 
13 
(1.5%) 
5 
(1.8%) 
4 
(1.5%) 
5 
(1.8%) 
14 
(1.7%) 
11 
(2.0%) 
9 
(1.6%) 
7 
(1.2%) 
27 
(1.6%) 
 Leflunomide 2 (0.7%) - 
3 
(1.0%) 
5 
(0.6%) 
3 
(1.1%) 
7 
(2.6%) 
1 
(0.4%) 
11 
(1.3%) 
5 
(0.9%) 
7 
(1.3%) 
4 
(0.7%) 
16 
(1.0%) 
 Cyclophosphamide 2 (0.7%) 
3 
(1.0%) 
1 
(0.3%) 
6 
(0.7%) 
2 
(0.7%) 
2 
(0.7%) 
2 
(0.7%) 
6 
(0.7%) 
4 
(0.7%) 
5 
(0.9%) 
3 
(0.5%) 
12 
(0.7%) 
NSAIDs 59 (20.6%) 
56 
(19.4%) 
58 
(20.9%) 
173 
(20.0%) 
119 
(43.3%) 
114 
(42.1%) 
101 
(37.0%) 
334 
(40.8%) 
178 
(31.7%) 
170 
(30.4%) 
159 
(28.2%) 
507 
(30.1%) 
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Demographic characteristics of Target population (Table A3.1 clarification document) 
  BLISS-52 BLISS-76 Combined BLISS 
  SoC 10mg/kg SoC 10mg/kg SoC 10mg/kg 
 Total enrolled n=107 n=112 n=96 n=81 n=203 n=193 
Gender Male 10 (9.3%) 3 (2.7%) 6 (6.3%) 4 (4.9%) 16 (7.9%) 7 (3.6%) 
Female 97 (90.7%) 109 (97.3%) 90 (93.8%) 77 (95.1%) 187 (92.1%) 186 (96.4%) 
Race Caucasian 29 (27.1%) 23 (20.5%) 61 (63.5%) 54 (66.7%) 90 (44.3%) 77 (39.9%) 
Asian 40 (37.4%) 53 (47.3%) 5 (5.2%) 4 (4.9%) 45 (22.2%) 57 (29.5%) 
Black/African American 1 (0.9%) 6 (5.4%) 13 (13.5%) 7 (8.6%) 14 (6.9%) 13 (6.7%) 
Alaskan/Native American 37 (34.6%) 30 (26.8%) 17 (17.7%) 16 (19.8%) 54 (26.6%) 46 (23.8%) 
Hawaiian/Pacific Islander 0 0 0 0 0 0 
Multiracial 1 (0.9%) 0 0 0 1 (0.5%) 0 
Hispanic origin 55 (51.4%) 46 (41.1%) 28 (29.2%) 25 (30.9%) 83 (40.9%) 71 (36.8%) 
Age Years       
n ≤ 45 yrs 93 (86.9%) 100 (89.3%) 78 (81.3%) 65 (80.2%) 171 (84.2%) 165 (85.5%) 
n > 45 to < 65 14 (13.1%) 12 (10.7%) 17 (17.7%) 16 (19.8%) 31 (15.3%) 28 (14.5%) 
n ≥ 65 to < 75 0 0 1 (10%) 0 1 (0.5%) 0 
Weight (kg) Mean (SD) 62.1 ± 13.9 61.4 ± 14.1 688󲐀± 13.7 70.0 ± 16.7 65.2 ± 14.2 65.0 ± 15.8 
Range 34.7-127.6 39.5-128.5 45.4-108.6 47.0-131.7 34.7-127.6 39.5-131.7 
Region & country USA/Canada 0 0 45 (46.9%) 24 (29.6%) 45 (22.2%) 24 (12.4%) 
W Europe/Israel 0 0 24 (25.0%) 30 (37.0%) 24 (11.8%) 30 (15.5%) 
E Europe 10 (9.3%) 11 (9.8%) 12 (12.5%) 12 (14.8%) 22 (10.8%) 23 (11.9%) 
America excluding USA/Canada 56 (52.3%) 48 (42.9%) 15 (15.6%) 15 (18.5%) 71 (35.0%) 63 (32.6%) 
Asia 39 (36.4%) 53 (47.3%) 0 0 39 (19.2%) 53 (27.5%) 
Australia 2 (1.9%) 0 0 0 2 (1.0%) 0 
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BLISS Target population disease characteristics (Table A3.1 Clarification document) 
  BLISS-52 BLISS-76 Combined BLISS 
  SoC 10mg/kg SoC 10mg/kg SoC 10mg/kg 
 Total enrolled n=107 n=112 n=96 n=81 n=203 n=193 
        
SLE duration yrs; mean (SD) 6.70 ± 6.96 5.26 ± 4.99 7.42 ± 6.40 7.94 ± 7.47 7.04 ± 6.69 6.38 ± 6.28 
        
BILAG organ involvement At least 1A or 2B 65 (60.7%) 78 (69.6%) 78 (81.3%) 58 (71.6%) 143 (70.4%) 136 (70.5%) 
At least 1A 18 (16.8%) 25 (22.3%) 21 (21.9%) 7 (8.6%) 39 (19.2%) 32 (16.6%) 
At least 1A or 1B 99 (92.5%) 103 (92.0%) 94 (97.9%) 78 (96.3%) 193 (95.1%) 181 (93.8%) 
No A or B 8 (7.5%) 9 (8.0%) 2 (2.1%) 3 (3.7%) 10 (4.9%) 12 (6.2%) 
        
SELENA-SLEDAI mean (SD) 12.6 ± 3.0 12.8 ± 3.6 13.0 ± 3.5 12.4 ± 2.9 12.8 ± 3.3 12.6 ± 3.3 
        
PGA category 0 to 1 15 (14.0%) 13 (11.6%) 8 (8.3%) 8 (9.9%) 23 (11.3%) 21 (10.9%) 
>1 to 2.5 91 (85.0%) 97 (86.6%) 86 (89.6%) 71 (87.7%) 177 (87.2%) 168 (87.0%) 
>2.5 to 3 1 (0.9%) 2 (1.8%) 2 (2.1%) 2 (2.5%) 3 (1.5%) 4 (2.1%) 
        
SLICC Damage index; mean (SD)  0.6 ± 1.0 0.5 ± 0.9 0.8 ± 1.4 0.8 ± 1.2 0.7 ± 1.2 0.6 ± 1.0 
        
Prednisone or equivalent dose  0 mg/day 5 (4.7%) 4 (3.6%) 15 (15.6%) 12 (14.8%) 20 (9.9%) 16 (8.3%) 
>0 - ≤7.5 mg/day 26 (24.3%) 27 (24󲐀󲐀󲐀) 31 (32.3%) 24 (29.6%) 57 (28.1%) 51 (26.4%) 
> 7.5 mg/day 76 (71.0%) 81 (72.3%) 50 (52.1%) 45 (55.6%) 126 (62.1%) 126 (65.3%) 
        
Average prednisone or equivalent dose; mean (SD) mg/day 12.8 ± 8.4 13.7 ± 10.4 󲐀0󲐀3 󲐀󲐀8.8 10.4 ± 8.1 11.6 ± 8.6 12.3 ± 9.6 
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8.5 Appendix 5 Justification for pooling results across trials 
 
The ERG points for clarification requested “Please provide further justification for pooling results for 
Target Population”.  The manufacturer’s response is shown in full below: 
Pooling studies under nearly identical protocols but with subjects of varying demographic and 
baseline characteristics can be justified by extension of the same principles outlined in ICH E9 
(Statistical Principles of Clinical Trials) for which different centres in a single multicentre trial are 
pooled together, i.e. adherence to a common protocol that has been implemented in the same way at 
all centres using the same standardised procedures and evaluation criteria (as has been done in these 
studies), and a homogeneous treatment effect across studies (as is the case with these studies). In 
particular, when pooling the data across these studies, we considered study design, inclusion and 
exclusion criteria relative to disease severity, and whether the studies were run contemporarily such 
that the SoC treatment options were similar. These studies followed very similar protocols, were of 
nearly identical design, had identical inclusion and exclusion criteria, and were conducted over the 
same time period. Nevertheless, given the heterogeneous presentation of SLE disease and the fact that 
the Phase 3 program was run globally, one should expect to have variation in the patient population, 
both within the studies (e.g. between different centres) and between the studies (analogous to 
differences between centres within the same study). 
  
Since it has been established that the conduct of the studies was effectively the same, one must then 
determine whether the relative treatment effect is different in one study compared with the other study 
when evaluating whether two studies are similar enough to pool.  Each of the Phase 3 studies 
achieved statistical significance for belimumab 10mg/kg on the pre-specified primary endpoint of SRI 
response at Week 52; therefore, these nearly identical, studies provide independent replication of 
results.  While pooling is not necessary to establish the effectiveness of belimumab, it was considered 
appropriate in order to evaluate treatment effects in high disease activity subgroups of interest, given 
that the individual studies were not designed to provide sufficient power to demonstrate effectiveness 
within subgroups.  When the two Phase 3 studies were pooled a test for a treatment-by-study 
interaction was undertaken for the SRI analysis and the treatment-by-study interaction was >0.5.  
Likewise, for the Target Population of high disease activity, the treatment-by-study interaction was 
>0.7. 
 
Additionally, a multivariate logistic regression model was developed in order to determine predicators 
of SRI response.  Of the characteristics highlighted as being different between the two studies neither 
age, race, proteinuria, nor raised IgG were predictors of response.  SLICC Damage Score and 
166 
 
complement levels (and their interaction terms with treatment) were included in the final model and 
neither study (p=0.54) nor the treatment-by-study interaction (p=0.95) was a predictor of SRI 
response.  This result further substantiates that the study is not a predictor of SRI response, thus we 
believe that is reasonable and valid to pool the two studies. 
 
 
 
 
